<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3107245710
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AREKSA 25MG F.C.TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EXEMESTANE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        79.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="INTAS PHARMACEUTICALS LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            INTAS PHARMACEUTICALS LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Accord Healthcare Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BG06 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Areksa belongs to a group of medicines known as aromatase inhibitors.<br />These drugs interfere with a substance called Aromatase, which is<br />needed to make the female sex hormones, oestrogens, especially in<br />postmenopausal women. Reduction in oestrogen levels in the body is a<br />way of treating hormone dependent breast cancer.<br />Areksa is used to treat hormone dependent early breast cancer in<br />postmenopausal women after they have completed 2-3 years of<br />treatment with the medicine Tamoxifen.<br />Areksa is also used to treat hormone dependent advanced breast cancer<br />in postmenopausal women when a different hormonal drug treatment<br />has not worked well enough.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Areksa if you<br />&bull; are or have previously been allergic (hypersensitive) to Exemestane<br />or any of the other ingredients of Areksa. See section 6 for full list of<br />other ingredients<br />&bull; have not already been through &lsquo;the menopause&rsquo;, i.e. you are still<br />having your monthly period or<br />&bull; are pregnant, likely to be pregnant or breastfeeding<br />Warnings and Precautions<br />Talk to your doctor, pharmacist or nurse before taking Areksa tablets.<br />&bull; Areksa contains Sucrose. If you have previously been told<br />that you have intolerance to some sugars, contact your doctor before<br />taking this medicine. Areksa tablets contain Sucrose (a type of<br />sugar), which may cause a problem in a small number of patients<br />with hereditary intolerance to some sugars (Glucose-Galactose<br />malabsorption, Fructose intolerance or Sucrase-Isomaltase<br />insufficiency).<br />&bull; Before treatment with Areksa, your doctor may want to take blood<br />samples to make sure you have reached the menopause.<br />&bull; Routine checking of your viatamin D level will also be made before<br />treatment, as your level may be very low in the early stages of breast<br />cancer. You will be given vitamin D supplement if your levels are<br />below normal.<br />&bull; Before taking Areksa, tell your doctor if you have problems with<br />your liver or kidneys.<br />&bull; Tell your doctor if you have a history or are suffering from any<br />condition which affects the strength of your bones. Your doctor may<br />want to measure your bone density before and during the treatment<br />of Areksa. This is because medicines of this class lower the levels of<br />female hormones and this may lead to a loss of the mineral content<br />of bones, which might decrease their strength.<br />Other medicines and Areksa<br />Please tell your doctor if you are taking or have recently taken any<br />other medicines, including medicines obtained without prescription.<br />Areksa should not be given at the same time as Hormone Replacement<br />Therapy (HRT).<br />The following medicines should be used cautiously when taking Areksa<br />tablets. Let your doctor know if you are taking medicines such as:<br />&bull; Rifampicin (an antibiotic)<br />&bull; Carbamazepine or Phenytoin (anticonvulsants used to treat epilepsy)<br />&bull; The herbal remedy St John&rsquo;s Wort, (Hypericum perforatum), or<br />preparations containing it.<br />Areksa with Food, Drink and Alcohol<br />Areksa should be taken after meal at approximately the same time each<br />day.<br />Pregnancy, Breastfeeding and Fertility<br />Do not take Areksa if you are pregnant or breastfeeding. If you are<br />pregnant or think you might be, tell your doctor.<br />Discuss contraception with your doctor if there is any possibility that<br />you may become pregnant.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Driving and using machines<br />If you feel drowsy, dizzy or weak whilst taking Areksa, you should not<br />attempt to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Use in adults and elderly<br />Always take Areksa exactly as your doctor has told you. You should<br />check with your doctor or pharmacist if you are not sure.<br />Areksa should be taken by mouth after meal at approximately the same<br />time each day. Your doctor will tell you how to take Exemestane<br />tablets and for how long.<br />The recommended dose is one 25mg tablet daily.<br />If you need to go to the hospital whilst taking Areksa, let the medical<br />staff know what medication you are taking.<br />Use in children and adolescents<br />Areksa is not suitable for use in children.<br />If you take more Areksa than you should<br />If too many tablets are taken by accident, contact your doctor<br />immediately or go straight to the nearest hospital casualty department.<br />Show them the pack of Areksa.<br />If you forget to take Areksa<br />Do not take a double dose to make up for a forgotten tablet.<br />If you forget to take your tablet, take it as soon as you remember.<br />If it is nearly time for the next dose, take it at the usual time.<br />If you stop taking Areksa<br />Do not stop taking your tablets even if you are feeling well, unless your<br />doctor tells you.<br />If you have any further questions on the use of this medicine, ask your<br />doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />Exemestane is well tolerated and the following side effects observed in<br />patients treated with Exemestane are mainly mild or moderate in<br />nature. Most of the side effects are associated with a shortage of<br />oestrogen (e.g. hot flushes).<br />Hypersensitivity, inflammation of the liver (hepatitis) and inflammation<br />of the bile ducts of the liver which cause yellowing of the skin<br />(cholestatic hepatitis) may occur.<br />Symptoms include feeling generally unwell, nausea, jaundice<br />(yellowing of the skin and eyes), itching, right sided abdominal pain<br />and loss of appetite. Contact your doctor promptly to seek urgent<br />medical advice if you think you have any of these symptoms.<br />Very common side effects (may affect more than 1 in 10 people)<br />&bull; Depression<br />&bull; Difficulty sleeping<br />&bull; Headache<br />&bull; Hot flushes<br />&bull; Dizziness<br />&bull; Feeling sick<br />&bull; Increased sweating<br />&bull; Muscle and joint pain (including osteoarthritis, back pain, arthritis<br />and joint stiffness)<br />&bull; Tiredness<br />&bull; A reduction in the number of white blood cells<br />&bull; Abdominal pain<br />&bull; Elevated level of liver enzymes<br />&bull; Elevated level of a hemoglobin breakdown in the blood<br />&bull; Elevated level of a blood enzyme in the blood due to liver damage<br />&bull; Pain<br />Common side effects (may affect up to 1 in 10 people):<br />&bull; Loss of appetite<br />&bull; Carpal tunnel syndrome (a combination of pins and needles,<br />numbness and pain affecting all of the hand except the little finger) or<br />tingling/prickling of the skin<br />&bull; Stomach ache, vomiting (being sick), constipation, indigestion,<br />diarrhoea<br />&bull; Hair loss<br />&bull; Skin rash, hives and itchiness<br />&bull; Thinning of bones which might decrease their strength<br />(osteoporosis), leading to bone fractures (breaks or cracks) in some<br />cases<br />&bull; Pain, swollen hands and feet<br />&bull; A reduction in the number of platelets in the blood<br />&bull; Muscle weakness<br />Uncommon side effects (may affect up to 1 in 100 people)<br />&bull; Hypersensitivity<br />Rare side effects (may affect up to 1 in 1,000 people)<br />&bull; A breakout of small blisters on an area of the skin in a rash<br />&bull; Drowsiness<br />&bull; Inflammation of the liver<br />&bull; Inflammation of the bile ducts of the liver which cause yellowing of<br />the skin<br />Not known side effect (frequency cannot be estimated from the<br />available data)<br />&bull; Low level of certain white blood cells in the blood<br />Changes in the amount of certain blood cells (lymphocytes) and<br />platelets circulating in your blood, especially in patients with a<br />pre-existing lymphopenia (reduced lymphocytes in the blood) may also<br />be seen.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse.<br />This includes any possible side effects not listed in this leaflet. You can<br />also report the side effects directly to the National Pharmacovigilance<br />Centre (NPC) (see Section 6). By reporting side effects, you can help<br />provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of sight and reach of children.<br />Do not store above 30&deg;C. Store in the original pack.<br />Do not use this medicine after the expiry date which is stated on the<br />pack. The expiry date refers to the last day of that month.<br />Do not use Areksa if you notice any visible signs of deterioration.<br />Medicines should not be disposed of via wastewater or household<br />waste. Ask your pharmacist how to dispose of medicines no longer<br />required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Exemestane. Each film-coated tablet contains<br />Exemestane 25mg.<br />The other ingredients are:<br />Tablet core: Mannitol, cellulose microcrystalline, crospovidone,<br />sodium starch glycolate (Type A), hypromellose E5, polysorbate 80,<br />colloidal anhydrous silica,<br />magnesium stearate.<br />Tablet coating: Hypromellose 6cp (E464), titanium<br />dioxide (E171), macrogol 400.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Areksa are white to off white, round, biconvex film
coated tablets debossed with ‘E25’ on one side and plain
on the other.
Areksa is packed in blisters and is available in different
pack sizes (15, 20, 28, 30, 90, 98, 100 or 120 tablets per
pack).
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder (MAH):<br />Accord Healthcare Limited<br />Sage House, 319 Pinner Road,<br />North Harrow, Middlesex HA1 4HF,<br />United Kingdom<br />Manufactured for Accord Healthcare Limited by:<br />Intas Pharmaceuticals Limited,<br />Ahmedabad, Gujarat state, India.<br />For any information about this medicinal product, please contact the<br />local representative of the MAH:<br />Accord Healthcare KSA Scientific Office<br />At Zimmo Trading Company Ltd.<br />Riyadh, Olaya, Al-Arfaj Street,<br />Branched from Abdulmalik Bin Marwan Street,<br />Behind Ministry of Interior, Atlas building, office No. 1<br />Tel: +966-11-217-0140<br />E-mail: mena-pv@accord-healthcare.com<br />This leaflet was last approved in 12/2020, version number SA-03.<br />To report any side effect(s) in Saudi Arabia, please contact:<br />The National Pharmacovigilance Centre (NPC)<br />SFDA Call Centre: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 12/2020, version number SA-03.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي أريكسا إلى المجموعة الدوائية المعروفة باسم مثبطات الأروماتيز.<br />تتعارض هذه الأدوية مع مادة الأروماتيز اللازمة لإنتاج الهرمونات الجنسية<br />الأنثوية ومنها الإستروجين في المرأة خاصةً بعد سن اليأس. يعد خفض مستويات<br />الإستروجين في الجسم طريقةً مستخدمة في علاج سرطان الثدي الذي يعتمد على<br />الهرمونات.<br />يُستخدم أريكسا في علاج الإصابات المبكرة لسرطان الثدي التي تعتمد على<br />الهرمون في المرأة بعد سن اليأس بعد استكمال عامين الي ۳ أعوام من استخدام<br />تاموكسيفين في العلاج.<br />يُستخدم أريكسا أيضًا في علاج الإصابات المتأخرة لسرطان الثدي التي<br />تعتمد على الهرمون في المرأة بعد سن اليأس وذلك في حال عدم الاكتفاء<br />باستخدام علاج هرموني آخر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناولي أريكسا<br />&bull; إذا كنت تعاني من الحساسية تجاه مادة إكسيميستان أو أيٍّ من مكونات أريكسا.<br />يجب أن تقرأي قسم ٦ ، للاطلاع على قائمة المكونات الأخرى.<br />&bull; إذا لم تتوقف الدورة الشهرية، أي عند عدم بلوغ سن اليأس بالفعل. أو<br />&bull; إذا كنت حاملاً أو تعتقدين بأنك حاملاً أو إذا كنت مرضعاً.<br />التحذيرات والاحتياطات<br />&bull; يحتوي أريكسا على السكروز. إذا قيل لك في الماضي بأنك تعانينن من عدم<br />تحمل سكريات معينه، إستشيري طبيبك قبل إستعمال الدواء. إن أقراص أريكسا<br />تحتوي على السكروز (نوع من السكريات)، الذي قد يسبب مشكلة لدى قسم صغير<br />من المرضى الذي لديهم عدم تحمل وراثي لسكريات معينة (قلة إمتصاص<br />جلوكوز &ndash; جالاكتوز، عدم تحمل للفركتوز أو نقص في السكروز &ndash; إيزومالتاز).<br />&bull; قد يحتاج الطبيب إلى أخذ عينات من الدم للتأكد من بلوغ سن اليأس وذلك قبل<br />البدء بالعلاج بأريكسا.<br />&bull; يجب إبلاغ الطبيب قبل تناول أريكسا إذا كنت تعاني من اضطرابات في الكبد أو<br />الكلية.<br />&bull; يجب إبلاغ الطبيب إذا كنت عانيت في الماضي أو تعانين حالياً من أي<br />اضطراب يؤثر على قوة عظامك. قد يحتاج الطبيب إلى قياس كثافة العظام أو<br />مستويات ۲٥ هيدروكسي فيتامين د أو كليهما قبل وأثناء العلاج بأريكسا. يرجع<br />السبب في ذلك إلى أن الأدوية التي تنتمي لهذه المجموعة تقلل من مستويات<br />هرمونات الأنثوية، الامر الذي قد يؤدي إلى فقدان محتوى العظام من المعادن،<br />و الذي يقلل من قوتها.<br />أريكسا والأدوية الأخرى<br />يرجى إبلاغ الطبيب إذا كنت تتناولين ، أو تناولت مؤخرا أي أدوية أخرى بما<br />في ذلك الأدوية التي تصرف من غير وصفة طبية.<br />ينبغي عدم إعطاء أريكسا بالتزامن مع العلاج الهرموني البديل.<br />يجب إبلاغ الطبيب بالأخص إذا كنت تتناولين أي من هذه الأدوية التالية:<br />&bull; ريفامبيسين (مضاد حيوي).<br />&bull; الأدوية المستخدمة في علاج الصرع (كربامازيبين أو فنيتويين).<br />&bull; الأدوية العشبية المستخدمة في علاج الاكتئاب (نبتة سانت جونز وتسميتها<br />.(Hypericum perforatum اللاتينية<br />أريكسا مع الطعام والشراب<br />يجب تناول أريكسا بعد الوجبات في نفس الموعد تقريبًا كل يوم.<br />الحمل، الرضاعة الطبيعية والخصوبة<br />يجب عدم تناول أريكسا إذا كان هناك حمل أو في حالات الرضاعة الطبيعية،<br />كما يجب إبلاغ الطبيب المعالج إذا كنت حاملا أو تعتقدين بأنك حاملاً.<br />يجب مناقشة استخدام وسائل منع الحمل مع الطبيب إذا كان من المحتمل<br />حدوث الحمل.<br />يُرجى طلب نصيحة الطبيب أو الصيدلي قبل تناول أي أدوية.<br />القيادة واستخدام الآلات<br />يجب التوقف عن القيادة أو تشغيل الآلات عند الشعور بنعاس، دوار، أو تعب<br />أثناء استخدام أريكسا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب تناول أريكسا بعد الوجبات في نفس الموعد كل يوم تقريبًا.<br />يجب تناول أريكسا دائمًا كما أوصى الطبيب بالضبط. كما يجب الإستيضاح من<br />الطبيب او الصيدلي إذا لم تكوني واثقة.<br />الجرعة المُوصى بها هي قرص واحد ۲٥ ملغم يوميًّا.<br />عند الحاجة إلى الذهاب للمستشفى أثناء العلاج بأريكسا، فيجب إبلاغ الأطباء<br />عن الأدوية التي تتناوليها.<br />الأطفال والمراهقون<br />هذا الدواء غير مخصص للأطفال والمراهقين.<br />إذا تناولت كمية أكثر مما يجب من أريكسا<br />إذا تناولت عدد أقراص أكثر مما يجب عن طريق الخطأ فيجب الاتصال<br />بالطبيب على الفورأو الذهاب إلى أقرب مستشفى. يرجى اصطحاب علبة الدواء<br />لاطلاع الأطباء عليها.<br />إذا نسيت تناوُل أريكسا<br />يجب عدم تناول جرعة مضاعفة لتعويض الجرعة التي سهوت عن تناولها.<br />عند نسيان تناول الجرعة المقررة، فعليك تناولها لحظة تذكرك. إذا حان تقريبا<br />وقت الجرعة القادمة، فيرجى تناول الجرعة التاليه في الوقت المعتاد.<br />إذا توقفت عن تناول أريكسا<br />لا يجوز التوقف عن العلاج بالدواء إذا لم يخبرك الطبيب بذلك، حتى لو طرأ<br />تحسن على حالتك الصحية.<br />يرجى استشارة الطبيب أو الصيدلي إذا كانت لديك أي أسئلة حول استخدام هذا<br />الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع باقي الأدوية، قد يسبب أريكسا بعض التأثيرات الجانبية إلا أنها<br />قد لا تصيب الجميع.<br />يتم تحمل إكسيميستان بشكل جيد، والأعراض الجانية التالية، التي لوحظت لدى<br />مريضات قد تم علاجهن بأريكسا هي بالأخص خفيفة أو معتدلة بطبيعتها. إن<br />غالبية الأعراض الجانبية مرتبطة بنقص الأستروجين (مثل هبات من الحر)<br />و إلتهاب القنوات (Hepatitis) قد تصابي بفرط الحساسية، إالتهاب الكبد<br />الصفراوية في الكبد و الذي يسبب اصفرار الجلد (اليرقان الركودي). تشمل<br />الأعراض شعور عام بالتعب غثيان، يرقان (اصفرار الجلد و العينين) ، حكه،<br />ألم بطن في الجانب الأيمن و فقدان الشهية للطعام.<br />يجب التوجه إلى الطبيب بشكل فوري إذا كنت تعتقدين بأنك تعانين بأي من هذه<br />الأعراض.<br />الأعراض الجانبية الشائعة جداً (قد تُصيب هذه الأعراض أكثر من شخص واحد<br />من بين ۱۰ أشخاص)<br />&bull; اكتئاب<br />&bull; صعوبة في النوم<br />&bull; صداع<br />&bull; هبات سخنه<br />&bull; دوخة<br />&bull; شعور بالتعب<br />&bull; تعرق زائد<br />&bull; ألم في العضلات والمفاصل (بما في ذلك التهاب العظام والمفاصل، ألم في الظهر،<br />التهاب المفاصل، وتصلب المفاصل).<br />&bull; إرهاق<br />&bull; انخفاض عدد خلايا الدم البيضاء<br />&bull; ألم في البطن<br />&bull; ارتفاع مستوى إنزيمات الكبد<br />&bull; ارتفاع نسبة تكسر الهيموجلوبين في الدم<br />&bull; ارتفاع مستوى إنزيم الدم في مجرى الدم وذلك بسبب تلف في الكبد<br />&bull; ألم</p><p>الأعراض الجانبية الشائعة (قد تصيب هذه الأعراض على ما يصل إلى شخصًا<br />واحدًا من بين ۱۰ شخص)<br />&bull; فقدان الشهية<br />&bull; متلازمة النفق الرسغي (تشمل الشعور بوخز مثل وخز الإبر، تنميل، والألم<br />الذي يصيب راحة اليد بأكملها باستثناء الإصبع الصغير) أو شعور بالوخز في<br />الجلد.<br />&bull; ألم في المعدة، تقيؤ (شعور بالتعب)، إمساك، عسر الهضم، وإسهال<br />&bull; تساقط الشعر<br />&bull; طفح جلدي، شرى و حكة<br />&bull; ترقق أو تآكل العظام (هشاشة العظام) مما يؤدي إلى الإصابة بالكسور في<br />العظام ( كسر أو شق) في بعض الحالات<br />&bull; ألم وتورّم اليدين والقدمين<br />&bull; نقص الصفائح الدموية<br />&bull; ضعف عضلات<br />الأعراض الجانبية غير الشائعة (قد تصيب هذه الأعراض شخصًا واحدًا من بين<br />۱۰۰ شخص)<br />&bull; حساسية<br />الأعراض الجانبية النادرة (قد تصيب شخصًا واحدًا من بين ۱۰۰۰ شخص)<br />&bull; بروز بثور صغيرة على منطقة من الجلد بشكل طفح جلدي<br />&bull; نعاس<br />&bull; التهاب في الكبد<br />&bull; التهاب القنوات الصفراوية في الكبد و الذي يسبب اصفرار الجلد<br />الأعراض الجانبية غير المعروفة (عدد حالات الإصابة من البيانات المتاحة<br />غير معروفة)<br />&bull; انخفاض نسبة نوع معين من كريات الدم البيضاء<br />قد تحدث تغيرات في نسب خلايا دم معينه (الليمفاويات) والصفائح الدموية<br />الموجودة في الدم خاصةً لدى المريضات اللواتي لديهن نقص في الليمفاويات<br />(انخفاض نسبة الليمفاويات في الدم).<br />الإبلاغ عن الأعراض الجانبية<br />تحدث إلى الطبيب أو الصيدلي، إذا كانت لديك أيٌّ من الأعراض الجانبية. ويشمل<br />ذلك أياً من الأعراض الجانبية المحتملة وغير المذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدًا عن مرأى و متناول أيدي الأطفال.<br />يجب عدم تخزين الدواء فوق ۳۰ درجة مئوية. يجب التخزين في العبوة الأصلية.<br />لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المذكور على العبوة. يشير<br />تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.<br />لا تستخدم أريكسا إذا لاحظت وجود أي علامات ظاهرة من التلف.<br />يجب عدم التخلص من الأدوية مع مياه الصرف الصحي أو النفايات المنزلية.<br />اطلب من الصيدلي معرفة كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه<br />الإجراءات ستساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ماهي محتويات أريكسا<br />المادة الفعّالة هي إكسيميستان.<br />يحتوي كل قرص مغلف على ۲٥ ملغم من إكسيميستان.<br />المكونات الأخرى هي:<br />أساس القرص: مانيتول، بللورات السيلليلوز الصغيرة، كروسبوفيدون،<br />، بوليسوربات ۸۰ ،E هيبروميللوز 5 ،( A جليكولات صوديوم النشا (نوع<br />السيليكا الغروية اللامائية، ستيرات الماغنسيوم.<br />6)، ثاني أكسيد التيتانيوم cp) E الطبقة المغلفة للقرص: هيبروميللوز 464<br />. ماكروجول ٤۰۰ ،(E171)<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما هو شكل أريكسا ومحتويات العبوة<br />أريكسا عبارة عن أقراص مغلفة دائرية الشكل ذات لون أبيض أو أبيض مائل<br />وفارغة على &quot;E للأصفر، محدبة من الجانبين، محفور على أحد جانبيها &quot; 25<br />الجانب الاخر.<br />، تتوفر أقراص أريكسا في شرائط وعبوات بأحجام مختلفة ( ۱٥ ، أو ۲۰ ، أو ۲۸<br />أو ۳۰ ، أو ۹۰ ، أو ۹۸ ، أو ۱۰۰ ، أو ۱۲۰ قرصًا لكل عبوة).<br />قد لا يتم طرح جميع الأحجام في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>حامل تصريح التسويق<br />شركة أكورد هيلثكير ليميتد<br />ساج هاوس, ۳۱۹ بينر رود، نورث هارو، ميدلسيكس<br />٤ إتش إف، المملكة المتحدة إتش أيه ۱<br />+٤٤ ۲۰۸ ۸٦۳ هاتف: ۱٤۲۷<br />+٤٤ ۲۰۸ ۸٦۳ فاكس: ۱٤۲٦<br />mena-info@accord-healthcare.com : البريد الإلكتروني<br />تم التصنيع لصالح شركة أكورد هيلثكير ليميتد<br />بواسطة إنتاس للأدوية المحدودة، أحمد آباد، ولاية جوجارات، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة في 2017/12
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Areksa 25mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 25mg Exemestane.
Excipients with known effect
Each film-coated tablet contains 90.40mg Mannitol
For a full list of excipients, see Section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 25mg Exemestane.
Excipients with known effect
Each film-coated tablet contains 90.40mg Mannitol
For a full list of excipients, see Section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each film-coated tablet contains 25mg Exemestane.<br />Excipients with known effect<br />Each film-coated tablet contains 90.40mg Mannitol<br />For a full list of excipients, see Section 6.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adult and elderly patients<br />The recommended dose of Areksa is one 25mg tablet to be taken once a day after a meal.<br />In patients with early breast cancer, treatment with Areksa should continue until completion of five years of combined sequential adjuvant hormonal therapy (Tamoxifen followed by Areksa), or earlier if tumour relapse occurs.<br />In patients with advanced breast cancer, treatment with Areksa should continue until tumour progression is evident.<br />No dose adjustments are required for patients with hepatic or renal insufficiency (see section 5.2).<br />Children<br />Not recommended for use in children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Areksa are contraindicated in patients with a known hypersensitivity to the active substance or to any of the excipients, in premenopausal women and in pregnant or lactating women. (See section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Exemestane should not be administered to women with premenopausal endocrine status. Therefore, whenever clinically appropriate, the postmenopausal status should be ascertained by assessment of LH, FSH and estradiol levels.<br />Exemestane should be used with caution in patients with hepatic or renal impairment.<br />Areksa tablets contain Sucrose and should not be administered to patients with rare hereditary problems of Fructose intolerance, Glucose-Galactose malabsorption or Sucrase-Isomaltase insufficiency<br />Exemestane is a potent oestrogen lowering agent, and a reduction in bone mineral density and an increased fracture rate has been observed following administration (see Section 5.1). During adjuvant treatment with Exemestane, women with osteoporosis or at risk of osteoporosis should treatment baseline bone mineral health assessment, based on current clinical guidelines and practice. Patients with advanced disease should have their bone mineral density (BMD) assessed on a case-by-case basis. Although adequate data to show the effects of therapy in the treatment of the bone mineral density loss caused by Exemestane are not available, patients treated with Exemestane tablets should be carefully monitored and treatment for, or prophylaxis of, osteoporosis should be initiated in at risk patients.<br />Routine assessment of 25 Hydroxy Vitamin D levels prior to the start of Aromatase inhibitor treatment should be considered, due to the high prevalence of severe deficiency in women with early breast cancer (EBC). Women with Vitamin D deficiency should receive supplementation with Vitamin D.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In vitro evidence showed that the drug is metabolized through cytochrome P450 (CYP) 3A4 and aldo-keto reductases (see Section 5.2) and does not inhibit any of the major CYP isoenzymes. In a clinical pharmacokinetic study, the specific inhibition of CYP 3A4 by Ketoconazole showed no significant effects on the pharmacokinetics of Exemestane.<br />In an interaction study with Rifampicin, a potent CYP450 inducer, at a dose of 600mg daily and a single dose of Exemestane 25mg, the AUC of Exemestane was reduced by 54% and Cmax by 41%. Since the clinical relevance of this interaction has not been evaluated, the coadministration of drugs, such as Rifampicin, anticonvulsants (e.g. Phenytoin and Carbamazepine) and herbal preparations containing Hypericum Perforatum (St John&#39;s Wort) known to induce CYP3A4 may reduce the efficacy of Exemestane.<br />Exemestane should be used cautiously with drugs that are metabolized via CYP3A4 and have a narrow therapeutic window. There is no clinical experience of the concomitant use of Exemestane with other anticancer drugs.<br />Exemestane should not be coadministered with oestrogen-containing medicines as these would negate its pharmacological action.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />No clinical data on exposed pregnancies are available with Exemestane. Studies on animals have shown reproductive toxicity (see Section 5.3). Exemestane is therefore contraindicated in pregnant women.<br />Lactation<br />It is not known whether Exemestane is excreted into human milk. Exemestane should not be administered to lactating woman.</p><p>Women of perimenopausal status or childbearing potential<br />The physician needs to discuss the necessity of adequate contraception with women who have the potential to become pregnant including women who are perimenopausal or who have recently become postmenopausal, until their postmenopausal status is fully established (see Sections 4.3 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Drowsiness, somnolence, asthenia and dizziness have been reported with the use of the drug. Patients should be advised that, if these events occur, their physical and/or mental abilities required for operating machinery or driving a car may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Exemestane was generally well tolerated across all clinical studies conducted with Exemestane at a standard dose of 25mg/day, and undesirable effects were usually mild to moderate.<br />The withdrawal rate due to adverse events was 7.4% in patients with early breast cancer receiving adjuvant treatment with Exemestane following initial adjuvant Tamoxifen therapy. The most commonly reported adverse reactions were hot flushes (22%), arthralgia (18%) and fatigue (16%).<br />The withdrawal rate due to adverse events was 2.8% in the overall patient population with advanced breast cancer. The most commonly reported adverse reactions were hot flushes (14%) and nausea (12%).<br />Most adverse reactions can be attributed to the normal pharmacological consequences of oestrogen deprivation (e.g. hot flushes).<br />The reported adverse reactions from clinical studies and post-marketing experience are listed below by system organ class and by frequency.<br />Frequencies are defined as: Very common (&ge;1/10); Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1,000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:539px"><tbody><tr><td colspan="2" style="vertical-align:top; width:536px"><p><strong><em>Blood and lymphatic system disorders: </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common </em></p></td><td style="vertical-align:top; width:437px"><p>Leucopenia(**)</p></td></tr><tr><td style="vertical-align:top"><p><em>Common </em></p></td><td style="vertical-align:top; width:437px"><p>Thrombocytopenia(**)</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known </em></p></td><td style="vertical-align:top; width:437px"><p>Lymphocyte count decreased(**)</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:536px"><p><strong><em>Immune system disorders: </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon </em></p></td><td style="vertical-align:top; width:437px"><p>Hypersensitivity</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:536px"><p><strong><em>Metabolism and nutrition disorders: </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Common </em></p></td><td style="vertical-align:top; width:437px"><p>Anorexia</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:536px"><p><strong><em>Psychiatric disorders: </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common </em></p></td><td style="vertical-align:top; width:437px"><p>Depression, insomnia</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:536px"><p><strong><em>Nervous system disorders: </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common </em></p></td><td style="vertical-align:top; width:437px"><p>Headache, dizziness</p></td></tr><tr><td style="vertical-align:top"><p><em>Common </em></p></td><td style="vertical-align:top; width:437px"><p>Carpal tunnel syndrome, paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare </em></p></td><td style="vertical-align:top; width:437px"><p>Somnolence</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:536px"><p><strong><em>Vascular disorders: </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common </em></p></td><td style="vertical-align:top; width:437px"><p>Hot flushes</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:538px"><tbody><tr><td colspan="2" style="vertical-align:top; width:535px"><p><strong><em>Gastrointestinal disorders: </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common </em></p></td><td style="vertical-align:top; width:434px"><p>Abdominal pain, nausea</p></td></tr><tr><td style="vertical-align:top"><p><em>Common </em></p></td><td style="vertical-align:top; width:434px"><p>Vomiting, diarrhoea, constipation, dyspepsia</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:535px"><p><strong><em>Hepatobiliary disorders: </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common </em></p></td><td style="vertical-align:top; width:434px"><p>Hepatic enzyme increased, blood bilirubin increased, blood alkaline phosphatase increased</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare </em></p></td><td style="vertical-align:top; width:434px"><p>Hepatitis (&dagger;), cholestatic hepatitis (&dagger;)</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:535px"><p><strong><em>Skin and subcutaneous tissue disorders: </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common </em></p></td><td style="vertical-align:top; width:434px"><p>Increased sweating</p></td></tr><tr><td style="vertical-align:top"><p><em>Common </em></p></td><td style="vertical-align:top; width:434px"><p>Alopecia, rash, urticaria, pruritus</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare </em></p></td><td style="vertical-align:top; width:434px"><p>Acute generalised exanthematous pustulosis (&dagger;)</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:535px"><p><strong><em>Musculoskeletal and bone disorders: </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common </em></p></td><td style="vertical-align:top; width:434px"><p>Joint and musculoskeletal pain (*)</p></td></tr><tr><td style="vertical-align:top"><p><em>Common </em></p></td><td style="vertical-align:top; width:434px"><p>Fracture, osteoporosis</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:535px"><p><strong><em>General disorders and administration site conditions: </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common </em></p></td><td style="vertical-align:top; width:434px"><p>Pain, fatigue</p></td></tr><tr><td style="vertical-align:top"><p><em>Common </em></p></td><td style="vertical-align:top; width:434px"><p>Oedema peripheral, asthenia</p></td></tr></tbody></table><p>Includes: arthralgia, and less frequently pain in extremity, osteoarthritis, back pain, arthritis, myalgia and joint stiffness.<br />(**) In patients with advanced breast cancer thrombocytopenia and leucopenia have been rarely reported. An occasional decrease in lymphocytes has been observed in approximately 20% of patients receiving Exemestane, particularly in patients with pre-existing lymphopenia; however, mean lymphocyte values in these patients did not change significantly over time and no corresponding increase in viral infections was observed. These effects have not been observed in patients treated in early breast cancer studies.<br />(&dagger;) Frequency calculated by rule of 3/X<br />The table below presents the frequency of pre-specified adverse events and illnesses in the early breast cancer study (IES), irrespective of causality, reported in patients receiving trial therapy and up to 30 days after cessation of trial therapy.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse events and illnesses </strong></p></td><td style="vertical-align:top"><p><strong>Exemestane </strong></p><p><strong>(N = 2249) </strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen </strong></p><p><strong>(N = 2279) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Hot flushes</p></td><td style="vertical-align:top"><p>491 (21.8%)</p></td><td style="vertical-align:top"><p>457 (20.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>367 (16.3%)</p></td><td style="vertical-align:top"><p>344 (15.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>305 (13.6%)</p></td><td style="vertical-align:top"><p>255 (11.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>290 (12.9%)</p></td><td style="vertical-align:top"><p>204 (9.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Sweating increased</p></td><td style="vertical-align:top"><p>270 (12.0%)</p></td><td style="vertical-align:top"><p>242 (10.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Gynaecological</p></td><td style="vertical-align:top"><p>235 (10.5%)</p></td><td style="vertical-align:top"><p>340 (14.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>224 (10.0%)</p></td><td style="vertical-align:top"><p>200 (8.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>200 (8.9%)</p></td><td style="vertical-align:top"><p>208 (9.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Osteoporosis</p></td><td style="vertical-align:top"><p>116 (5.2%)</p></td><td style="vertical-align:top"><p>66 (2.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal haemorrhage</p></td><td style="vertical-align:top"><p>90 (4.0%)</p></td><td style="vertical-align:top"><p>121 (5.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Other primary cancer</p></td><td style="vertical-align:top"><p>84 (3.6%)</p></td><td style="vertical-align:top"><p>125 (5.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>50 (2.2%)</p></td><td style="vertical-align:top"><p>54 (2.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Visual disturbance</p></td><td style="vertical-align:top"><p>45 (2.0%)</p></td><td style="vertical-align:top"><p>53 (2.3%)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:357px"><tbody><tr><td style="vertical-align:top; width:178px"><p>Thromboembolism</p></td><td style="vertical-align:top; width:91px"><p>16 (0.7%)</p></td><td style="vertical-align:top; width:85px"><p>42 (1.8%)</p></td></tr><tr><td style="vertical-align:top; width:178px"><p>Osteoporotic fracture</p></td><td style="vertical-align:top; width:91px"><p>14 (0.6%)</p></td><td style="vertical-align:top; width:85px"><p>12 (0.5%)</p></td></tr><tr><td style="vertical-align:top; width:178px"><p>Myocardial infarction</p></td><td style="vertical-align:top; width:91px"><p>13 (0.6%)</p></td><td style="vertical-align:top; width:85px"><p>4 (0.2%)</p></td></tr></tbody></table><p>In the IES study, the frequency of ischemic cardiac events in the Exemestane and Tamoxifen treatment arms was 4.5% versus 4.2%, respectively. No significant difference was noted for any individual cardiovascular event including hypertension (9.9% versus 8.4%), myocardial infarction (0.6% versus 0.2%) and cardiac failure (1.1% versus 0.7%).<br />In the IES study, Exemestane was associated with a greater incidence of hypercholesterolemia compared with Tamoxifen (3.7% vs. 2.1%).<br />In a separate double blinded, randomized study of postmenopausal women with early breast cancer at low risk treated with Exemestane (N=73) or placebo (N=73) for 24 months , Exemestane was associated with an average 7-9% mean reduction in plasma HDL-cholesterol, versus a 1% increase on placebo. There was also a 5-6% reduction in apolipoprotein A1 in the Exemestane group versus 0-2% for placebo. The effect on the other lipid parameters analyzed (total cholesterol, LDL cholesterol, triglycerides, apolipoprotein-B and lipoprotein-a) was very similar in the two treatment groups. The clinical significance of these results is unclear.<br />In the IES study, gastric ulcer was observed at a higher frequency in the Exemestane arm compared to Tamoxifen (0.7% versus &lt;0.1%). The majority of patients on Exemestane with gastric ulcer received concomitant treatment with non-steroidal anti-inflammatory agents and/or had a prior history.<br />Reporting of suspected adverse reactions<br />To report any side effect(s) in Saudi Arabia, please contact:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical trials have been conducted with Exemestane given up to 800mg in a single dose to healthy female volunteers and up to 600mg daily to postmenopausal women with advanced breast cancer; these dosages were well tolerated. The single dose of Exemestane that could result in life threatening symptoms is not known. In rats and dogs, lethality was observed after single oral doses equivalent respectively to 2000 and 4000 times the recommended human dose on a mg/m2 basis. There is no specific antidote to over dosage and treatment must be symptomatic. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Steroidal aromatase inhibitor; anti-neoplastic agent<br />ATC: L02BG06<br />Exemestane is an irreversible, steroidal Aromatase inhibitor, structurally related to the natural substrate androstenedione. In postmenopausal women, oestrogens are produced primarily from the conversion of&nbsp;androgens into oestrogens through the Aromatase enzyme in peripheral tissues. Oestrogen deprivation through Aromatase inhibition is an effective and selective treatment for hormone dependent breast cancer in postmenopausal women. In postmenopausal women, Exemestane p.o. significantly lowered serum oestrogen concentrations starting from a 5mg dose, reaching maximal suppression (&gt;90%) with a dose of 10-25mg. In postmenopausal breast cancer patients treated with the 25mg daily dose, whole body aromatization was reduced by 98%.<br />Exemestane does not possess any progestogenic or oestrogenic activity. A slight androgenic activity, probably due to the 17-hydro derivative, has been observed mainly at high doses. In multiple daily doses trials, Exemestane had no detectable effects on adrenal biosynthesis of cortisol or aldosterone, measured before or after ACTH challenge, thus demonstrating its selectivity with regard to the other enzymes involved in the steroidogenic pathway.<br />Glucocorticoid or mineralocorticoid replacements are therefore not needed. A non dose-dependent slight increase in serum LH and FSH levels has been observed even at low doses: this effect is, however, expected for the pharmacological class and is probably the result of feedback at the pituitary level due to the reduction in oestrogen levels that stimulate the pituitary secretion of gonadotropins also in postmenopausal women.<br />Adjuvant Treatment of Early Breast Cancer<br />In a multicenter, randomized, double-blind study, conducted in 4724 postmenopausal patients with oestrogen-receptor-positive or unknown primary breast cancer, patients who had remained disease-free after receiving adjuvant Tamoxifen therapy for 2 to 3 years were randomized to receive 3 to 2 years of Exemestane (25mg/day) or Tamoxifen (20 or 30mg/day) to complete a total of 5 years of hormonal therapy.<br />After a median duration of therapy of about 30 months and a median follow up of about 52 months, results showed that sequential treatment with Exemestane after 2 to 3 years of adjuvant Tamoxifen therapy was associated with a clinically and statistically significant improvement in disease-free survival (DFS) compared with continuation of Tamoxifen therapy. Analysis showed that in the observed study period Exemestane reduced the risk of breast cancer recurrence by 24% compared with Tamoxifen (hazard ratio 0.76; p=0.00015). The beneficial effect of Exemestane over Tamoxifen with respect to DFS was apparent regardless of nodal status or prior chemotherapy.</p><p>Exemestane also significantly reduced the risk of contralateral breast cancer (hazard ratio 0.57, p=0.04158).<br />In the whole study population, a trend for improved overall survival was observed for Exemestane (222 deaths) compared to Tamoxifen (262 deaths) with a hazard ratio 0.85 (log-rank test: p = 0.07362), representing a 15% reduction in the risk of death in favor of Exemestane. A statistically significant 23% reduction in the risk of dying (hazard ratio for overall survival 0.77; Wald chi square test: p = 0.0069) was observed for Exemestane compared to Tamoxifen when adjusting for the pre-specified prognostic factors (i.e., ER status, nodal status, prior chemotherapy, use of HRT and use of bisphosphonates).<br />Main efficacy results in all patients (intention to treat population) and oestrogen receptor positive patients are summarized in the table below:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint </strong></p><p><strong>Population </strong></p></td><td style="vertical-align:top"><p><strong>Exemestane </strong></p><p><strong>Events /N (%) </strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen </strong></p><p><strong>Events /N (%) </strong></p></td><td style="vertical-align:top"><p><strong>Hazard Ratio </strong></p><p><strong>(95% CI) </strong></p></td><td style="vertical-align:top"><p><strong>p-value* </strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Disease-free survival </strong><strong><em>a </em></strong></p></td></tr><tr><td style="vertical-align:top"><p>All patients</p></td><td style="vertical-align:top"><p><strong>354 </strong>/2352 (15.1%)</p></td><td style="vertical-align:top"><p><strong>453 </strong>/2372 (19.1%)</p></td><td style="vertical-align:top"><p>0.76 (0.67-0.88)</p></td><td style="vertical-align:top"><p>0.00015</p></td></tr><tr><td style="vertical-align:top"><p>ER+ patients</p></td><td style="vertical-align:top"><p><strong>289 </strong>/2023 (14.3%)</p></td><td style="vertical-align:top"><p><strong>370 </strong>/2021 (18.3%)</p></td><td style="vertical-align:top"><p>0.75 (0.65-0.88)</p></td><td style="vertical-align:top"><p>0.00030</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Contralateral breast cancer </strong></p></td></tr><tr><td style="vertical-align:top"><p>All patients</p></td><td style="vertical-align:top"><p><strong>20 /2352 (0.9%) </strong></p></td><td style="vertical-align:top"><p><strong>35 /2372 (1.5%) </strong></p></td><td style="vertical-align:top"><p>0.57 (0.33-0.99)</p></td><td style="vertical-align:top"><p>0.04158</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>ER+ patients</p></td><td style="vertical-align:top"><p><strong>18 /2023 (0.9%) </strong></p></td><td style="vertical-align:top"><p><strong>33 /2021 (1.6%) </strong></p></td><td style="vertical-align:top"><p>0.54 (0.30-0.95)</p></td><td style="vertical-align:top"><p>0.03048</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Breast cancer free survival b </strong></p></td></tr><tr><td style="vertical-align:top"><p>All patients</p></td><td style="vertical-align:top"><p><strong>289 </strong>/2352 (12.3%)</p></td><td style="vertical-align:top"><p><strong>373 </strong>/2372 (15.7%)</p></td><td style="vertical-align:top"><p>0.76 (0.65-0.89)</p></td><td style="vertical-align:top"><p>0.00041</p></td></tr><tr><td style="vertical-align:top"><p>ER+ patients</p></td><td style="vertical-align:top"><p><strong>232 </strong>/2023 (11.5%)</p></td><td style="vertical-align:top"><p><strong>305 </strong>/2021 (15.1%)</p></td><td style="vertical-align:top"><p>0.73 (0.62-0.87)</p></td><td style="vertical-align:top"><p>0.00038</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Distant recurrence free survivalC </strong></p></td></tr><tr><td style="vertical-align:top"><p>All patients</p></td><td style="vertical-align:top"><p><strong>248 </strong>/2352 (10.5%)</p></td><td style="vertical-align:top"><p><strong>297 </strong>/2372 (12.5%)</p></td><td style="vertical-align:top"><p>0.83 (0.70-0.98)</p></td><td style="vertical-align:top"><p>0.02621</p></td></tr><tr><td style="vertical-align:top"><p>ER+ patients</p></td><td style="vertical-align:top"><p><strong>194 </strong>/2023 (9.6%)</p></td><td style="vertical-align:top"><p><strong>242 </strong>/2021 (12.0%)</p></td><td style="vertical-align:top"><p>0.78 (0.65-0.95)</p></td><td style="vertical-align:top"><p>0.01123</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Overall survivald </strong></p></td></tr><tr><td style="vertical-align:top"><p>All patients</p></td><td style="vertical-align:top"><p><strong>222 </strong>/2352 (9.4%)</p></td><td style="vertical-align:top"><p><strong>262 </strong>/2372 (11.0%)</p></td><td style="vertical-align:top"><p>0.85 (0.71-1.02)</p></td><td style="vertical-align:top"><p>0.07362</p></td></tr><tr><td style="vertical-align:top"><p>ER+ patients</p></td><td style="vertical-align:top"><p><strong>178 </strong>/2023 (8.8%)</p></td><td style="vertical-align:top"><p><strong>211 </strong>/2021 (10.4%)</p></td><td style="vertical-align:top"><p>0.84 (0.68-1.02)</p></td><td style="vertical-align:top"><p>0.07569</p></td></tr></tbody></table><p>* Log-rank test; ER+ patients = oestrogen receptor positive patients;<br />a. Disease-free survival is defined as the first occurrence of local or distant recurrence, contralateral breast cancer, or death from any cause;<br />b. Breast cancer-free survival is defined as the first occurrence of local or distant recurrence, contralateral breast cancer or breast cancer death;<br />c. Distant recurrence free survival is defined as the first occurrence of distant recurrence or breast cancer death;<br />d. Overall survival is defined as occurrence of death from any cause.<br />In the additional analysis for the subset of patients with oestrogen receptor positive or unknown status, the unadjusted overall survival hazard ratio was 0.83 (log-rank test: p = 0.04250), representing a clinically and statistically significant 17% reduction in the risk of dying.<br />Results from a bone substudy demonstrated that women treated with Exemestane following 2 to 3 years of Tamoxifen treatment experienced moderate reduction in bone mineral density. In the overall study, the treatment emergent fracture incidence evaluated during the 30 months treatment period was higher in patients treated with Exemestane compared with Tamoxifen (4.5% and 3.3% correspondingly, p=0.038).<br />Results from an endometrial substudy indicate that after 2 years of treatment there was a median 33% reduction of endometrial thickness in the Exemestane-treated patients compared with no notable variation in the Tamoxifen-treated patients. Endometrial thickening, reported at the start of study treatment, was reversed to normal (&lt; 5mm) for 54% of patients treated with Exemestane</p><p>Treatment of Advanced Breast Cancer<br />In a randomized peer reviewed controlled clinical trial, Exemestane at the daily dose of 25mg has demonstrated statistically significant prolongation of survival, Time to Progression (TTP), Time to Treatment Failure (TTF) as compared to a standard hormonal treatment with Megestrol Acetate in postmenopausal patients with advanced breast cancer that had progressed following, or during, treatment with Tamoxifen either as adjuvant therapy or as first-line treatment for advanced disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />After oral administration of Exemestane tablets, Exemestane is absorbed rapidly. The fraction of the dose absorbed from the gastrointestinal tract is high. The absolute bioavailability in humans is unknown, although it is anticipated to be limited by an extensive first pass effect. A similar effect resulted in an absolute bioavailability in rats and dogs of 5%. After a single dose of 25mg, maximum plasma levels of 18ng/ml are reached after 2 hours. Concomitant intake with food increases the bioavailability by 40%.</p><p>8<br />Distribution<br />The volume of distribution of Exemestane, not corrected for the oral bioavailability, is ca 20000 l. The kinetics is linear and the terminal elimination half-life is 24h. Binding to plasma proteins is 90% and is concentration independent. Exemestane and its metabolites do not bind to red blood cells.<br />Exemestane does not accumulate in an unexpected way after repeated dosing.<br />Metabolism and excretion<br />Exemestane is metabolized by oxidation of the methylene moiety on the 6 position by CYP 3A4 isoenzyme and/or reduction of the 17-keto group by aldo-keto reductase followed by conjugation. The clearance of Exemestane is ca 500 l/h, not corrected for the oral bioavailability.<br />The metabolites are inactive or the inhibition of Aromatase is less than the parent compound.<br />The amount excreted unchanged in urine is 1% of the dose. In urine and faeces equal amounts (40%) of 14C-labeled Exemestane were eliminated within a week.<br />Special populations<br />Age<br />No significant correlation between the systemic exposure of Exemestane and the age of subjects has been observed.<br />Renal insufficiency<br />In patients with severe renal impairment (CLcr &lt; 30ml/min) the systemic exposure to Exemestane was 2 times higher compared with healthy volunteers.<br />Given the safety profile of Exemestane, no dose adjustment is considered to be necessary.<br />Hepatic insufficiency<br />In patients with moderate or severe hepatic impairment the exposure of Exemestane is 2-3 fold higher compared with healthy volunteers. Given the safety profile of Exemestane, no dose adjustment is considered to be necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Toxicological studies<br />Findings in the repeat dose toxicology studies in rat and dog were generally attributable to the pharmacological activity of Exemestane, such as effects on reproductive and accessory organs. Other toxicological effects (on liver, kidney or central nervous system) were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.<br />Mutagenicity<br />Exemestane was not genotoxic in bacteria (Ames test), in V79 Chinese hamster cells, in rat hepatocytes or in the mouse micronucleus assay. Although Exemestane was clastogenic in lymphocytes in vitro, it was not clastogenic in two in vivo studies.<br />Reproductive toxicology<br />Exemestane was embryotoxic in rats and rabbits at systemic exposure levels similar to those obtained in humans at 25mg/day. There was no evidence of teratogenicity.<br />Carcinogenicity<br />In a two-year carcinogenicity study in female rats, no treatment-related tumours were observed. In male rats the study was terminated on Week 92, because of early death by chronic nephropathy. In a&nbsp;two-year carcinogenicity study in mice, an increase in the incidence of hepatic neoplasms in both genders was observed at the intermediate and high doses (150 and 450mg/kg/day). This finding is considered to be related to the induction of hepatic microsomal enzymes, an effect observed in mice but not in clinical studies. An increase in the incidence of renal tubular adenomas was also noted in male mice at the high dose (450mg/kg/day). This change is considered to be species- and gender-specific and occurred at a dose which represents 63-fold greater exposure than occurs at the human therapeutic dose. None of these observed effects is considered to be clinically relevant to the treatment of patients with Exemestane.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core<br />Mannitol<br />Cellulose Microcrystalline<br />Crospovidone<br />Sodium starch Glycolate (Type A)<br />Hypromellose E5<br />Polysorbate 80<br />Colloidal Anhydrous Silica<br />Magnesium stearate<br />Tablet coating<br />Hypromellose 6cp (E464)<br />Macrogol (400)<br />Titanium dioxide (E171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.<br />Do not store above 30&deg;C. Store in the original pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Areksa is white to off-white, round, biconvex film coated tablet debossed with &#39;E25&#39; on one side and plain on the other side.<br />Areksa is packed in blisters and is available in different pack sizes (15, 20, 28 30, 90, 98, 100 and 120 tablets per pack).<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Accord Healthcare Limited
Sage House, 319, Pinner Road
North Harrow
Middlesex HA1 4HF
United Kingdom
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2017 (SA)
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="data:image/png; base64,iVBORw0KGgoAAAANSUhEUgAACSMAAAZ2CAIAAADVZbb1AAAKQ2lDQ1BJQ0MgUHJvZmlsZQAAeJydU3dYk/cWPt/3ZQ9WQtjwsZdsgQAiI6wIyBBZohCSAGGEEBJAxYWIClYUFRGcSFXEgtUKSJ2I4qAouGdBiohai1VcOO4f3Ke1fXrv7e371/u855zn/M55zw&#x2B;AERImkeaiagA5UoU8Otgfj09IxMm9gAIVSOAEIBDmy8JnBcUAAPADeXh&#x2B;dLA//AGvbwACAHDVLiQSx&#x2B;H/g7pQJlcAIJEA4CIS5wsBkFIAyC5UyBQAyBgAsFOzZAoAlAAAbHl8QiIAqg0A7PRJPgUA2KmT3BcA2KIcqQgAjQEAmShHJAJAuwBgVYFSLALAwgCgrEAiLgTArgGAWbYyRwKAvQUAdo5YkA9AYACAmUIszAAgOAIAQx4TzQMgTAOgMNK/4KlfcIW4SAEAwMuVzZdL0jMUuJXQGnfy8ODiIeLCbLFCYRcpEGYJ5CKcl5sjE0jnA0zODAAAGvnRwf44P5Dn5uTh5mbnbO/0xaL&#x2B;a/BvIj4h8d/&#x2B;vIwCBAAQTs/v2l/l5dYDcMcBsHW/a6lbANpWAGjf&#x2B;V0z2wmgWgrQevmLeTj8QB6eoVDIPB0cCgsL7SViob0w44s&#x2B;/zPhb&#x2B;CLfvb8QB7&#x2B;23rwAHGaQJmtwKOD/XFhbnauUo7nywRCMW735yP&#x2B;x4V//Y4p0eI0sVwsFYrxWIm4UCJNx3m5UpFEIcmV4hLpfzLxH5b9CZN3DQCshk/ATrYHtctswH7uAQKLDljSdgBAfvMtjBoLkQAQZzQyefcAAJO/&#x2B;Y9AKwEAzZek4wAAvOgYXKiUF0zGCAAARKCBKrBBBwzBFKzADpzBHbzAFwJhBkRADCTAPBBCBuSAHAqhGJZBGVTAOtgEtbADGqARmuEQtMExOA3n4BJcgetwFwZgGJ7CGLyGCQRByAgTYSE6iBFijtgizggXmY4EImFINJKApCDpiBRRIsXIcqQCqUJqkV1II/ItchQ5jVxA&#x2B;pDbyCAyivyKvEcxlIGyUQPUAnVAuagfGorGoHPRdDQPXYCWomvRGrQePYC2oqfRS&#x2B;h1dAB9io5jgNExDmaM2WFcjIdFYIlYGibHFmPlWDVWjzVjHVg3dhUbwJ5h7wgkAouAE&#x2B;wIXoQQwmyCkJBHWExYQ6gl7CO0EroIVwmDhDHCJyKTqE&#x2B;0JXoS&#x2B;cR4YjqxkFhGrCbuIR4hniVeJw4TX5NIJA7JkuROCiElkDJJC0lrSNtILaRTpD7SEGmcTCbrkG3J3uQIsoCsIJeRt5APkE&#x2B;S&#x2B;8nD5LcUOsWI4kwJoiRSpJQSSjVlP&#x2B;UEpZ8yQpmgqlHNqZ7UCKqIOp9aSW2gdlAvU4epEzR1miXNmxZDy6Qto9XQmmlnafdoL&#x2B;l0ugndgx5Fl9CX0mvoB&#x2B;nn6YP0dwwNhg2Dx0hiKBlrGXsZpxi3GS&#x2B;ZTKYF05eZyFQw1zIbmWeYD5hvVVgq9ip8FZHKEpU6lVaVfpXnqlRVc1U/1XmqC1SrVQ&#x2B;rXlZ9pkZVs1DjqQnUFqvVqR1Vu6k2rs5Sd1KPUM9RX6O&#x2B;X/2C&#x2B;mMNsoaFRqCGSKNUY7fGGY0hFsYyZfFYQtZyVgPrLGuYTWJbsvnsTHYF&#x2B;xt2L3tMU0NzqmasZpFmneZxzQEOxrHg8DnZnErOIc4NznstAy0/LbHWaq1mrX6tN9p62r7aYu1y7Rbt69rvdXCdQJ0snfU6bTr3dQm6NrpRuoW623XP6j7TY&#x2B;t56Qn1yvUO6d3RR/Vt9KP1F&#x2B;rv1u/RHzcwNAg2kBlsMThj8MyQY&#x2B;hrmGm40fCE4agRy2i6kcRoo9FJoye4Ju6HZ&#x2B;M1eBc&#x2B;ZqxvHGKsNN5l3Gs8YWJpMtukxKTF5L4pzZRrmma60bTTdMzMyCzcrNisyeyOOdWca55hvtm82/yNhaVFnMVKizaLx5balnzLBZZNlvesmFY&#x2B;VnlW9VbXrEnWXOss623WV2xQG1ebDJs6m8u2qK2brcR2m23fFOIUjynSKfVTbtox7PzsCuya7AbtOfZh9iX2bfbPHcwcEh3WO3Q7fHJ0dcx2bHC866ThNMOpxKnD6VdnG2ehc53zNRemS5DLEpd2lxdTbaeKp26fesuV5RruutK10/Wjm7ub3K3ZbdTdzD3Ffav7TS6bG8ldwz3vQfTw91jicczjnaebp8LzkOcvXnZeWV77vR5Ps5wmntYwbcjbxFvgvct7YDo&#x2B;PWX6zukDPsY&#x2B;Ap96n4e&#x2B;pr4i3z2&#x2B;I37Wfpl&#x2B;B/ye&#x2B;zv6y/2P&#x2B;L/hefIW8U4FYAHBAeUBvYEagbMDawMfBJkEpQc1BY0FuwYvDD4VQgwJDVkfcpNvwBfyG/ljM9xnLJrRFcoInRVaG/owzCZMHtYRjobPCN8Qfm&#x2B;m&#x2B;UzpzLYIiOBHbIi4H2kZmRf5fRQpKjKqLupRtFN0cXT3LNas5Fn7Z72O8Y&#x2B;pjLk722q2cnZnrGpsUmxj7Ju4gLiquIF4h/hF8ZcSdBMkCe2J5MTYxD2J43MC52yaM5zkmlSWdGOu5dyiuRfm6c7Lnnc8WTVZkHw4hZgSl7I/5YMgQlAvGE/lp25NHRPyhJuFT0W&#x2B;oo2iUbG3uEo8kuadVpX2ON07fUP6aIZPRnXGMwlPUit5kRmSuSPzTVZE1t6sz9lx2S05lJyUnKNSDWmWtCvXMLcot09mKyuTDeR55m3KG5OHyvfkI/lz89sVbIVM0aO0Uq5QDhZML6greFsYW3i4SL1IWtQz32b&#x2B;6vkjC4IWfL2QsFC4sLPYuHhZ8eAiv0W7FiOLUxd3LjFdUrpkeGnw0n3LaMuylv1Q4lhSVfJqedzyjlKD0qWlQyuCVzSVqZTJy26u9Fq5YxVhlWRV72qX1VtWfyoXlV&#x2B;scKyorviwRrjm4ldOX9V89Xlt2treSrfK7etI66Trbqz3Wb&#x2B;vSr1qQdXQhvANrRvxjeUbX21K3nShemr1js20zcrNAzVhNe1bzLas2/KhNqP2ep1/XctW/a2rt77ZJtrWv913e/MOgx0VO97vlOy8tSt4V2u9RX31btLugt2PGmIbur/mft24R3dPxZ6Pe6V7B/ZF7&#x2B;tqdG9s3K&#x2B;/v7IJbVI2jR5IOnDlm4Bv2pvtmne1cFoqDsJB5cEn36Z8e&#x2B;NQ6KHOw9zDzd&#x2B;Zf7f1COtIeSvSOr91rC2jbaA9ob3v6IyjnR1eHUe&#x2B;t/9&#x2B;7zHjY3XHNY9XnqCdKD3x&#x2B;eSCk&#x2B;OnZKeenU4/PdSZ3Hn3TPyZa11RXb1nQ8&#x2B;ePxd07ky3X/fJ897nj13wvHD0Ivdi2yW3S609rj1HfnD94UivW2/rZffL7Vc8rnT0Tes70e/Tf/pqwNVz1/jXLl2feb3vxuwbt24m3Ry4Jbr1&#x2B;Hb27Rd3Cu5M3F16j3iv/L7a/eoH&#x2B;g/qf7T&#x2B;sWXAbeD4YMBgz8NZD&#x2B;8OCYee/pT/04fh0kfMR9UjRiONj50fHxsNGr3yZM6T4aeypxPPyn5W/3nrc6vn3/3i&#x2B;0vPWPzY8Av5i8&#x2B;/rnmp83Lvq6mvOscjxx&#x2B;8znk98ab8rc7bfe&#x2B;477rfx70fmSj8QP5Q89H6Y8en0E/3Pud8/vwv94Tz&#x2B;5fBhlYAAAAJcEhZcwAAHsMAAB7DAbyXl9oAACAASURBVHic7N29ruzIeahh6mAiJw58B0qcK1jYoWBAd&#x2B;BoLsHAzgRBgGIBgqFsAF/CROcOBBgKN3bg/CS6gxM4cSRgO2i71cOf6uLHIvkV&#x2B;TzRzFrdbPbv6uK7q/izb9&#x2B;&#x2B;DQAAAAAAAMBK/&#x2B;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&#x2B;P&#x2B;gt/&#x2B;fp1vz0BAAAAfvbt27ez9wEAAJi31NXeJrSaIKfDAQAAwEZKGwAAZBHuak1uZb9bBAAAgKtS2gAA4BzHdLW13nY4EQ4AAACelDYAADhCzq62islwAAAAMKK0AQDALi6Q1lYxGQ4AAIAbUtoAAKCBu3W1VUQ4AAAArkppAwCA1XS1VqxICQAAQNeUNgAAeENXO4vJcAAAACSntAEAwE/oal0wGQ4AAIAMlDYAAO5uttmINP0S4QAAADiM0gYAwL2YsnZzVqQEAACgIaUNAIBr&#x2B;v43v/jxX/9DV6OeyXAAAACspbQBAHAR3//mF3/583ezv/r5L/86&#x2B;smP//of&#x2B;&#x2B;8R1yHCAQAAMEtpAwCgV0vxY9rVVhHhWMuKlAAAALeltAEA0IfFdSD/9Ifxj/7&#x2B;n6YX&#x2B;/43v9i4AwocASbDAQAAXJvSBgBAUivSWqV9CtwgwhFlMhwAAEDvlDYAAFJo39VWEeFIxmQ4AACALihtAACc4OSuVm&#x2B;uwA0iHAcqJDelDQAA4HRKGwAAu&#x2B;umq62yW4RT4G6uPJvtWdc&#x2B;fXwobQAAAKdT2gAAaOyaXW0Va1GyRmVam15LaQMAADid0gYAwCZJutr3v//1Ybf14&#x2B;/&#x2B;GLymtSgZhiGa1qYbUdoAAABOp7QBALBOhrR2ZFerFy9wg7UoL65JWptuU2kDAAA4ndIGAECJrtZE8whnGlxy5bQ2ROva6CaUNgAAgNMpbQAA/E2GrjZcIq1VyjkNbhDh1jsgrU1vUWkDAAA4ndIGAHBfSbra5//3d4//&#x2B;P//91&#x2B;OvN3kRLjkjk9r0x1Q2gAAAE6ntAEA3EW2rlYguRUocGc5Pa2NKG0AAAAZKG0AAJfVUVqrJ8IViHBtZUtrI0obAABABkobAMBFXLKr1VPgykS4GsnT2ojSBgDQ3NsvhA&#x2B;&#x2B;hgGvlDYAgC7dvKvVU&#x2B;DK0ha44ZAI11daG1HaAAA2WhxVLX/LqklxvqTB3ShtAAAdSNLVhh7SWiUFrmxTgRvyToPrOq2NKG0AAKsEulqrm9jjtoA8lDYAgHRu3tV&#x2B;&#x2B;Pg0DMPnr1&#x2B;Ov&#x2B;kHEW5qa3h7dWyEu/DBDqUNAKDggK62islwcGFKGwDAye7c1R5RrcYjvL1e/vgUp8C17G1TjQrcX/78XfkClzl&#x2B;obQBADxl62prXfjfh8EdKG0AAEe7fFqb7Wefv34Z/Xz6k&#x2B;1OmQl3qwK3b2xbUoxw90lrI0obAHBbvXe1VUyGg/zeDEoBANjo8l2t0jSqPVeJbN7bDvYP//xvS7&#x2B;6VYTb0X/&#x2B;&#x2B;&#x2B;v/ffrVb//3P&#x2B;eHMz//5V933iEAAA41O6q6SV4q383HI1OocTd5lOBc5rQBALR0567WNpg9Z6etXWGylentNtx&#x2B;pwXunAltP0lr814PH0xXm5yevO0azGkDAK7qVlPWdmVRSjiG0gYAEJenqw3t0tp0jcf6Cx/jsCUi19677TuWsMCdUtfep7XXt9hP15ZU2gAA&#x2B;qKrnUKEg4aUNgCAWpfsaq9is8cOm8p2yjnYZgXu8sadP7LAdZDWRpQ2AIB&#x2B;6Gpd0OFgFaUNAGDR/MkArtLV3rr2fLXtNj4&#x2B;re7p9giXc03IFW80pQ0AICtd7XpEOJhS2gAA/sclp6wVatCo9JzS1V511NhGwg/drne5UOC6T2sjShsAQA66GuUO55XAVX139g4AAJzjkl1tlbPS2sFF7YePT2tvcfaRKWwkcCq7Ax6Ef/jnf/vbPvzjf&#x2B;19c7P2SmsAAOQgrTFSeOo/fXzocFyVOW0AwC3oasNL8vn89cvGM42Vrz6dLXfWfLVw5Vr1&#x2B;ARKW&#x2B;VuhN0rrZnTBgBwiKVR1c9/&#x2B;dfnf1/1qxd7E&#x2B;HomtIGAFyQrnbuUpBJ1oE8fT3MguYPUc60NhzzplPaAAB2UNPVVrnqtzL25sxw5Gf1SACge6m62rBbWpt2o&#x2B;kks7f95nGBtgkqSVebik3da3jru27/1mkNAIDWqkZVP/0XTg/Tf&#x2B;e0pHBJEY6CckgrL0opwnEMc9oAgP6kSmuHTVnbGI2e4aewoGLlTaRNa0ta9bbpHT9yZUhpbZE5bQAAK7UfUm2LcAVX/S7HAUyG4zBKGwCQ3YW72uuJ0wLXWqVc2mqu2KNWefJ4Z3W1oYu0NqK0AQAUnTmkmitwQ4sId9XveBzGmeFoSGkDAHJJ1dWGfaas1eeftaVnv8lbmb3e69Ger3pAzr3X0lqc0gYA8FPZRlXzTIMjjelbxjdtVlHaAIAzZRsBHrYU5KsDJpm9vYlTIlPDxSo3zvM7hbTWjNIGANxbtlFVAyIcOyunNd&#x2B;0WUtpAwCOk20EeEpXe2o1/&#x2B;wpz0S0mrs2u7fNH5O3t3gkaW0vShsAcCfZRlWHshYlUatmrfmmzVrfnb0DAMBlJRwBnpvWAqZxqNCiRr86JiyF29jSFZd226y1VS6e1gAAbiPhqOpM//nvsz/&#x2B;8Xd/3DgNrnBJEa5Ts&#x2B;8d/YydKG0AQDPZBoFdLAW5x9Z2zUu7TjsrOH1GWg1pDQCALbINqXoyF&#x2B;GWCtwgwl2RtMaJlDYAICjbIHC/rvbalnL2ngxp7bkPB5x2Lg9pDQCALebbgC9yDa2cBjeIcP2Q1shDaQMAqmTrasNRU9ZG3ehtRvr89Utg1tejNq1dUPEA011auoNvd/55AWktRloDAOhdwlHVre22FmXhwgrcFtIaaf3s27dvZ&#x2B;8DAJBOwhHg6adYi/Wz7WstdtSlZu9sR/s/S1rrwE&#x2B;Pg0wPalz1cIbztANAcglHVWy1eRpcwVW/tW5xVlrzTZu1zGkDADKOAM/qaoGVDwtXSXiWtV31u&#x2B;evpDUAAAISjqpoz1qUOzNrjU4pbQBwRwkHgT1OWVu61tqpbNcIVJ06sasN0hoAQLcSDqk4mbUoQ6Q1rkFpA4DrSzgIPL2r1QusAJl8EcWau5Nnb5uT1gAAWCvhkIqezEW4O0&#x2B;Dm76hpDV6p7QBwNUkHAT2shTkVJPglKpaVT4m04uluherSGsAAKw1P8/GNzfaus1alNIal6e0AUDfEna1oaspa2V3O9FawQ8fn3q5X9IaAACr5BxVcWtLEW4hkjVZi7Kw/bWkNe5GaQOAnuQcAZ7Y1ZZKWH0Tmr1kIbDlqU2xNSpfL7B9zl8S0hoAAPVyjqqgyp7T4AoXflvgpDVu7mffvn07ex8AgHk5R4AJu1rBIyw1TEqnlLbwHd94K3my4kjytDac/Sa9nZ8eU5geHch8jootPn18OH4BAG/lHFXBoVpEuJG//Hk8h&#x2B;dKX01902Ytc9oAIJGcg8D8S0GOglDzdQ5PD06fv35ZG9tGl6&#x2B;5C6ffzQJpDQCAGjmHVHCyFmtRTtPaz3/51/J24D7MaQOA0&#x2B;QcBCbvaquCU81KiZnz0lsb5&#x2B;plvu/SGiuY0wYAd5VzSAVX8Pf/NPv&#x2B;&#x2B;vL16x2&#x2B;b/umzVrmtAHAQXIOApN3tYdwT7rMeciWrE1lowek&#x2B;eS/Lc5Na4PTrZ3k&#x2B;9//&#x2B;vnfP/7ujyfuCQDQhZyjKriG2THRlz/9YWnxSeBJaQOAXeQcAZ7b1eq7V&#x2B;DkatNidMlJbBuluu/S2j29prWlX0luAMBDzlEVXMZiWgNWUtoAoIG0I8AT09qW&#x2B;WRvr9v7WcdmFe51d/dl6vSuNkhrJymktcJVxDYAuKG0oyq4DGkNdqK0AcBqSyPA4exvqKcvBRmra8&#x2B;MVH/15yVPTFDlvW27Yz1GOGntzgJ1bboFsQ0Ark1XgwNIa3AMpQ0A3ss5CGze1damo8ow9vnrl/IlZ38byG8HK9&#x2B;v6a92SmJ5zrUmrd3Z9rQ2u02xDQAuI&#x2B;eQCq5HWoNTKG0AMJZ2ELhrWvv89cvadDRUVLTpFSsT2tK1jjd6lF5/tbRXs3etPC9t7UnsMpDWbu70SbQAQFpph1RwPdIaZKC0AXB3aQeBbY9i1/ewR8h5/G9sOlpgTwr57ZSwtHS/ng9L&#x2B;erlC0w33uS8dAeQ1m7u&#x2B;LRmWhsA9CLtqAquR1qDhJQ2AO4l7Qhwp0PYG0vYUvdqvqLjs2AlSUqFu7lq/ll5U2&#x2B;vdTpp7eYyzFoT2wAgobSjKrgkaQ3yU9oAuLLMI8BjDmGvzUJvFWak9bj&#x2B;YVmT/aw/m93229pOWiNDXQMAUsk8qoJLktagO0obAJeSdhB44sHryvOibblufX5L0pPWaj6Hb0jzUEhr5E9rprUBwJHSDqngwqQ16J3SBkDH0g4Ccx65DixjuPacaqPrNlkN8vVWjq9TTRpbkqj2IK0xZP2MAgCOl3ZIBdcmrcHFKG0AdCPzIPDcw9ZLZ1ObVVN9Vs1gOzIjnVvdVsmze9Iaw9mfUQBAEpmHVHBt0hpcm9IGQFKZB4HZulrlZerbz/SSSzd6QE9aOtXcMbtU/1A0v&#x2B;kwaY3h7I&#x2B;p5iwgCQAxmUdVcG1LYyLvPrgkpQ2AFDKPAJMcsN6&#x2B;jOGW/HZYQ1rVz04pcEvlb&#x2B;mm937oMnS1QVrLIcmHFQBwlsyjKrg8aQ3uTGkD4ARLI8Ahx3fQTo9WLxWdVUtBFrazq7cdcafQOITu76qHuvlim9IaT51&#x2B;WAEATehqcC5pDXhS2gA4QuZB4OmHqusbUmE21artVO7PkcntcVuFOWHb713NKpQb7/Lbq8fuRS9pbcjxjr620z&#x2B;vAICzZB5SwU1Ia8ASpQ2A9jIPArMdp16VXlq1tIe3BeuHj08Hz28r3Nza3jbtakuz915/vvddrty4tMarbJ9aAMABMg&#x2B;p4D6kNaCS0gbAVskHgacfpI7lsdcks3YL05yz6nxmhe2EFW6rNj6tfBBWNblVW96DtMar0z&#x2B;1cvr&#x2B;97/&#x2B;8Xd/PHsvAGAXyYdUcB/SGhCjtAGwTvJB4B5HqAtLGlZeuMmN1re3x29fL185IWy/5lTYgcoI12QNyQxR7UFaY0RdA4BbST6qgvuQ1oAmlDYASpKPAHc6Nl2Tc1qdzGxtP1u67trbOsXsDqw981zhXixt6vQ7PkhrTEhrAHAfyUdVcCvSGrAHpQ2Av1kaAQ5pvnTuemw6dg6wjbOs3vaztudmO1FgDcy3c&#x2B;BGj1XhKsfHNmmNEWkNAG5CV4NUpDXgAEobwK0lHwQefGC6fn3CXevXaOMZ5mNtF3jElhrk689fE9rpSVJaY0pdA4DLSz6kghuS1oDjKW0AN5J8EHjYKdZqrOo3axdFrLyVazS2hh5dbdTbTjz5nLTGlLQGANeWfEgF9yStbfF49DxWsJHSBnBZyQeBex&#x2B;PbrWoY/k8avVnWSu7dlTb45G57WqQg7SWj7oGABeWfFQF9yStAdkobQAXkX8EmO1g9DTVFM4K9rjwUt05fd3CEzW/73miY560NlTUtTzv9DvI9mkGALSSf1QF91QYEHl7AhkobQBdWhoBDmm&#x2B;ZZ5&#x2B;JLpw0rXCNKmlbvR6PrDnT1bdbp6A1NbGWX2pHhZpjSWnf6ABAHvQ1SAtaQ3oi9IG0Ifkg8C0h6HXhpxybKvZwuscuMuovFPlCyxNGTzxsZLWKEj7sQYAxCQfUjFSs2T6q8fzOLqWJ7cj0hrQNaUNIKP8g8CGx6BXTTs7QCG2vb1i853J4PlohCNintU1pTUKpDUAuJL8Qypere1qhS14inshrTX06Ve/jT1o2996wIPSBnC&#x2B;/IPA/Q5A108gO7Jj1cS2q3a1qdF6mK&#x2B;PTOW57t5ufD/SGmXqGgBcQ/4h1Z09GsDSl&#x2B;HZ56hw&#x2B;cotkJC0tqvZ2PZ4zN8&#x2B;vB5/2E5pAzha/kFg80PPTaY0Hdzepqcfu09amzV7/rmEk/&#x2B;kNcqkNQC4hvyjKl4VvhjP/qr8Rdqz3AtpLYnCjDdPBLSitAHsq4sRYNtDz4ctFXhYAOuusdU8BbE7FZjEZtbaq1Rv/JuQ1gDgAroYVfGq4ZJ0nuWOSGs5efDhAEobQEtLI8Ah0zebU7raKLdsqXHdda&#x2B;cWp0e7/inQ1rjLXVt6oePTz48AeiFrtaFtS3t8fRZE/JipLUj1SwFObrMqoVYgS2UNoBN8g8Cdz3iXB/M3q79WNjUlY4Olx&#x2B;x0&#x2B;9pzmPx0hpvSWtlh001BoCA/EMqmpBkrsHzeLrCUpCz3l648lxuQJnSBrBCF4PAI484V1aZ2YO8ox8mDDx7&#x2B;Pz1S&#x2B;GQ92voCje5VYfUcz7sfaW1IdknwE1Ia/VkNgBS6WJIxdSu02Ic6M9MWgOoobQBLOpiENjF4ebAyb36teUcaT98fKp8ZMIPYMK0lqqr3bFiQwAAIABJREFUDdJaYl183AEAr7oYUrGkEMCmP9RjLsNTmdZjKchVz8Lz2fTcBXz6&#x2B;Pjy9evZe0E3lDaA/9HFIPAyB5oT9p5WHnetXMLerqW5xy7lIa1R6TKfeNs9PzTWvp0v/M8aAMipi1EVS2a/GNf/8MnT3Z2lJ9RTmc3bZ6Rwgddn2TMLzSltwE0tjQCHZF84Mhxorj9Qm63oNFe/ouPa1R3bHg3P9kRIa9TL8KGXTfjzQWYDYG&#x2B;6Wr&#x2B;arAbpie6XtNajwgS1x3S3w/cI&#x2B;BulDbiLLgaBeQ4xx47PXv7Ua2/Psla5kS1Xr9zauaQ16uX53AMAyroYUjFrj0Pwnve&#x2B;WBPyPp7rvr4&#x2B;6aMXwOsqlCodNKG0AdfUxSAw7fHlQvJ5dp2aLHTwGomVau5dwdrJauGLhXfjFNIa9dJ&#x2B;9J3ih49P576dw&#x2B;tSAnB5XQypeMvctduS1vZWOJHhiZ7P&#x2B;&#x2B;gF8NjPUXub/hAIU9qAK&#x2B;hlEJjn&#x2B;HJ58tnSzK3yjK6aC5w46W1tBgvs29u7H5bwCLi0xip5Pv2SyLCu42gfHv&#x2B;b8NMGgGP0MqRilpzGIK3dyeuMtNHPy1ccpTWNDRpS2oD&#x2B;9DIITHJkee3ks8dh1tjB1sxndCtksNmdWXXh2d9uOZKe8GC3tMYqST4AWZIh9QFwol6GVAwLE1MCpgvEmc7SO2ntLK3eNUvBrJXXd713OuxNaQOy62UQmO2wcvgo6h6HX5N0o7WLQ84&#x2B;FK2W1gzs28GkNdbK9jHISM2stdNXswRgJ72Mqpgqn2zpeZnpD6enZVra/rYd5DjS2pU8ns1Wse352ngt6OoaHElpA3JZGgEOyb445jmgPJ2OdozRbZ21G/sJ1LJVV0n4KElrrJXnk5CpwieSCW0Al6erXcCqQ&#x2B;Sx/Lb3fBq2k9Yyy/kUrProeGa5nPcF&#x2B;qK0ASfrZRC40wHlt4c7l3rM0nSr5&#x2B;Uf/xE&#x2B;nLr26gm70UaVJ12rXC4y5&#x2B;MjrbGWtJbQ9f6hAwBr9TKkYknNqZXWzk1Zeva9KpKT1rrwfEtuaVRNNjKsn7i21OC9wGAjpQ04VC&#x2B;DwDxHk0fx5u1R1NHCX29XCQv8qmY3rqGcG6cPQvKHJVtXG6S1TuT5PMzp3OUWRx9QTXbGApIAyfUypOKpfKK1t2Xl069&#x2B;W5PiNuwgZ5LWDtYqKQX69/C/T/dzB9ZuZHpuxY1jastLQkNKG7CjXgaBJx5Hnh7NLCeumllWFz7R2in6ve/SGjHSWr1zl2F8O7m5xsYJ0ADsrZchFSOF7731h7br14SkI9La6Xqcv9VqViuwH6UNaKajQWDm48iF858df&#x2B;v0RVojLPOn4ikuPK/LlGWAzHo5azVvxea7vN1m2w1yDGntPlo1vNftVH6SbLldr0NoQmkDgjoaBOY5grw9m1WePGx0lbc74NBqp6Q1wvJ8MKay6gM24YS256/Wfqo//rj4WwBwvI7&#x2B;tSJLAkVtugTc669G68vRHWntDqbP8vOka8O7J7oc5FYtDrnxFbXHvwmA21LagCq62katDsg&#x2B;tlMTz6YX&#x2B;Pz1i6OovZPWCMv52div5pntdYM7fVbPLhT5DGz&#x2B;QAAcQFe7nthB6vKykF4P3ZHWGFlqac&#x2B;y9bhAuNM35CW65MvXr4VjoTCltAHzOhoE5jl8PHvgdY9jl6MbervgpOOn/UqY1ob9/2EdreT5eKRsqX5tUT8HevpvOABooqMhFW&#x2B;1mvbh2b&#x2B;G8uvBs7yrDJM&#x2B;lya0bdzI01KlW3sTwJGUNmAYuhoEpjpwXHMQ83kEMzABYtXctdlr0R1pjS1SfUJSafbjvRzbpv/eYvscO70NYKOOhlTUqPkCvOrYuldC16S1bGYnjT2fpuOfkemSsLFztlnLEfqltMEddTQITHjUOFy8Atns3JMAcYxO09qQ8hPjhhJ&#x2B;SPJUnn/cVpPYNjSaTgdwBx0NqVilPMukfP6k0QW8GLomrSVRH882NqrXMFa&#x2B;0bdz0Z4XiMU2oFNKG1xfX4PA/Y4avz0EWXls8Xmx&#x2B;hOkTbc/va1VR0gdBu2atMZG6lp&#x2B;gWlqYbPbLNxWqyYHcCsdnbWaGrORbPQf00uW09rjil4P/ZLWutZkKtj03Gk1qex5mT0mucbO5QacQmmDq&#x2B;luEHjAIeMmE8imhyzfnh2tvP3CjDcuRlpjI2ntns6aXmZaG8DQ279W5FVhMkrhC/Dsr7786Q9vl6fzkuiXtNaX&#x2B;vlhbZ&#x2B;7ythWv7X6G9XYoC9KG3Svx0HgwUeNG57Apnwrqy7/egHHNK8kZ1cbpLXeqGtv5QlCozOcFT7/d91nk9UAwnocUvFWYH6JL8zXJq0lV7lQ5CNBLV1m6eePjcdmko1u7vW/YzGsZjdGW/b6hPyUNuhDYabaQy9/dM86dly/5OPjkoGDleHjm0mOFBMmrdGEtNaL8qf9xr8FsauvvZYmB9ycrta76bnQXo&#x2B;hB5Zxm72818MFSGsdWXqyXqNXILAFduP5SbJ2Gcm3O1M5QvdxBJ1S2qBj3f2tzXAc&#x2B;e2hzL0PPupqFyCt0USGj8R&#x2B;CUVPsYdiS9gD6Iuudm2z51GbXfVx9iqvvCQuQFrrS&#x2B;UktqVrLf0q9kSPkt6qaz1vcVWQq7&#x2B;JthsEdqK0QTem/7Clr7nkqY4p109xe7uFWVaGvBhpjVZSfRL263p96Ky/FHobcD262lWtmqNWbmleDFcirV3DdKLqq7VnLCvkrprtrJ0RO7qt2Vsv38HZDdbM5ANSUdqgJ9O/34X/9Ze4Rv1BxlWHQdW13klrtCKt5Tc6y1pba9dprLl8qzD2PGmc3gb0q7DGvm9E/apfOa1wtqTpoXkviWuQ1q6t/Gb/9Kvfvp3Qls0xe6XGQQZKG3Ssr/D2wz/&#x2B;V9ojzjVT3J6/UtEuSVqjobSfddfQMAi9bqrJZkcbeXasbBEr2/4A1DNlrWvlIWrgALrocgee5QsbLb3Y0HSzayfGPa/VbqeCG3x7lcf9Cj&#x2B;SW5bcBF4pbXAd&#x2B;cNb5tj2sH1VSXohrdFQ8k827qPm34LM/oHzVw/ISVe7tsASbRlGtexNWruVmqUXD7ZlB2aXvtx1N3LO5IN7UtrgsnKGt2feSH5g&#x2B;rmUlhlslyGt0VDyTzBqNGxLs38p6v98bPxDs&#x2B;Xqjz9zMhuQhK52AbMLP7Y6ECyzXZW0dknhmVKF2Pb8PKk81dna2117lVQ2vlMyNE7ondIGd5EtvL1mj7THrGW2rklrtJX2k4qpaTpq&#x2B;HleOKvZ7K0071hLbazmhHPTK&#x2B;76WAEU6GqXNO1qhZOuZVjJjVO8feo90Zfx2m&#x2B;WWk6qxpNnT2o830p97TZcldIGN5UqvI2KiMPZxEhrtOWzqFM1ZeuYWVynzBUrnFXU3DXgREtdbfAt6Fpqvveuqiy9zzLhQVpjycZzjK29oWHhxdbpR83birnk9fINZx7DzSltwDAIb/RJWqM5Hzh9mValpZh0/GrAGbLW7Ow3y0UCxzBl7Q4KX3ofT3T90dvCYnGBHeN00hojTYra9iDUUWYLL79Zv31vQ2hLaQNmZA5vg0Phd5W2qw3SWs98njDsEJ9OT1nhrGjpSCBGV7u8tUeihZa78Yyn8ow0W2rKxhLznClV3k5sQtXbbU4vX9hU4Ypt7RrPtjxfprVBE0ob8F6q8DaY9HYb0hp78InRr7f5qnyB57S2pVOstcpja7ezcb7d4&#x2B;pNdl5mAyrpapex62Hf0bQ2L4&#x2B;Lkdaymb6dt7eT2XhT/7nx2m&#x2B;2t5y2L7nCKSR3cmTK2ns&#x2B;HDBLaQNWE97YibTGTnwsdGR2tcNdb7Ht9jcWr9jV115raVXJwE0Dd6CrXdXz&#x2B;23NEedVc0ReL&#x2B;91chnS2q3MPt2vP2y&#x2B;9uBOIWppytqo/HWd2ZYOyr3tbRaQhLaUNmAr4Y0waY2deON3arYYHXaKtZ1OYJbzvGiv0/s0NuCVrnZ5Nd9yl9rb62FZL4nLk9Z6dPDEqbNeA29vt/fhfP2ktNgz/rq2Z&#x2B;DqwCylDWhMeKNAWmMn3toXUMhRNbFtdPXCQpFH2ililetd4UZHv9LYgKWuNvjac1HT4dh0dcfyXBaLkl2YtMbT6&#x2B;qvTRZabFV0tpyKrMkObFG/Dw331sQ1OIzSBuxLeLu53tPakOMbObO8f/tSnj61UxJ7O59s16Uj6zfe8FxrI&#x2B;auASOmrN3K26&#x2B;7o7Xgphfwwrg2ae3yNj6Ds1cfnQpudmnZ0dqMTYbeq&#x2B;5LtvNEvv5ThvqdGf3LhspT8U3/2YTYBsdQ2oBDCW&#x2B;XJ62xH&#x2B;/QHo3q0R7J5xoBqdWJ02avdY2HCAjQ1a5n6bjq0hfd0eHmVbxOrkdau4&#x2B;dnsq3meftr2q23Eq21/PBa3u&#x2B;vczzb0e2Bwo6pbQBZxLeLkBaY1fehl1bmqTV6tRrSxspzJw7vjkdOV1PUYOb09Vua/vxbi&#x2B;Sq5LWbqjwnG7PKtP5ahvd/Dxh9bPNaiao1T&#x2B;YeWb7wZUobUAiwlsXpDV25Y321vVWAqxsUUlOvVbpgCfIypBwc7oaw7uTq1VelyuR1m7rGcDexpvyBWquHti3tVe5j9EDvqqGVk4xBI6htAF5CW9JZE5rQ/WqCAfsCTH3eSttlKow1ZyQrLzD5ella09aNr3w6Q/Xxvlz9dfV2OAmdLX7WHW0tP7CXipXZTRENrOvt9lJVLeaWVXzVl26TLiilZ8LoC2lDehG8vA2XCUYJO9qg8HkJVzjzbK3tHOVZrPWaD&#x2B;3hK7HptbGtla33lbDPUn4SgD2s9TVBl9yLqf8zbY8AirzUrkqoyGWbF/XcdWZIOtfZrNX13sKHhPdHo/82gfK2x/OorQBvcoW3oZuJ71Jaxygl7fDKfJkoRpnnXots8JjEtvg6EHo8TEB1jJl7W6Wvt&#x2B;Ojmj7GszgZUAjbctWOLNNd&#x2B;MOr97RB3vNXd4S2JYmC75u8w4POxxMaftv9u6e1bLj3vf9RKBkd6DgvABl6sCoAxkWC5zpIHCyERdu1GKz49Ng3xsJwX4DQuxgXzXoxsao04M5iUHYnMSwWGAFAgfbwQW/BAfdiZIblHepup5GPde/qr4fVtC91pxjjjlmjTGr6jeqCsAmCN7SEa1hDDllXrI9YrbirZEh3ZzRexwT4ATkaufI7Sr1doNWjibBilhuDTI1L3iU5DEYQQgMQNIGYE/ygzelaxQhP1HTiNb2QLSWa9eYzX2kSo9CWyhY5q2V8Wmf9xVJ14C9kasd6DIby1qwh6JyAqI19FY8t6R6Vn0JdK&#x2B;BlOp0bY8VRx7ogaQNwBEEBm/KQmFYW0RreyBaq7FWzJbiMrVKXHqt&#x2B;ZFJzLFGfiJEa8DGyNU2lj62zDscjQowTERrGC8lbOsxas2dL/Hw4t170U33mB9&#x2B;wIExSNoAnEhs8LYxeha2Qbq2NCtMGpP3ZL1Kq7hrSpR1GSUSsAH7IVc7ivpYs9oO8XaHd/vYFdEaJLgsZlZC02TWQcp2fDZg62FNBvxxzIHxSNoAgOCtC6K1bRCtbcMNgdLnThw2l2OT7RQEWv3eIOkasJNQrnajVrOvmoXWlPioAnfQG2VpG0RrWB2Le43HFwGwLpI2ALARvJUhWtsJ6drq3LFrnaZkvNxses7UKeu6HMbX9nXNw0LGBmyAIWuHc2v&#x2B;Bf3O7rRp1jZL9gwiEa1huuLF2EzxOwZQw/yAOKrAZkjaAOACwVsI0dpOiNYG86Y7idlVZJsFiVr6sDZT5CmX0yd6HzBmzFzD6Mt9I&#x2B;bGydiAFTFe7VjpddreK&#x2B;tgOURrAHK5k3Mmzi0JQDiSNgDIc3LwRrS2E6I1aaxspu1QsAE5Vk22VL97Vu6l48NQotnkgOiXIFcDNkbFZnXe6mtkzEdodSKqwVCI1iBf80JIqe7BvZgQswGrI2kDgCp7B2/0KWyGdE2sVsOhxo8MU6lV86gpcXifhJRr&#x2B;g4A6Gr1uhy8IlXcyJxpFIYzEa3hKNaNCBTvSomLrvH9AuyBpA0AWlo9eCNa2wzRGpq4nBCy7cs12eCY0BHAflavy53gshc4JRpJHzqgV1nj4z4E0RoORwmfi&#x2B;MPrIukDQA6kt9ZQ7S2GaK1beig6LQhU7nvVx2o3Ge1mkBye8eWQ0CTX5c7QfoQtNBHcPnRuNkbn&#x2B;Y5aBABmIVrC7ATkjYAGEdCZ03iDbxU&#x2B;BZCurYNNRdi1wQocVbG28CIZVjidflGCJMAXJJQlztQ&#x2B;hC00MOIUmCiPACYjosMsB&#x2B;SNgCYZkxnDdHafojW9tM8bfImdpdJ0oDQK/0lcncmN6S0Hk/M5mLYH3CJ4G2M9Jke4/gIjkW0dojENbGAYSiNwFFI2gBAiladNURrWyJd28aA9KIsNNo7VvEeE9K1RBwoIBHBWz23Hps4IWSoAqzHw3HAj0K0BgAABiNpAwChsjprCjYI4YjWcLKy2C80rI2gqJKa13T2XgDrIXhT9DsNvcd4tbZgQkjrhTY&#x2B;ttCI1s7RKTs3ixBFBQBQgKQNANaQeN9u5CkQjmitGHMAmvQR6L3kWyc9JtJsu0EAKHNm8Ga&#x2B;r/Txai5rqbZtjg&#x2B;K0Ro6ymVg32Tj5m8oPACAXCRtALAks&#x2B;rfteGBrkjXysgMkI4N/OJv3BwOVfPBJQ6rOurIA1jaNsFbvCKqflkwLq34kdgV0RrqEdgDAPohaQMAYByitWKi0jW9M00ypM2kj6UrS8UWHau3NPJLYIAVg7esuc2tQWkpWGLtcERrp&#x2B;lx/6i5TfeSRfkBADRE0gYAQF&#x2B;ka5sxYx7175NziJTQK/6YguTMfMrJB78r4kxgriWCN/26KYnIZQ538w03oR/8KERraKVsFGx8DC4AAHEkbQAANEa0lmuh1MQbP9RnEvLfuClxIseupu/A9tQRJm8DhBAevBUsJ5yyHWyPaA1ZQoWhOOw3h7VR0gAAlUjaAACoRbRWxu3EFz5EbOnUoeCodv0gLjeuB66JLQ8AMMvqwRs92sciWjtNqwkhI08vmJa24FkAAFwiaQMAoATpWqVIajVlyJS1P/12QPhQIe8bD03wGHoXuRNCuo9Xu0HGBgAp1grecBSitZO1TbO8qzamFzAWfQQA9EbSBgBAEqK1hqTlTN7RdafFPFnvt/ITdF&#x2B;LpdcAoBXhwRv2lhiuUPAQZ87reKuek5YRbACAAUjaAAAIIl2bpVPQ5R04FQqNrH2Qlg4KZB6u3GFtNwI2eSjzwB4I3tAV0Rq8asIt9dysUWgP331ZvFobAABNkLQBAPATorUQs8&#x2B;9MhHp0X2fsksMXBOCYw4AExG8oRLRGrJcLrEWLyrW4Db36XoLiWEbAACdkLQBAI5GtHZJ5riWy7TGigYjA9cq90Hm8WnucoxafELI0GMAAHMRvOES0Rp60OVq4gpqFFoAQEMkbQCA45CuhTQcuJbyEv1Yr1L/ou4W9PEpmCbxHERrU6gC2fDgM/oTOAfBG25Ea2ezBor1fpWQfgPUst7XxBQQALAckjYAwP6I1iLEpkRm5z5Do4TjE5FD7BkNYEUEb4cgWkM/kekfrYfpf/ebDVLvyZhAEQBwFJI2AMCGiNYipHXErzgH45nBUmj03plHQ6a1ziMAyyF42wbRGrqKFzArVGNxNQDAHkjaAACbIF2LkN//Pn0OxhUDv/FYek0ySi&#x2B;AwQjeFkK0hk5qznTKGwBgJyRtAIBVEa0lktz/XpzTtF1SrnIL02PCkYjWZOpRAo8q2ADqEbyJQrSGKdy5Ii/LmBrW1nVwm9547oWIEwQAkI6kDQCwEtK1pbXqtbe2Y67oFpebHKRvGZiIPAyAQARvgxGtYTxvqUuMzcyiKKpYitoZAMBCSNoAAKIRrc2yVsiUsrfqAQzTwRi6mC10HgFAPwRvzRGtoauss1LCcmu5OyA26gMALIqkDQAgC9HaSDoDCIVPC4VS8bCt7E9AmfiJ0zbG9r4WpRqAcARvBYjWIIoukKrITQzb3CkrXZHd45QBADRB0gYAmI90bYrpffHTd&#x2B;BwHP9WrOFrKfl01zGjNVtWO0/ZADAYwZsX0Rp6W/rkMsOzlJNlrXcHAFgOSRsAYAKitZHMTvOFxqgV9PWvNePlRBylekJOJXc3Ih8uJwiAVRwbvKUPCdrpXcOiisGAj3j6fI&#x2B;anD0BAKAYSRsAYBDSNezayy8kdAnZ9bCP1&#x2B;SD7lpaLj9rwjYAK9o4eCNaQ29uGVNlyVv2vGeT&#x2B;mXlDI2dhF6R8wVINyzdB7ZH0gYA6IVoDZiLTKWJTtmY5NBL8r4BwNLBG9EaRkqfgDQUyA1QGc7pneeUAWqkpOkA4kjaAAAtka6hTCTMED5iTA6ikR62KX7bvBEAsAgP3ojWMIBZzHIL0qyC17Bbn3MHyEI4DXRC0gYAaIOMbT9iu&#x2B;Z1pCR2D0ciYIPGWDQAmB68Ea1hALOj3C3k7u8TZ1msnP4x97kpe2hSe8uJAzTBIDagOZI2AEAtMjZUcgOzxLTgV48PU8I2M88YvwNEKdOFPv0lgq7IThJdA9jPgOCNaA3DxAuw&#x2B;XuzsOmAKlJWZRZOvVcydw/Yg7o4cJYB9UjaAABViNkwWDzJWCLqKLPr&#x2B;1rOZQkctiehHaCoAEBIk&#x2B;CNaA1CFA9Bq1wardKKmR&#x2B;wrshckSpgm3tBAHZC0gYAKETGhiYukwmZscGAQEXmGz/NilOVFodtswaJAsAsWcFbwQaBdJVjSrwzSd6MMim5M51pIYFOJJ/4wH5I2gAAJYjZ0M/hCdPhb397TdIstYVfPT6QjQFAQ/HgLeUpQBlV2IrXOfOWw2EZmzUsJuWk4MQBBgid&#x2B;4xjAzp5Z/YOAADWQ8y2NzfpIfvpegQ4vBggfe3D3nsCAKt4&#x2B;O5L8yfyS5ygSce0dyNloyfj6VrBxu8/&#x2B;SJrT8zXotcemCXlzHWvDPoawskLNMSYNgBAHmI2NHTscBzyDBTwTgvpHdbGam0AAGSJLGV0axqzWS/UZJLS0EbG96Fb&#x2B;0YaDfSTeIJzGgLDkLQBADKcGbNZvdj0X3fF4QW89IXIzdXUWXNsbg0AQKWuiVRoHJs3lGq4J9am4vPFlb1uZJt07gPN5a7maCb6nJLAACRtAIBUxGxoq8ex7RfURRbEYq0sNKTXYMt9olUOzWFtlE8AAHpzk61Ze&#x2B;JyU71WkZ6otwlsryAzi5zs&#x2B;lLAiQw0QdIGAMACQqNYNrPlm8IJrJRrVvjqhm3j96GfV//277N3AQAAP7cv29shbkVc&#x2B;t&#x2B;turkTF28zd6Bh6gagH8aPAvKRtAEAkpw5oE2CUF/56usw5WYA&#x2B;vET37U3Pln6UwAs3hOTQg4AWE7zECvlteJS9qQs9zK3bI1QuVwQzvw9s0ECC9FTznpPTwarAeORtAEArhGzzRKPo1YP2yyh9yJqXI4ZtoV2eKcPBUsQdY4AALAZHT416bnuOoYsZWhd8VJPANLVXy5Cqbn3ke5pnv4SAFp5Z/YOAAAAv417z1u9tVkT9KmfubtxssMPuLn6mvpptWWGbAIAcP/JF&#x2B;qn4LkP330pMJfyvh3vzJa3/3oLAt8FsKL6KCt9C6ELV8rpTOQGNEHSBgC4wIC2KeZmCWb3uvq3jpc69bynb/bwlAXpBaB5EDWRfhfj3xFhGwBgupr0K/eFvP9OeUp86InA7MrcJYG7B6zIum40PLOaXwNJ14DmmD0SABBDzNZQjwWQ&#x2B;k0gKbl7Xb3rruNvrE0x1meKVsVbfXzjP7KCVzQTNXPsWsvdunppmV7927/P3gUAwBw13cHx&#x2B;dZSHlMQR43vvy5&#x2B;RQI2YAlZc9gW3DHApQBogqQNAIDuIl3Y3ixhVpf3mCiiSWrV6RDJ2RMoxWGb&#x2B;7n0XtdQp796GGjlBilaAAC0zZCK54SMPLFseaQmQjum54E0/0pPOlBPp&#x2B;/exKvtGVe2piMj1YCJSNoAAEEMaGvisru8dwCQYvoOmPQRG7BXxS8RGleHroQf8Pohqq32xBXfN&#x2B;ulRV0QAABooncHdJPt12&#x2B;EOSGBrqyhrllPvGWelSpscy8L5j6EHpP&#x2B;EmVPBOAiaQMAoBl3krqGXecNc52J3ejet9DkfaW/qVZvX3jqs42CKDr00TRPteWXJXMKSvIzAMC6cruDrckh07uhcx9vvdxgDFwDxCqI1kLc61LuNS399wCKkbQBAPwY0JYi3j9e1nseWc6tPmxbsat9raFjKx5hmcwPfaECkGXwJKjmy3W6IaATFmkDAERYPc413cc1Q1XMjRQEdWUzxd3oLgdWYC60FjpnL5O59KsElwVgCpI2AIAIh89dFh9uctrRKOA9RA2P21ppH3qQfxpG9jCyal2TdRMBAAhpMqoj8vT4vGqhTTUcglaT85n95qyuBGwpcbbJeBSXcn0gXQOmI2kDAEy2WYBhztU2d092kht0zYoKjooo3LlShTjq1Ks5/qscKAa0AQBuFb3PN2cmyVvRsLNLeuP9MjN60oHmitddc7W6sGRthMsCIAdJGwDAY/rUkUssKVTWT71KaNTD4LnygM20Wq&#x2B;u4UsAABBR2el8wnivHpkfgEQ9zj4d3YXO7vpsj3QNkImkDQCAZuKd1PqvbthmPjFrCrhzhBLKYcHAZUQ6MqLQe0Iusp/eRZ2pUAEAArnDzgpGdSwaWZnd8XSgA9LUBGPW2V15jeL6AAhH0gYAsI0c0Darw7d&#x2B;aaKGe5740nSOT0&#x2B;Vpqd9ioSSoPdB8vDT0Dpk8pklrcfhFVKSUzB1JACcwOx9LujUth4/tzO6rCedDnRAsspRaOqywMUB2B5JGwDgON4u5vrAIHFAm/5v&#x2B;iuuGBXsSmAU0VzuuTB&#x2B;wbaU14oMIZ0uskvmbnd6afMf5m4ILNvEbABwArf32e3Ujvc1m3O1Nd&#x2B;9dClvRKHrHFhOw&#x2B;XcvBu3fsNVAlgRSRsA4CyRPveu0Ze7cWK2EIE9/nKMiUbGh2ethIZqLXEetT3gKW95xY8YALCiUCd1aJCHfnziKBD1MLF902J3DIAoXCuApZG0AQCEKh5kFokiLrueu06FVzZU6Bx0&#x2B;qcbEx2l522Hz3BYoPf8kN5XHPAqDTGgDQBWlztVWv0iRr2XS2PJAAAgAElEQVTzNu/23d0WNZslsKuug8xMBZcm&#x2B;RNFCr87AVgUSRsA4C0jF2nrweqaN8OtrslEwQC1&#x2B;FMOidmW6/2fyyo/PUaebVPw9Lkv9h31LvzjwzwAAHT/ckoHrtkZrad/rAzbbgP73zVz&#x2B;B0910AP1vlVf6Eo0&#x2B;QaBWBXJG0AgGma9IA370a/HHnW6hWP7QQ/7f32IDY9assd1sao0CyrTJvpYkAbACyhVbZUvIXiXu8efeVkbEBvY3J098pmXWrkD1kDMMU7s3cAAIBCL&#x2B;/u0zuRJQxoC3H3bdHO8Uu/enwgZmuL45nlwMO14klHzAYAS8jqa&#x2B;7Xxfzw3Zf0XwO76j2ALLIeZPFLu/PHcpkCDsGYNgCAXF1XTVuO8Knw0JZ3Zsh1hygBiYjZAECa&#x2B;CJkESOnWYt0l5tadZ0DGMA9YaefiYnXkOn7CWAKxrQBAHYWT6eaxHhNNmLuoXdvSRzPFM/VmpcK9&#x2B;VCLzGsQFLyz/Hq3/6dmA0ApHG7lUWtUXT/yRfuYm&#x2B;ugl7v1YehqCOjf2bvDlCr&#x2B;Hy0yn/WSaEeph&#x2B;f8qx1LxoA6pG0AQB&#x2B;8qv//KfZuzCO6sH39uNnDRsaMMaIsOFk5iypZmGTUyrk7AkWRcYGADKFupWFJDfNU8BtusiF56PAYFnl303mWu9Od&#x2B;TrwCwkbQCAOeZOgmdmA51yAuIHFJt1dqy4ple6jd/aolTARsYGAF5dRyMVbFlyClUw0ET/V/1j6eFrFuH5KOCVclEquHCpx&#x2B;uzu&#x2B;FZ0PaiMf76s80VDxCFddoAAFJ416Baeqm2rFW1Qu903bePXN612W5OMNw7h9NzrradGXVuSeY8koNoDQAu9QtFzC1bfdAROo4Sm9acNqtb8eJ5wOruP/miSYEPbSdyoeNEAxBH0gYA2Fz60lM1LxFZzmru6D0sJ1JgRsZFI0&#x2B;Tyz3hJNoAARsAuLxZV8rCY8Wv5f2991XEhmpaqEM85aDJf3dlvAncrm8WwiVm&#x2B;ePLZ/pNA9OjNfMYtooY468CoAZJG4D1jKwHdGrooitpg1f0/qSkBfHHkDdsLPHDXasMjN9bN5aTdkE4CukaAET06F/uMdRp0UaQudv6sCz3Xrx7XjyAr19PPc6UUqIklDq1D/rEcc8gd3bZKfmf&#x2B;V/zuHWd7Nc8LNM/KWB1rNMGYFXcmgcvyb3qahGs3KWwdGywVsSCViQXaUVaydRHbO9l5yRjATYAKFZzn5/bPmo&#x2B;B1rvftjKDuXElZNWaUi6U32azDcbf0f0nqMf79pp5i/jxc982GVBNQv83uM1699XaE0765e7HkBgFsa0AViM1d4oaDa0vVWHgfZlpnfNN9&#x2B;B3JnxcpdwK9opYKaJyy4SsI333/7Pb14&#x2B;fTN7LwDgXOkdpgIXXXMbaOnNq7LRG/IV7OpltkGjFT3UlKv4hUj91bw&#x2B;1Fy4rOdGdnvuhaL3Op2MXQP6IWkDsLbisE3/u9Vquq02dSzVM&#x2B;7Nn5r3zo8MrvRrXb6FyBHA6grK8MSSkLi0IWUVt9uNdA0AGoo3Ui5nPAttc5Xp3fptvGZFt65Cs32GBqMUR2jT3yn2c3nOJpY6c3TasIJqvpDkZLosWcydEFLUjRfA0pg9EsDy0qdJCT1d/zTfEwwmaiDLy7v7MTkEaccGvEuLxSc/7PS5ezdb8FoUy729fPpG/czeEQA4RXweMCuiy&#x2B;rgniixg7vTfk5/&#x2B;4nLrYkdeYPDRUrm9JMrLn5OCRnQlpIF5u5taLlHriRAKyRtAPZUVlcwU7eaLRQ8EWvx5h9mtHAZM5BDnCb&#x2B;iQsJicUWSyHHB&#x2B;MDtkW/Uu/v7vTP7H0BsIwms26Yc6zFHzBY8YpxrXbY6raengSkLKFUsAVADgl9I&#x2B;pkTxz&#x2B;23zqo1yJi9s1fCEAbZG0AdiN99bOyk0NeyI2lpXDYSeJH3d8BBswESPYsljpGmEbgHrT&#x2B;38T9yTeCEoJ27pmYOl97kJc5qYpfwU2oGOw0ISriaZfAVLSx6xLK6c/IArrtAFYjHcK6dD00wOWHAhNac3KbRGXg3sGLNUWefUmj/FqErBZx4dsZjPqA93pI7ZK7LBzGZUm5mpLf4F6c7X7u7uHx8fxOwNgIYlZmvqT2QARssRa5TI/09/CROYiVQVPOfnQYQkNr1G9V3Pst3GLhOu2Rdr&#x2B;AIsiaQOwM291ITQ5dc2rhLYjsAoFV1m/f9tE0HyWd8vmwwgqjrJiNMUIznVNH7jGohEADpc4miF&#x2B;t994kfFqXMwjQneLFj8XkOCyDLvTJC56rcgKvBPfoLcTqcfx4RoCNEfSBmAZKbORqNkA0qsgrVK3yK2I3GyYYnyQ0PsVI2lZ8dOXi1uwFiKxk00P2JQVe1hMkYkiGdYGIEJ4sqK7fcuu0rSDXKt/3wFKWfxj3VaVslhj6IaD3JfuJOVdZE0CnH7HtvVI4d8mwPZI2gBsxa1npNch6lM3BretQlpk5d0faTuJMgXx1YDZU9VLdCpjJHYLERKwKcK7HXWKRmAGYDrrgll//czqI055PA0fabj7EwOUFbOUK5jMouuOzEs5AjXvxdutJLwKDRyFpA3AGtJrD27Ls6AqY1WVmqB5I1nZALImE0iSqGEwXWgb5m2q2HfN2DhTWhGVrmmV69t3ZY1UC41OiwxoA4B0kcZLwVJel68V38LlK1qPEXX1lmz68ESgOXPxyGEv17U8my/hnjuRt1kw/aN3&#x2B;/XvLn2fATRB0gZgSfE6h&#x2B;T2Hs2beF985K/LrVaVEjys9Y6wgbZhmFnIGcomnMyAzatHR0Mxb35WNhUkE0gC6C0xXau8qFpPP7xpU09y0xVI5N4yFQl1itf7kCl3FqXQRbhynt7LXXJH4AFojqQNwIYuq25j2jPxhcqp35jm9tH3e/V42EbMBleowPRLmlO27D6AXG0VSwRsYjsZGaYGYIrcCfDNoSTe&#x2B;fDjva6JG49sCibJR0zUzmAtketJZBG1SH9I6ClZOzNAZG/VJde9YkfeSMoB0Rfeyy2bBzn9ZnQA/ZC0AdhTfMk067/jw7ber4u4y2ghPdK4nEBS/cN6DBkbivWYpNEqsZG0r&#x2B;3ropMl0jWvhb4WLweoPTw&#x2B;EtQBSJc&#x2B;yCN3UjJXVhS00JU5UfO7Hq0p5ty/pne7d2ohhhb22&#x2B;/DRSfpV6fLOSTd35ct9tEqOqo56bxX44IX9d7ToMO2gt0wX6hsDwGUIWkDsK2sW6LS7wYq2w3uIZJGRwtjwgOiNdw6jEvL3WC8tEc2Rca2hEUDNrH9fVk5GaEaNMnDWbCQ0DI/1mO8v7f&#x2B;iq7M4yznmHNPJ/oxS5d1Fcpaqq2miLbtt2l7vnj3Lf0l5FxGABR4Z/YOAMBQKbdWNazc3H/yhfpptcHDlXX3h/KDl3f3nfIDcjVoxYVhcCnqsdwaJ8IYL5&#x2B;&#x2B;UT&#x2B;zd6S9dXsJ1XA3VmXDzagKUhtEhLrcNbno5Za0da&#x2B;048k/l8lcMUComGWVtPrVIgdcuxomebe0dLD52cqymsBgjGkDAI&#x2B;y25pC83JAW2JkTG48oGbbI1TA6tqenuqM4LzoZ79obbkb8C8nkAQsYpckxIoiDY30gZWUw7jiUdfu&#x2B;J7QFtyxQQ3nxAu9FlAvvaCuXvDiM1WGFlRruwPWP8qeDmAAkjYA50qZ3fuyXkKchhtxAjpYIpYO4YzoZL90TSxmg0RvpG7wslY5Spl/TI&#x2B;HK17mDS7v8mnmyknuYXRjuaylpBquO5X&#x2B;iiNfDtvoPTOkNOp8V4P2QlP49rDTMQTOQdIGYEnF3RNWGybSpFnu5no0cZkQECGgLXNAZDxdqxw6qTfee4VCzpHmzgnY&#x2B;OYFgDgmhxzAe5Dj31C9c7L6xM7ceUoFOqFoubKWKeEAAqsjaQOwvIYdc2PuJaT&#x2B;VKMsbFATPJa9IrEBettm9tE93oUc5wRsJrFh28PjIwPdkMIswMx8gALusLbEFop7Q2GvXdxF/eEKZXLl&#x2B;/RfO1OzEffpFAbUiJfGY0tX6LCMH58KQA6SNgA70B1zKcvMus/y/rehY2ufxRKH&#x2B;PR7XWBXNalzaIMNt4bbeQHbEv0Raj02wjYA0litDBod6bzzQ9588VunL6mUdmtx&#x2B;5SSgOYoVP3IrwkDSETSBmATZjskvU2iJ91uvj/URF3x/v3e/fWXAQOBAWpYpSu3OA0Y1tZ20kjOl7ZOS9fixA5rA2ow1g1lIsPauFReqhm15n18q5ajuxF3mTf3kXzi2MASt1iVCU3cylkMnIOkDcA&#x2B;rCmw08O2Jq9OnanMyP76SNhGbIAabrmSOSFkVszmJnMC39HqDg/Y9O385o0yU/foH6yBa2pAW/rjgUvD&#x2B;hnp3VsUuVq9glMs1H70fhwpjU0&#x2B;Mmwga9KgPZS95cg1R19DvNsMpewAVkTSBgA/KWiSUR&#x2B;qMb7j3pqXkuQA9WpGibkj4dyttZrvsSBmu3GO9HFIwFYzNG3pYW2XyRwAoKvQ8mnuN0uT&#x2B;SEjc3he9qGHZlhhrTUgol86lX41aHKjmJCbzAC0QtIGAFW4WXi8JqOFyA/Qm6hhbWUxG9qaGLCFbqTtHWiFtp81bgDY0vjSHn85KrHS8IkMEDnIWV9eZS&#x2B;tT8lQc9J8DOUB0Np&#x2B;e4a&#x2B;jtPP98v5Id16OKOWgV2RtAHYhHVD4pSaCqlbc61G80AOUflTvZTymVWMzTkbJw76RCuSh6&#x2B;p76xOYZvVg5DSxaDo3oqlh7WF3N/dMeLtWFOKdHqeR4f&#x2B;CWZ9uA1nn0spqG6LrFOqfbnZ&#x2B;tOK8xFbqinY9aezt9MmNLo0UeIVqeDpANZC0gZgB7pqklI9SlyRvrK6Q&#x2B;pmITCTrHn6FdqgKgbbTN3Zr1SbB6f3ubPBByGQ5IBNOAlj2kJhWO76bYBVL51bvBP7EA9ckmcijnM69waOymXSCg6&#x2B;ekqrAanMD4mFyLz/qWCXsk7etqmeSeDBBNAESRuAJeXO9ZHy4H7ZGLcJ90ZUUKN5&#x2B;qU3GN/aNnlblshhsf40IJw&#x2B;7eAPIDNgcxv5letJtJpTKzR3FoCG9JierBv2ZXaqYkXFl/fEFc4Kd6unrHWeyLaxCuuMm34Cjl&#x2B;hLesVydGBM5G0AThOqD1D7Wc55ATNbTa1Y43LILBJEmZNLJm4zdxZVd0H8yk3JDNd68rtW3Hne0zp0NfPij9MyLezNaANSCRk9UHz3Iw8TMKu4nChBZPG70mirC&#x2B;&#x2B;yNMB&#x2B;SSciepESzlxQvVVAOiHpA3AoVqNYDOn9q7dp8Mk9vWboQLxgATFadxOM4jOfS&#x2B;VZwTnURMHBmwh6V9/lWtgTETMhhoLFfuui1oBloJpP6wi6u1wT1wpIF3lRsjSsLTQV9jEgn25KJq1&#x2B;pr5p9vbl5H0&#x2B;70KZm7IejyAPZC0AUCb1K15ow4awUBzOi3LTYyypprcdX5I70HTb1N4oLjfxzHYigFbZKWo3K&#x2B;8futVWIr7NXrwxmws0oYskbBNQiG3CNwlzNV8hsOsRdfcQC592HTNHpYt5MaUccAA8Zw&#x2B;PpotfnHgnAVQg6QNwD6aLIfWMHUjb9OEZw9nqv9QvEGau9mlZ6RM3PmaN5g7FWSNdT&#x2B;I6VYM2EJyV4VJ7AANPTjrq5DeDWxMbPHut1AxYNJfEKH5IUOj0wqaVA1bYaHRPAtl50Al90yUWc7r556V&#x2B;b4ALISkDcCS4hWmVsvzVtYmF5osCEeJ5DoFSUxNkLZi8MOaZ&#x2B;fYKV2zFAxlU09J/15r1a/R6gtdCEbCHUvsMBc3LNf/lrOTmKumOVPz3PSbPDoRe9oCU8g5BawBapU7Jud9AdgASRuAPTXvm2s1hQiwmcScaY9xjZcxm/C3ufT4wmE2Dthcl&#x2B;PVCr74cueHrN/UFPd3d8RmSBEqxhJS5DE3ruEQiTGt&#x2B;7CsxT7L9iQ&#x2B;iq7su4azA5AsfQE2AGiIpA0AOpLcSzgLHf3rqomRypaFmyVxPwtitobln1OprW0CttyJlGs60&#x2B;mdBGpMj7K8E4K1HSuAQ2Stu6a4D2he3nK3Fhm9zYkA7IFzGUBXJG0AFmbWk8qmuwltAW0RCcgxPusyP30zb1uuVIQO3YBDah2r3KXdRi4Ft5xtArYmEvtG1ddl73Uv9PbF9vUzrA2XLk8TCcVbndR6N5iPAbkS110LFfWJRS6y1hozqQKi1HxdcgoDGIakDcDCVBMoa/GYSKupppmX2E4DBNLpV0H0VZaWzc3YcnM&#x2B;dWS8SVWT&#x2B;Kps2bzlckpRNk7Xsr5xxiy9Q&#x2B;8G4JI2buyctRJRo6AwdGoKZe1G2ZzGFHtgdZzFAMYjaQOwhkg7Tbf6cutS3nstvVHc5ToWly9B3gbhLpMbIYOi9G6MjJpGvncitH42DthcrToXrDxg5A7ob2Q6SrCHhe6&#x2B;WmhX0VvKuEz978tWT&#x2B;78xhbvZCTxTVGSgQ1YJ3LoS8q8BFF7BDAFSRuArXS68bZmm1T1IIo1PEvnOpdj2hIXWus6UaGQtK8h6x0Rs/VwYMCWOFzG208RukEk0lnp3X79d5&#x2B;0b081UeT93Z35SyaQRJm1oiyGtR2iYQwmROQ77sb9HMDKQrn&#x2B;Qt&#x2B;tALb0zuwdAIBmUlaOsZpS9VUxKnNYTk2c4y66NowVSpWlbvtldbkOOQIvn77RP7P3ZYKyTsOy4Wv9BhM8fPelkN7Ph8fHrDjNSuMALyHFO0T47qE56yug/urdtQhVtr/07sn5ogHQEOc1gFkY0wZgQ1n33pr3b/aLzbgdGKJYIVlW&#x2B;pIVsIUenLtY2mCdRubFD3vXo9F1rKEcZ&#x2B;ZqEZc3oISGtaVsnC81ANhDk8v&#x2B;lMZO4ivyhQXshwFtAAQiaQOwiawb8L0Prq&#x2B;ZxRcnIGzDISKhTmhc2uBV4sQmfChDwFav4Rpse3dzPDw&#x2B;MmQNZdJnZBVirSkuccm7FvXtquWSVQwq559M336cuc80vrAEJjKtxxcWAAlI2gCsYcWaEz0U2JJ3mbfcJ7bak7k7UEPUziyKgC2d&#x2B;j5yb/hImXVZb6HXzq2P&#x2B;A0h/e7uwk5C5aHJhTdUAr0bL2i8RMZGT/zi4DsLC9FnEDfmurzHJH7nCscQwEQkbQA2kdUyTHlwkyoaYRv2lpt19d5OQ8XTLXrfyOV0ndLevlika00UTxR2OUogNGYCAOCKX43ru90vr/buRXt84&#x2B;XymyW0S3zLYKJWqZgbGlGwlbLJITl6AOYiaQOwD90MS6lgxWd6LEPNGCvSqU9K3JUbPult1gzhWmL4F1FZVwRscenffcPWYOPbEFC46Qo1hjUual4lvZDrR&#x2B;a&#x2B;L/cl&#x2B;JbBRGVXdTfY5tuhEtcBANKQtAFYUqv59/Vzi2/Dtxp&#x2B;VJdxGoHD0bzS14RLV7apJYJDIQjYKuV28Ue&#x2B;/hJ7RQkVTNaUkg&#x2B;Pj7P2BHPFzwv5HYUN9vC9jz2//Psfazd7sIJ2UNeefW&#x2B;TKkXWlCR5&#x2B;wQIoKtP8bFrVJ8KcE0AIBBJG4BVhVYXuHyit2nao6JGdRmbmR4RFc/o2Hw3Uh6mdvVy3sj0DZ6DgG2wxG/AYePhNnB/d0euhptzI5d7Ekk4X0KDYtvUY70Zm/snUre3P4LIwa&#x2B;cay5lVFlNp3/6cxmjhu2ZC7BFHjZr4tYlhA4OVwwAMpG0AThXj&#x2B;VkqCIDrn5TRw4bUVf8KuZYuoViwvFI1yoVfIvRSXFJDUozMzNrmNrlc3GgeIAxeGfiQrMyNLsXLRKzRR55ZOpmHWezQWGWKG8rIyVs61f20kfXpYeC0s4UINHlbN4pfQUsSKG4V8VZewIA6UjaAOB2q0vdSNdwuGFxl3qhMXmV&#x2B;SpN3l1ot4dFX0KiPgsB2zBZS5laetyYIhw5GWrkjumZclrFR031mjEy94lHpm7jDSuBqmjFB3ce8i2DY5njStVv6EkAiukaO5NJQAiSNgCwla18cFlFpt0IgdKjl6yQJjfUCaVN7kYEZkUhMpMtIQjYGhq5yM0hX2TpMRuteqSTNkyh741iTsz2/POP3Ee9&#x2B;ur71O2cF7m5H5B704N33NssoRTN1Wq9bWCu4vOu66KJwCGs6jozt0MIkjYACMq6iz/&#x2B;AJqREOicHMicwjHr8elP8boM2wbP5Th96kgCtkXRJXTp4fExns/R&#x2B;D9HJGyQdhKZp7a12w0jHG/G5v7pInVTkdt5eZtX72ZFcUH1PlHsCoVAmZorefHsAgAuEbZBApI2AGtoeONtWY8hSwsAI3VKAYdNdKlFwrbpudcYpGvbOPbbTbfbmVISW2p/ahsD2iIxmyUpdXvv42PDtvQQq2zjxcUgtA9MCIk99JhA23vGcZpgrrViYOrkEIukDcChzDpE/Y1p3s0CktVEWW3nRTQDJwnD7Jrvg3qD1ma3j9kI2CSQNoDmWNxgexpW8FXSY7bIE&#x2B;3U7eCwTZnY1uC&#x2B;Q5zGncG1VYTsDfCYVRXjxQu5TJGYjWFtmI6kDcCS2tYAWqVutz53vQHNjQy0zGFk3teVkK5p/XZm&#x2B;2hNIWCTg47&#x2B;hrxNeqslfzmBJI6y&#x2B;pyrcsJClbq9lbcdH7ZNFBqLQwsIEtQMynFTrtA1sODymPUUa17frBcCsgj5ogd2QtIGYFWVYVtoLNpl3brsJaglYwnpkyu2HdY2Uug9Lvp2JCBdE44voLm4tRaKnOwqV16V25g6sqHnn39E2NaV/pTLSilfNFiUW&#x2B;DdK16Tq/dlJ8OiXxBAQ9Yta1ShsSKSNgALKw7bvFXqW3hFAVI37MSdxjA3ZCoLpeREWWpPvJM6Ih0Bm1h01lQqHp3mPpE&#x2B;gsNZ0YW3bjmsWjh4SqjiqSMjGwyu34YWmBIfcKkToe2a8brnQf1jifn6sCshQ/C9FW/vVJCXVXQmkMRcJG0AjhOpRoRmaWhb92UGdsgxZkpDmWlWyl4dMuVjFgI2mVQ3zfR28jlCbfiatr3qO6B3YD/e&#x2B;t6USuDqVdC3wjaGtbWQ8sWxaGkBakRGnhWcEZdTQVJ/w3i61FH8gIZI2gCsrcctYFnbbDv0DejNjZdkxmCmyDJvJGHDELDJ5/0OoocUmEvOOKFIphK6egis2RK2jcF3B/aQPq/MgJE9KTdFuUtaAJ2o0iihlhIZpsYANSyHpA3AWRJrz2UBnswuCSCkx1prXXO7wbkaMR7p2uropumENj8ShaYrV3TH7vhT1XzRSN1V1WylXUmYRrItt/0i7RMHylgFe/DVzHtpdc811piAEIsWv&#x2B;Ip34FOSNoArKFTgjUgGyN&#x2B;g1gNU7F&#x2B;AVuTuKsgUzw5ZiNg28OiDWYhaLdjAAn1Q2YOxI1PGTvKusCGToF&#x2B;pwZj1yCB2VV1OcdpJ1n1be&#x2B;DqbRDlHdm7wAATBOvRmTVztW4&#x2B;9Cdaw/ffal/svcSaKcmD5uSPM2Ku86M2V4&#x2B;faN&#x2B;Zu8I8shZAmozbVdiowsAAkmI&#x2B;so8//yjf/zrvY&#x2B;n7khHKZ9OzcJ7fE1gG5GW&#x2B;BRCZuQDEglfDyVShWaSCQjEmDYA&#x2B;IeyydkTm8HctoZVvLy7H5AzXQ4ym5h1nRazEa1tgG&#x2B;WYTo16cnhMIZ79/p45sSPPwVmCLOu8PUz4PGVgZ0kDsxVD5MwHe70HQA0fV7M3hFgHyRtANbgLiaxViVVQrUeKNZ19TWta8SVOIHkITEb6RqQolWuFg/SiNkgwZTZzknd0hWnpDRAsLHQudCqx8BtwhdvkDMRwk2pBlAHxn5I2gAspv4uTrOZOnhVZGrYWEungE2lWeMzrUjYRsAGYBjVrcCMN0exJk4wq6MSKocS9iE3dXv&#x2B;&#x2B;Uf/eMp7H9/&#x2B;/sd&#x2B;OzZFqyxNwicLDDAnJPDlcKKu7cClKedOBIuuYXUkbQCO1qlW4Y7AA6ZLj826jmCbm2kdkqhZCNgAOXT3wf3dHb0J54h0yA6&#x2B;E0tan5rX4WPdzA&#x2B;IznospzJqKni6emTXi1v6ljlnsQqrVEuoG6i70KgeY2kkbQDwD/V1C7divUR3BpA4s2L9q/R&#x2B;CWika4A0KlqzfqP&#x2B;oX5PtwLg0qnb9pFbynJT7mPo1sdOzBJ&#x2B;eRfCmFY2bXnsSn2n6BNNFfU9vlPcKjcwDEkbgONYszo0qT3vUSPBmXoHYARsIxGwAZKRpZ0sqwe5K6v2u0ol9tVX328ctnnbI957&#x2B;IbsDjCatEArHmxzNy22xFcMUI&#x2B;kDcCJUirHifUM82HefhMq4jgTAdtIBGyANNZ4NQsT4xwiUgmcWzmc2Jv20/pq&#x2B;fYO2yz0eGJXKyb9rnX3HNDMiaxvw28DsmrCjELDHt6ZvQMAMEfbOoQadz/mtYAy3uirbR72q8cH/dNwswh5&#x2B;fSN&#x2B;pm9IwDeYvYduJEbXQnHokJ4e3sNNiUrPCtO6dZCUcGuBC4NFeIurjlrT4CurDH3E/cE2ABj2gCcK7R4cm41OnK3MlNMQJRIAFazVBu5WpbPfv9n6zff/vLn6U8nVwMEMuO0y8FqjGY7iq4ByuylnVs71Rmb/schQVqIzEIC1MhdtcFcMmo6TknsTciJlihSf2auCMhB0gYALevQKl3TVRazaUFNHTshXSvjxmzql5dhGwEbIJa3ba8GrtHsx&#x2B;3teubht15dBmkpc0tuNockDQRA63Q6mE3yWfsACDe&#x2B;flJZVWaKCMjE7JEAjqNmetQ/3r9mbe3yN6FfAsthcshOvAncjfkhAZHu7&#x2B;7Uz83pIMjqL6CP4EyiunFF7YxipWjPP/9op1zNIvD441i5reDEbap/uDMx6t90bSbnbpxTEucQMuD&#x2B;4fFR/ejfsH4blsaYNgCn867JLKTaAYwUmkCSXK2VUJzmIloDhlHt&#x2B;fRmvHcNtstHWtQsN&#x2B;mbwuqs2iY1TAAb8LajLx884ALonWMm9MjeOwMsgVvDgSZI2gCIllV9z91g7l8vxaeVN5dtA2QywzYCtsFI14Bhmsda5gQ4l5PhuKkeMdverJqhqNu5dO1UbBebmisyZVZJACO5VzbrsjYyWnP3xyXkqgsIoQJpqxow/TShSozVkbQBkGt6x4SQ2gYwEgFbJ6EBbR&#x2B;&#x2B;&#x2B;&#x2B;PgPQEOl9iGj491iy&#x2B;9TjcBtMgNWDcZlcyRGZsVmG224hqwt8tbYBPvK211zdED17wbtGri/s8AACAASURBVBadknCxBSSTcI649WemjsRySNoALGb8yLCsV7Qq&#x2B;oevew8ghIANWML93V1uI/8yZjMfYCV2dChsRn4lcHpNVQVv5G2AZIkLk3tN7L6XkBwAknGOAM2RtAFYT6uwTfhsOQCkMcelffvLnxdsgYANkCw3JIs/xUrRQjfqqoeRsZ1JwtTibtg2fpeYGRJoqHLaxqynj2lQyxkEDGxs7onGgDbs4Z3ZOwAASazV44tr8269QW05Xp9IfDlCO2BXn/3&#x2B;z9b0j6HZIF0vn755&#x2B;fTNh&#x2B;/&#x2B;SMwGyPHw&#x2B;Kh&#x2B;9G/Sp3xMafl7p5eMzEWZ&#x2B;NJYmrfCKaH2GFpdqYey4WtEccAY5ukfuhToK0Zlj3xKMzyyG9YOJG4NgEWt1iahNmK5v7tjPnYshzFtAIQKzbeu/1R8F7DeiLWFsjvyps&#x2B;6A6C3UKj22e//HBnZ9vLpG/3v19/80H63ANTJbb0Xt/azUjfsyuybPrzqaK3WdomYDRAi1F5Ov6x5752ticeI1oAykQ635RDIQQ7GtAFYz7Cv/8rb4uhJAbbnhnBqBJsZswEQKNQm1wGYNdzNfXz8TtvI9q2xdDiQwJ4sgbuksIQbMFF9Y9baAq1jQCDJQ0ILUjSq2ZiIMW0AFuCd8rGmmp713MsKB4kasLGUWSLJ1YBV9LvpNb5l2vyASeVnDFYDevC2XtMHkLGWOXCC1XuxWOQYMjGmDcCqiu&#x2B;48c4&#x2B;ryen1rfzyLyjB4Acauk1YjYAOmaz2vwMX0MI9cxbwng1BrQB9awVmMb3rXtfMTf5A9AcJxfQHGPaAMCTveXWOdxb/7zj8Mp3EYAYH777Y&#x2B;5Tnrx4Fl&#x2B;q7cmLZxV7BCCbd&#x2B;20&#x2B;ONv/5Woxe&#x2B;iJVqDl7U88NI3kjekszRrfFskYyN&#x2B;Ay6VNWnNp9SPdwltIWWzXC2BMaR1Unnr5wxfw0JI2gCcxa2phxoANS2TrD8BEMucOrIgYAMgTW7App9lPd0cxBYa0AZYHc0C&#x2B;4t1d/z0fSM/A1q5vOyUNXUrVV5naE0De3Mr28CKSNoAHK1Jz4K1BbMZQJMAWBrpGoAI1SlAwIbVjY/ZzBFszCGJA0Xaj510XX3tcrOhbM8cQtd&#x2B;twCEhU5bTkagBuu0ARBqWHsjpLgdMv2mYACVXj59o37GvBxTRwLAruixclkTRb766nv9M2uXgJEqW4t6ffHiLQy7LlkvFP9v&#x2B;nYA7M17Ext3tmEJjGkDsIApE1wkis/IUTxFPoDxukZroaXaiNmAtdDORy4JczOGeIe5dK24xuO0rLFuwGmsU7WgjTy9Wdp2gQYAxTiz0rFQHNKRtAE4mtuz0KMrRHJSCGDk2DUrbCNmA4ATRGqYEqqIMrNAnboRuWFFoQZg23lT0puZDW8A1VeMlJBewiUOQJx5LnPOAjVI2gCgC6vZQ9gGiDIsXbMQrQFHUSu6cxssbkbXle7PElsz7FdrZX5IHCIlTossnNav1zs9b6tM38Ve3wBo6ute4K02wLpYpw2AXFZSZf6puDYQ2WY9WhSAcM0XYCM5Azb28PhISIZKekUlM2BTP3N3zCJtf4AzuQuwuS3W&#x2B;gtIj451vUsCr28ALq172qrb2gAhSNoALMPqqug0zWPlFiIVFO4VAmZpHrAB2BsBG7pyO9MBIEtit3hu73nipcna7Lp99ADW5c3YqMNjLmaPBCBafDB7w&#x2B;nmL1&#x2B;r7FkMxgdmIVcDUCa3iZ44RaTuDqAL4BzxSiBTi5sLsDGxJE7jXh86NRsj01SGpExye/jlC9jJ3G6rmrnWGdAGaRjTBkC65hNQ9GsVtJriEkCxtsPX4pNDMnUksJN&#x2B;c0Xe393REQCv0&#x2B;qKZrTm/kn/jNwlYKT0EWOhFqv7&#x2B;/ptlm0QwAb6zReVugO&#x2B;GjLVZqyLMW0AFlacmbn37LibKmuK0DIBphg/go2YDdhAQbSWfuNtqJvg/u6OYW3QRo5sM6upksejELbhZOaCZ/VNy5o5YMw9qdwNAEsYebITp2FLJG0AllRfA6DBAGxgQMD25MWz19/84P6y9&#x2B;sC6K1H3BWfIvLh8ZFuhWNNr3mGbg4rmFmulVdffU&#x2B;ohpOZWdqwySQBwKTrJ2oR2enVFZeuVF9WpLmVDdORtAHAT5rXKmggAZbPfv9n6zff/vLnWVuYMnzNDNuI2YCljWmEux0BZjfBgB2AZKLW8R28J88//8hcko2wDdvIPZXiDc&#x2B;2J6bqPU/ZpsBOdgCdiDrf9ZQP3JSGpZG0AViSzHttAMS5MZv6ZUrYNj5gM5GuAaeJj06LP0U/0fyN6kEgZoMyPmwTFe&#x2B;ZVPBG3oalpS&#x2B;WFnqkOawk66ULljzwPoXGNXCaVeaUBhZC0gYAAEbwxmz6T6GwbW7ABuA0iTfSpq/WVv8s7EHCXWK6l3/ujJGXvyd1w1oankoy43AA25Nw8UmphEcmkKSCDQlI2gCsSkKHxe3te38k1E6APRCwARgvd74aPdHN7e0xcCmD2&#x2B;r2FEsy666zKo1mxVVCRdpLp25EbpCm6xCQrMtC8Sg6sSc&#x2B;gJH0nTfCe7ES68xUrSEESRsANBNP3WjV4GSRAW0a6RoAaXLb7bTzYXI7sIT3Z/UWGtAWfzx5G&#x2B;YKnbbufZ8NR4uGNlVws6k1mBUATLPCtsjotE5PBAYgaQOALmjJAIk&#x2B;fPfHGzEbAGHMzCyyZpvV1L&#x2B;c0IauAQDYie6hrmz9uaPlIn3fndZyA3AaFd7LH9lmMcM25nKHKCRtABYmZAJJAHHeAW0qYNNef/PDkxfPRu0RAHioVrc102OTLTNj5LGW670CTtZkcsjKs/7ydS93kgYygEvWlUpmdSVSeaZeDZnemb0DAADgIB&#x2B;&#x2B;&#x2B;6P6mb0jAFDu4fEx3sL3DoljQNuZ4r3eJ/eJP//8I2aGhBwpc72qwR&#x2B;j9ggAxuH6BtQjaQOwNoH33QCw6HSNgA3AirJum3UHxinEbCcL9V6N6dK6/&#x2B;QL/TPg5SK8uZrK20jdMJf37Jh4yqS8NH3iAIrpi8zEC136XWvAKpg9EgAAdKGXXnv9h7k7AgCDpHQK0HFwsuk9400mx&#x2B;vHDNteffX9xD2BQNMXDhgWjbu/0S&#x2B;tZ3gTeP4CWJTAugG1ZSyKpA3AksxZpKc3ugCYdMCWhUXaAGzgcj02Og4Op6uvEuquwvvrGeIGU/Goi5QeZPfEnD4ANELsOQtgIUIudw&#x2B;Pj&#x2B;6sD8W15Xg9nOklMABJGwAAqFWWrgGAcKr9n9Uy9z6YgA1Qnn/&#x2B;kR6s9uqr74nT0EloNkixMZV5I6n&#x2B;zaydAXAOdamZePONNe96pzozMRvGYJ02AABQ6OXTN&#x2B;pn9o4AQBfpzXJvv4D6JTEboFlzQjJFJHqoH6JR091c/OrmixKzARhGyJpt6qfhNknXMB5j2gAAQB6iNQCIt951TwExG6Yzb1eP/3IKHbYxvg0FGi4vJOGkIGADMIzwSaQrqYq6mk&#x2B;SyA3DkLQBkM47y4eEfgFgIZ/9/s/Wb7795c9zN9IvYGORNgCSRZro5p/0v0nXIJA1N53A/jVzfBupG1JYTUJvs/EyP5s7mEPUOQjgWO4EtotyozXz36Ru6I2kDYBoe3zZA3O5MZv6ZUrYtvHwtdff/KD&#x2B;Qc4HIFckeBu8J0A6N3IQu2wVqRu8zIRYWjtRnU2JeyXzvAOAdV1GaNTSMQBJG4A1bHOLDTCYN2bTfwqFbSMDtvFBl87Y9H8J2wC4Em96pd0O4ahCY2neAhwq1VZ4rP&#x2B;d25ZMT8LMLae8BBkbAAkEDm0vYE4s4f0lI9gwGEkbALm860lEfr8Q/RZW3HksJBKzeXUK2J68eGaFWxN594SwDUCEbqVbzXUyNiDX888/MserARHp48NaxclW00zUoE85ewJgM4teXrxTRDKXO&#x2B;YiaQOwnlXqAcRpWMXEKSIH51uRwI&#x2B;wDUAimu4oI3PKu/HM2SBJ3eAqGHzWJGwzm2y5&#x2B;7DBnaAATrZE5cQ7gk2LLM8GDEPSBkAoK6Zaemy7WWtZ9C1gRfEBbR&#x2B;&#x2B;&#x2B;&#x2B;PtdvvyDw9j4iXvsDaSLQCSuXPOkLGhgFWnFVIVHLMbKkiLLLSm/0TktpZWNxTmtpKsuFrI2XQzwjY5uwQAl6wFJiVfwaw6OVNEQiaSNgAr2eBuwSXuFcLGVMA2xfRcTc4MlgBWwRQ0qGHV&#x2B;kTdejWyW02naCmR243U7QyVg8Ya0huvnCty&#x2B;kkNAOnMS9/sfQkKVcLjg9uAiUjaAEgXafN46wRyGjld24RAlokBGwAsjTY8elji/vFZSN22520ieRt96SdIk5aXNbwj8lqVLwQA0ki7soWWSQ49zOUOd2P0G3ojaQOwhvSVLWSuXE3khsHU1JEEbACQi2gNI42suIq6CSwUoVnj3iLD4LCEmqGcU9p0osaeAkA/wy5xBUPQQpGYNdtEPGZL3CbQEEkbgJUkdhCICtuU4hW2gVwvn7653W6v/0DG9hamjgQAQEiNNDJS7dVX35Ou7SFUwNwoS3jjSFq7EgDqDbiroHmyZYVnJGcQiKQNwALM5MyqBESacGIbRaJuKMY2VMAGAAAEElj9E1tVVjkcedt&#x2B;rAZa2xJYc355T0&#x2B;xJwgAtNUjdUuMweLD3dzpHy&#x2B;3751z0toO01egH5I2AEIl9kdIbgJJTvuwjcqA7cmLZ632BAAARAgZTzZd4tJrDG5bWlYJl5BDm/tACw7A9uYudJI&#x2B;HC1llsj41tQW1MPI2NAbSRuANSyaWjHRP3pg&#x2B;BoAAEub0sO1aHUaS0uZH3J6zKZwdgA4UNdZfHW&#x2B;5R1qZjJjsNwczvuiiQ8G2iJpAyCXhNsbG&#x2B;I2SVQiYAMAYCFmVTaUcg2uFq5VHWVYmzSJTbP4wxjcCQBy9L4OF&#x2B;dbiU90QzUmisREJG0AlmH2UCx9Ty5NykN89vs/639/&#x2B;8ufF2&#x2B;HgA0AgA2oGqCQGqycyE1naYmzSiJF87ZSWfvFXGnb2qUmDSK9TZpXAFCg98XzcnRaynC3gu0TsGEWkjYAolnD2tx/T&#x2B;8diJg78zUmMjM2/ZvcsG1AwMYibSaOBgCgLW8NUE7EJY2K3Ky8jWFtucS2OzoNZbM2FTmtOOMAYIysgC2&#x2B;0Jr1p5Ql2YCJ3pm9AwBwId4oEtuYvN1u9598oX5m7wiGcmO2&#x2B;O9NL5&#x2B;&#x2B;0T&#x2B;Vu0FuBACAZOMritOThldffW8FaW6KRq42kS6TVrHsPrdYcsnMutVyeoEHABSLTwtpenh8JGODECRtABZAMwmriMdpob&#x2B;2SteyEMUBAHCah&#x2B;&#x2B;&#x2B;1D&#x2B;z9&#x2B;V2Y8ZISVLStSYlxx2FlpXkRR5sTlYppIQDwMkKArCUp6hoTT2SjA2ikLQBWBiNKCytd8AWydIOjNnib/nAAwIAOJzYijTD2sYITdEf/&#x2B;Wt3U2QNSXQfaLMwgwAC2l2eS9Kv9zwzJxhsuELAf2wThuAJS3alFp0t5EoZX7I25AF2LQnL569/uYH95fDdmAJHBAAQG&#x2B;qEjhlUvHcMUPTMdCtt6zJIcWuLChtfwBgOaqGoOsJWTP0zkK6BslI2gCsKtTqUxWFGXtkc7tUlqi4oIcP3/1R/ePLPzzcng7NdVSM9PqbH8iTyB0BAHOZlcATVmhTo9Piydmrr743B7ERs93eLhutZmtM2U7XPNidNNL7ewDAMGbAZv5SVJ8Vs0RiISRtAJZkxVcyw7ZQu5G8bUveAW06YJuOPEnhOAAAhokPJjunKpiStynEbLfWyVPB1sYMgvS21yKNuHPOFwDAw&#x2B;OjmjqSgA1rYZ02ADvQrUH3H2LJ30MU&#x2B;/DdH9XP7B0BAADTXK6DdZTnn3/EAmxec&#x2B;PYMZNDel/l/pMvOC8AQAKBdzPoZduAhTCmDcAmxI5si5C/h0hHrgYIwbhhADKJXe9qpPTxbSdwc6ay5GmzorXHuwCAVWxw1b2/uyOWgwQkbQD2EZr9f5bl1p9HgZdP36h/vP7D3B3pyFrbjAkYIVZ8YmEAEGKzXKRAet527DC4y7LRvJXRo9mivosvt3zsiQAAQrRdH7RATU6m5pkEJCBpA7AVaeEWa33vSgdsipVFRSwXU7lv7fU3Pyz3LgAAEOjwMbjHpmj1FmpZuL23Vnvt2PIPAEJM/05hOBq2QdIGYFuiBjRYaxJM3BPUsAK27YUSRMI29JN&#x2B;6bYGhXjn4JLzLQAAh3v11fe50RpRnJf8psTlvY98OwOANIOvzLnpmhq4dvksPb6N9A5TkLQB2JnMblaBu4SI09I1LX2gHtBKYu/hZf&#x2B;d/F5IACfgRitFzxKp/xGK0IjWTLMaMp1elBYQAEhjTsI0Zpx91wCMaSQxHUkbgDXQczrGy6dvfvWf/zR7L0Q4NmBTLmM2hrVhlvjYNTryAMwVWoPt2BnFvYuxqV&#x2B;Sq0WEyok772KrEmWVWLfLVX/bpryi9Ui&#x2B;nQFAoGF1koKA7f7uLuVZOl2zYrbEpwNtkbQBWMZlD4U79T&#x2B;NOuQqC9ievHiWMgKMaAookHJJt74XuDkDwHShlaiOGujmjdnMvxK2abmFwbzFpHlBimww67VoiwHA4crirsvRaZHJJB8eHxnchllI2gCs57LNRh/rOT77/Z&#x2B;t33z7y58XbOfwEWyATAWzRHLxByDQ5UC3Y3nDNka8iWJ&#x2B;2/IlCwD7aTtC&#x2B;h/bHDJLZCRRY0AbpiBpA7CG3Dmj6bk4gRuzqV8mhm2D07WFBrRtv0Kb&#x2B;wYX&#x2B;nROEJkyi1kiASyNeRdcoZFtl4u67Y0SAgDoTcJ3TWR0WuTxmncEGzEbZiFpA7CS0Dw8aGiVpdq8MZv&#x2B;UyRsY/ja4bw5IsvOSdD8Tnm&#x2B;JgCIRZ3WxDSSyuW0HF2TWn1fo7sP7i8ptACwjVnjldvO8agjt9zoDmiIpA3AqiKrteUOgMNyIjFbSO&#x2B;ALb5UGymOEJHPiLBtistOw4LJTLj4A5jocl3hk6k4Lb5427GGfXklhnk3Z31BRmQCwGam3EWRHrDpR7qx2eVibPd3d4RtGO&#x2B;d2TsAAEkevvsy8VtfTy92/8kX9HFsKSVm0495&#x2B;fSN&#x2B;um8U7dbOE4jvwG8zEt0q2aeef3nKwDARKruSiah6VFr8bkiMVjW5PwUaQDY1RKX97bD4IDmGNMGYCWXc6ooVu/tEjUGUVaZQDLkw3d/vE2aJVKFanrgFBmbKNuvP7eWyORUXLQBrMuteZr/5Q4A5fnnHxGtTZFeAvkuBoBDTLzgm8POIiPYUtZm008kjcNEJG0AFkNvxeEiA9pUwCYBARtgKZhyqmDeSACQIHLFO3luSWsxNjdsY7W2riJFzvrCJWMDgAPNveUxKx4LPVjNGHk5sSTQD0kbgIVFKgEMa6u00LA2OQHbUUgTkc69IFvdeaHuv4Ke6NACMwAwXuSKxAXqRtgmDGUSAM40&#x2B;O4fd&#x2B;RZKBjLGqOmHsbybJiLddoAAOv58N0f9c/sfcEamDpylsSWm9vBl9Xko39wT&#x2B;99fHvv49k7AbTB&#x2B;pE3FmNrJ7LQqSXy/chXJwBgUWrsmvdPDGjDRIxpA7CnxBXd6m28qpDAYW0vn755/YcjojUrFmIAGVaRMqTMu0Jb8z3Z8rJ8EDNgU//&#x2B;&#x2B;x9n7QvQlpA5&#x2B;sbshnfUmvp9/AHwatLA4fsRAGCR8NWQPutjylg3RrZhCpI2ADsbVl3YOG&#x2B;T4OXTN7N3YRzv0KvX3/wgKmwTtTOYTl8AL2&#x2B;rdx9w2dWbvlqbOykl1sMINqwvPQuZdcmydm96JdYN25AiPXLjOxEA4KUrLdMrA1kup4gkZsMszB4JYFvjawn7zQg0N&#x2B;J6&#x2B;fSN&#x2B;tG/2X4CwMgbHPne40EaMRtM&#x2B;rrnvQCm9yN7e35zPXz3pfopeC4mC0wUeX9394/7VQnhsI4Vr0X9KrHuumusxAYAgARNmmCt1M/6qAI2YjZMRNIGAC0RttW/nBuwAeineN2gmgWH2nZAr9WdjbeogC2QorHKAlZkTaIrLXKLXLdHhm25D4B2WZwEljoAgEByOq/SszH9SLeZQMwGCUjaAKCx0MAOOfWYXANCL9K1m7ARe6GBawxo20nudSnx8bp3z3yw&#x2B;9z0TsDIi9KZuLBwwAasznvFOzz/IGzr59hChXo1TdSlm7cATNPrJ8V31&#x2B;l0jYANQrBOGwCMc//JF4s2hl8&#x2B;ffOr//ynHpttvk1luUAoJWYbvFqbei29Y8sdUoQUj2DT/4hcx7Iucd5MLvS6xa8CWUjXcLyUS98w6avKpfr7H9Vp/uqr763wjPXYWuFLELMkLs0LYCHCv1MiIRzpGgQiaQOA9iI90WutNGtqGLYVB2xPXjwTNfDrktrbpTOqHjtvfohyDo6cPeknt1sk1J9iXeLUvxM3bnYxx6&#x2B;ToeeueP3E7UbGBtgEXs163xMWH7hGFAeIZU1UMHFPADQhsGPq4fFR5Wo6XdP/0H&#x2B;6DQ/YzJcGLpG0AUAX6w5fi1AJWVneNnJmyOmRiRUHbpC3NcTBkebytoBW/SluIJd&#x2B;ndzvcnoQAjYcz1q5beKeyEfYdkkXJ3dwJKULribFg2gNgAQMYoN8JG0AZImvxzNyT&#x2B;rFR2ws93a0rLztwKXXQqPuInM/rjVQr8bEdxofELlf1JfSseL&#x2B;SV&#x2B;aQnM2lnW1RKZK2&#x2B;maDxsZGyDPiGnfwhNIpiBsy0IEguYu65DMHgnsZPrp7I5gs&#x2B;jF2MbtE1CKpA3AMpZOp/ZrkOgIzY3cuqZrlxNIzo1M4vs2eKE1aSIHZ&#x2B;6ROfBD8V5L1TUqdKXVMzdal7KUyzJj185CwAbIZl7JZdZOCdsSv1sH7AmOEp8t3ESFDdiDhK&#x2B;SyPSMpGtYzjuzdwAA3hKvtUuoB8RZ&#x2B;x&#x2B;ZL0j&#x2B;e0n08ukb62fizhwYmaxCwrg9b/HYsszIv7y4l3q6bHbw3sfEbMAShl1yiwOz559/VDAebgMP331Z9unwNYoBissnAOHU2S3nBH94fCRmw4oY0wZAnMhgC/0POTWAS&#x2B;bNgPuNbJsiNKxtemQiIUxCnCok5ywOV3mptC5ZNZev&#x2B;DJFC13S4dEuXWO9cWCYvpXS/5pA8lY6h6SyfdjW6uuPr9EzFc/44n2i94Kw9KQyAFKIOsdJ17A6kjYAS5Jc6SdOG0BnJMvNx7jcDjeRkkGOPDKHfAS5F0l97Qp1tbTZLePl2m4QEzQdwUbMBgy2RNgGS9k0zthM/c1Plwvl0p4FDiHhO4WADdsgaQOwqoXCNj0OjxZLc3IikwED2uS8WWzjctH7SnQI7qlRwKajtcjyDAC6sq7S/S7RhG0N8U2KYpetUUoXAADFSNoALExy2OYiZgMwUmSu3ZTLkfeJBZdcsxt3oSs2/PpMFEnMhi2tMuF5xz00hrXdCNuAfMNqUDRUgdOEGonDOtkYx4YtkbQBQJXQ9BqMYAMwRc2VJ3Lh0i2ugr5j&#x2B;R3NuDBwJTbd6iZ&#x2B;wx5Orw12C9teffV9k&#x2B;0A5zBzu/il6fQLF3AY65Rf6452QBSSNgBoIDT4g1YKWtl&#x2B;6sjt3&#x2B;CBaKHtoOlKbJe4uRXbW2WgW0tO2Kb&#x2B;0Wx829//2GY7wOKy5usONVRpvQJH4ZQH2iJpA4COUgaIYAOVi7Q9efEsvgVSKITE19e5vM5EHuC9mTGxMcb1bXmNArbf/Pbbf/2Xz8qey&#x2B;Jt2Nhxc&#x2B;q&#x2B;HbYp5qC03NSNAW2AJb27XF92uCsUOJl3Wibv7wGkI2kDgDZCnSbe&#x2B;sopHStwkJmhofhEH5HrTOhPkYlwL2cR4bK2iRYZ229&#x2B;&#x2B;631b2/epkaw6TiNAW3YQ1bn9UFD3NTIs8AVJmugGzEbYAmNTqu8tsSfftDlC9ia7rDipAbqkbQBQK2U/hTqK4iLDGsjnEOWhncoW3003OG4s3azRJoxm/nL4sFtwHKshS3xk2jedkuI3OyYjakjAUOkElgw6C3S7c7FDVidFbABaIKkDcDChMdX3BOELN6wjZgNIZ3uX74lZHXqJbi4bWLUSmxW2MYINpxAVOQWn214KB2PJURut9vt&#x2B;ecf&#x2B;cexEbMBvqlTai44oq5aAACshaQNwKqEdPJeNkLI205wudCafljlA3Z17BtPcbmcT&#x2B;8p9a0uG65mm&#x2B;gTsHkHtAGQNj5YSu00IXK7haaLJGYD3jb/jAawJlZoA1ohaQOwJMkNCe&#x2B;YEik9GlgEwQYSmzoNi4dV6szl2SiEW2m9Epvyr//ymfVLNYKtOHvT67cBm5k1ZKTh3MLtmbFZyjWKmA2nSly2QO7JDkASWnlAWyRtAJYkObiK7JXk3YYQbsO4yXyAkm08oO1yONrlEwfgunSQRuPYUsIzPVGkm8DdmDoSuN1uMy68Vv&#x2B;70ApGfKAbGRuO1KNmGJmHPHFCBQB7IJsHWiFpA7AG76150jqIE/dE2m5jjJQ8adc6bmR2zS1jttzP0bomlBWD3PuXQw/Wu8E1ajczYjYAKEeohnWUte&#x2B;Kb8lyVW7BrEZeVhEBbMNd6HHWngB7eGf2DgBArUXDiUV3GyHxxKgyT9qgtHiPwJYxW65Iv8blANn6F221QUjXZ1U2U9sV2pg6Ehjj/pMv9M/sfQHOYg0w7f1yBR3o5t1X9L8D2&#x2B;M0B&#x2B;oxpg0AmrEm4WGK/P3E51kKjdyy8qTQ7avuDWWblR/z&#x2B;GyTsbmfZsqnFnqMW8CGFQNaVrAkrsTmfVjlSxOzAVM0HF4DnKBs/tX6el1l5dCaH7LVZgGsSF3EzPW5Z&#x2B;8RsDaSNgDLuKz9T5mVkTbJOVI&#x2B;aCtsC2Vs&#x2B;r/xxQ/2K13bBGzK5Wo37m/SP9BhS7vRoIIrfYpIb9hWhoAN6C3xm4K&#x2B;NuDS&#x2B;Cp6&#x2B;ll5uW/MDwlAsb7xqQAAlUjaACxjid4BM&#x2B;3bfojSUdI/OzdMyh3k5C3A1HqlufxY02O2lLUxmqM43RLOu01kTh2ZuxKb&#x2B;nfb2SM9WLEJqEMtFOjqcrIK71MST8zLWgotBQC5qBgAzZG0AVhDViVgekuDKstmKmdoif&#x2B;VVvGKvB/rEp&#x2B;m/D0cJn2MKZROWdrD46N3NNvD42OPlwPg4uoHVIrHbLfADOHdd&#x2B;ttbrDHuQ9A4b5woIl3Zu8AALQxsVpAEwUNUZyWU7PCfNnT3WclLq5D6aIBabm/u1M/&#x2B;jfuSmzufFOauQAAIABJREFUs&#x2B;pXYrtkx2wMaMOa7j/5Qv3M3pHb7XZ7&#x2B;O5L7yzHfDUATZSd6c1PwPhu6Jfj3AcOJ6RyAmyGMW0A0MDlHUC0ZPbmXVTc&#x2B;0jvzKKJ24RAkQ86Mf2qRDlJ4a6od/hxc8eQ3d/duWPImq/EFmINa2M0G/Yz5hshhb4ATt8TYAP6bLJqGhN3Ros3RgDgxgUBaI2kDcAmpvecTt8BTJH1oZu3kYaeSClaSKRl4kY71rN6XzFoNSVKD7&#x2B;34Z2qUTETtVYrsSU&#x2B;K5auMaANG5EQufEFAVTKWlzNXIvXbAt02rfQbgBACFcJoBVmjwSwJO/ca1OaLqbQLBxUXHYVaWYf1XF/GrEf7vRroCh6xrbI53XggYrEbL2VzDn59z8Ss2FXoiaWBM7R&#x2B;7xLn&#x2B;iilXjz88CqDoACjHcHmmBMG4BVCcm03Gk6qJ3sbVYdlHK1NGtYW9YTQ3&#x2B;yRsVRQm5Xp6d3HCHd3F41K7H95rff6qeXTztJwIZjSBjlBiAkcUpG1&#x2B;BRa9QJARRgXn2gLZI2AGiJ7pL9JE7zeDkHXVmRoCCJ5X401m/KpiXUTZ2UcI7iYUpcLNM8aKe1Kq0BbWrCxvpRbma0pn9jPcZ8wMUybGRsOFXxPRkAOrmsJ8g5Z&#x2B;XsCYAlmK1O/ZupewTsgNkjAaAL76RAasQbNZj9NP9MKSo9tIpVrI/Gu9kmn91pOdAAnFPaRdyVyQ3bsl9XTRRJzIatXV6CuOwD05nLqoX&#x2B;SnUCwGa4rAFNMKYNAPry3iJEPUamsnlXrE&#x2B;2spvMel2mgmkl93ORdnOfkN1YV&#x2B;RUOvDYNozZUuaHvAjhSNdwBnWpKRvuDKC3tc7KA6suAJrjSgI0R9IGAIMwKZBk3tWbatYC/PXPfvH6mx/UP&#x2B;p3DyNZhSH3zOU0T1dwY3jb7FlvQe&#x2B;JtIS1t7KpI0Mj2P71Xz6Lzxv5FgI2HCxyXw7VRaCryD1tod8TkAMAgBTMHgkAVZjlbwOJK7ElPuXXP/uFN11TwVsxyphMPYKZQ8a/FvRYterkorNMSY/Z3PzsN7/9Vv1YvzdztX/9l8/8MRuzRAJv2/hSD4jlzvPvJeH0lLAPAADgEmPaAOxj7rz5l&#x2B;s2YVHxCSGtMTFxr7/54cmLZ&#x2B;kvTUEawLpuCDnmdKlo8cA75UBd3oou5EMfQ80bWTCULWWWSCU2VyQBW1NlQxIB4GRrLbS2yn6iHwY6A8BCSNoALKm&#x2B;77Ur5hgRKNSuLvuYQjPP1M8VKaEAbyn&#x2B;0buHPWXJPe&#x2B;AtvoeHHMLu15GUt5X2/fuPZ67Ht6QsphNZ2zeySH1n2KbIGBrjYxtRfFvh/p1XgGEXJ5cl9NH15yep01MjYb4XsBIa92IAMhE0gZgQ0KyCqvTRMIunckKVG7Rfi73Kekbb7UkmyrAFJ5ElWt9eamtqU&#x2B;hyZYvN9K8W2cVuWW7IIBMLCH6AXufbm5C8/D4WBnbMIhtGOuTUtEpJHPzsxMu7EArlRlV/HSLb1PabAfDCGlHH&#x2B;uE&#x2B;&#x2B;0gCuka0BZJG4A9DWskxOMQs4eFdssU3iaK97Mo&#x2B;HT6tX9oWTV32YpIKRXmYnv//X&#x2B;&#x2B;8j7GfdGImuduIDTp7oBLZWj4yN5X6fSc5je//dY7gs39ZTBma5ex0QVwI2Pb3QkXfECC3MGjTYayXRLyBceFSA76DTAFpQ6oR9IGYEmt5gBsi7lBpEmf/c&#x2B;S8glaz1UD2j794P3f/fVvkWeFlmqLtPwpThH1J773yHt79s2Y7Xa7/fpnv/j6L3&#x2B;q2bH0T3b7MuCO&#x2B;TDfsvUZlX3ol3dFFGxzaTqq0RHO/d3d//jV/6UfIGSiSO5WIWNbHdNCAlnK7q6ovF8nMh94rjNv5UGxyw4ESg4ALISkDcCGptdH6VKRYPCn8OkH7/fY7PTCvKjEDpf44TWbvlbMpvLUX//sF8//45&#x2B;tDboFzwqNLnY9cyeXVpBHNjyvNz6wlwrSmouA7dZ&#x2B;EBvI2LZB2AZ0Fb9fR6mJ7m5Nz&#x2B;KTqx9QuD0XcrhTlVIsgRokbQA2wWzmZ3Kbwd6HuWstuI3wmgETOomJD2i73Eji20FEj7l6rJjN&#x2B;tOTF88SG8yJr6ivZqsUgNz&#x2B;gsjwzVbX8Mh2VjmqzXkXY7N&#x2B;&#x2B;f&#x2B;&#x2B;/H/MYW3asJXY&#x2B;BK/EbBtKlJNJYcDtIJzIX2i&#x2B;MstFAwq8o7Ao0qPiPp5GoC2KIdAQyRtANaQ2A1BM&#x2B;YokSJRdltW&#x2B;rM63fZFAS42K5f63V//9vUnr8zfWBermvi2as&#x2B;EuZwMSv2pyaU&#x2B;ch/6Zke1jDtvpGnKSmxx5&#x2B;QQZGzbS7kEcZkCvLyVq8Rvh5rTquy5&#x2B;puLMxo3o53infrCvBN09J4BAJoiaQOAKrktPRSz&#x2B;srL7mB1U5DQB7fQiCJo9fc1u2e0WoHPdDlykZJjsm7ddefSzLp4Wh9QZDk377Nwu93u7&#x2B;4eHh&#x2B;9MZsycqLI29VgAmvJnF0/SjK2jckf2iJ/D4HL&#x2B;SGLW2SJjy9o6HEqbaYgOmX4GuSjZAJtkbQBWIZ1w5e01guRWz9u6zr9uTXlJKWYqQdEZhe0PHnxzH06ylzOEFhzMjIhrVf9DdrqtKq8e5fPpVIkZotJDtjSy0moE&#x2B;qcW7zJ2Pbmll5vtDyrMhC6PeVG/QTVBDbW4ur3dq33iyxZVZHLB6dUcvau/ADArkjaACwjZbFrCbyRm8xdFS59Qpj0pkh8yo5KWYu0USQKNFwO7dc/&#x2B;4XOR3/9s198/Zc/mS&#x2B;ht&#x2B;AOaCt&#x2B;xTPN6ibgE0mXFO20G8RmnmIpxWPjniYytsMxqy121eS6XXxfXY8Jh&#x2B;MrLOrpr9u&#x2B;aI2yZepQL2u56Jp7SQEAMpG0AViY2LBNET4IT7i26y7Et1bTJtefbFbMhlwpswYlfoivv/nBzc9U2Oa&#x2B;Sjxp&#x2B;/SD92&#x2B;32/P/&#x2B;OeU193A5RGO3F7QsOcr0j3NZTbXdbqTlrGZQxUjn0Lid2LoT3t8vgRssFBFBJSskUApj09/xZRvLu/&#x2B;VO5AEykT7F8&#x2B;F1qP2yDMjyZrs0LKGM5BkQMqkbQBQJX4wLVdwzYhN2LrV480vAsSu8iyUl7xPEaFMSgW7&#x2B;BoOOOKO7IthM80l77du2GnGHK5a7PFMp6cQWyVU4Cm9Azu8e1JxgZgewW1aPWPxAnbu0q5M2&#x2B;P7yM0kTWBDTVYyOR2pHCVA2qQtAFYm6iqgJD8qZ&#x2B;2LQRraykN7DFNFPeFLifT//ovf0qZZtBapA1tpayVGF9Rb1gZk6nt2jxtj&#x2B;ThH00rKtq5v7trlbFdSpwrMn3NxUW/XsnYcBN5HRO4S4ASuvj3GCJ/S6i0CJwiMos3E&#x2B;L0r5Fyh1Bi1fqyVLN8JrqiMgA0RNIGAO2t3ido6VHxcreZMpmYWQusObbWcyMvHfm997Aw2qnGZfhqtlpDn1qkuCYuumbZ/jMtOMHjp4z37C7Zs6g9rq5T&#x2B;GOepgGb4h3S7V7GsxY1ab2P3ZGxwUQHNw4Xr8aL6u1d8RsnJGUOdvdhiOh6rESdCNgbJQ1ojqQNwBoWrQQsuttKv52PzPgXang3eV13O23fYzySOWdAW9lI09zwNXEjlYjZstSfqvJXQ9lQ64wtcaGdxH49USPXs5Cx4RbuMA3NWT2edw8XPenQ2zkDa1Z8j&#x2B;59hLe0zGbFNyuQdVPR3J0BUkRm8QFQjKQNAGBrXsea2zIPBWyh/cla2s1sVkVmJjwqZuu05dzyU9ZasF4lPtvkjU/WJ37kI&#x2B;cdHRO9/P2Pt/c&#x2B;9v&#x2B;&#x2B;nazTLev2&#x2B;bWa/QRsCOl9O1ExOteQonhJzsElvKYwTz8Zy5Ql9wee9a0apMVD81MsWgixOgoe0ApJGwBUOXYioMTa2OU8cr3X4E0cx5Y&#x2B;wOJy&#x2B;65zwphE7loRTU6f&#x2B;JREZVNHnixrmfcUl1NFbTbvrixm2NZhosgQ/fleLmeywU33ZGy4JHZIEGEbmjC/xxcqUXJOyeJLRGS&#x2B;EP1vaw72wl1Ea3KKH05jNcO5LABNkLQBWIM30BJVMT0kcis&#x2B;5pH7uEe2xiMvFJ89KT1Rs0ZBEbNZ4mtFTFkoYvspIi&#x2B;552D8vwXjC83tJD5d1BV&#x2B;B8kBW&#x2B;UdD7o4pX/Qoen1Vvk&#x2B;JWNDSOjmHvUPrnLARNucgCnflSlvdqGv3Sz193FeTgLcapttXwJIR80EaIWkDcBihHz3RwK/UOQmZM/LXO68t3IWH9C2a2870VpE&#x2B;syc7i23OsJUo9O&#x2B;/sufmrxWjaM&#x2B;6/r&#x2B;l6x5WTFLysfkvZJnlZBtCgMZG2qI6tiyRhhL2CUgkTs1RaQAb1C2U25nmXLvmkA96q5l99earRv3s7MqURuUUgA4E0kbAGTbpovwUvEUkbnbaXsTZfpEZJFHbvDxtdKjKzB3zkB37sf4bJDxApA&#x2B;iO3Ji2ehpdp2itniI9h6c5c8hGSdFvJcixWw3cjYsAix01diLVlf2f2&#x2B;372VSfkqD4j1llNmhkhM3RY6hmPED0jN4SpofnLdRifmhZRiBtQjaQOAPN6Raj3mlFhU4oJnww6O2ZpNbxGd&#x2B;dk15O3Lsyrx6fFqKFQLZWChzTJLpCUxkM7tSigbzMpJN8WUpvXSfXkMYsO6GLJ2soZX&#x2B;9z5CSYSWM4Ljkn9YZz&#x2B;QUhTP3qs1SFNXKpAYEnGTqzpZChvQI13Zu8AACwvsgb1IQ2b&#x2B;nnqux6o&#x2B;NLfD999aTVyqFwWm1jgL9Pu4pjNHbv25MWzDQa01Q9FvcSptAF1fdZX6eK&#x2B;2vTpgsUWm/u7OzNme3h8JGZDlrnFe&#x2B;7YZawua2Lh6Zfx6TtQzLpKnNOWHKltcplV2EJLTgBzcZ0BGmJMGwD0deCNw9ZbDg0pG1mlu1wz77TPyDXlFraUIVPxWSJ//bNf6AXbvCscNHlHknO19A&#x2B;urF&#x2B;g03nKGbeEHpPrml2xcrpl4xjHhobKFvjpYfoOQKyFhjW4I&#x2B;eW2O0UkTO0ZrygnEvQSMXt8fjhKtjmNuUT2/DWzAEUI2kDgCqJ93huX6u2ambTVwJgAbYs9VPZpIeXufd&#x2B;vvq//1fW42&#x2B;lZ5zkOK1ePOf2rnRSdpLG5wjl7JursvM06yKfQn55IGNDJWojWIt7nS&#x2B;&#x2B;O83aVL8Cv9OplPI13SMxivxeiLJbcyrf1E5FC4ijtAOtkLQBQLn0G39OCNtwjgETDyqhldi0Tz94X49pa/7q24jch9u2Y4UVK3cSGXxWX2yElwoCNrQyLGy41OOaj820Kh5NtkNZ1bwnb9boE&#x2B;&#x2B;Vx1qZaSed1iHusRFADgoz0ARJGwBUCY3Y2Lumkn5fYXqnUvPup43nkxFIdSCmNPsvw7Nb5umT&#x2B;LE&#x2B;efEs8tI7DWjrMSNfp0W5sKKaGavkz0hGxoaups&#x2B;Yqk7D0KvvXXeFK6VAplfwhpH8JYK55JRShbKKVUyvnwDbIGkDgC7c29w2GNYWb72UNcK7HpPVD7hMNY1Ya9G13/31b7e311qbYsuY7ea75uTefqsfv8HlC2UKPvf40jJ1u9MRGRtGmtilJfk0xEhtBytXzjiNrnQtLuXKM/cS0ena6F1BvBKlF3tYaOFkYAkkbQBQ7pDe5x4NCfe4UcNbTm7XjBWzWX/6&#x2B;i9/UieU3mDo8Z9&#x2B;8H7mnv6Dd1jbrjGbq&#x2B;G4tNClj5N3XYkLtxSsmi6/VJCxYSL5Az0hwchy0mp&#x2B;DquWWNZo4tToGgtJXkz3ssCkzFwyfiymqGMIJGIqVKAhkjYAyGNV2XsM85Ijd&#x2B;enN9ho3lgK&#x2B;jXin6AbiNYX8k8/eF8NbrNevThRi7DCtp1iNi/3oxkTnGNv23ziZGzobfV6IKbrNNSs3/1tiRsM7ZjZ4bvNd41kix7kYStGp1j0GAIurr1APZI2AGjpkFFuidKPRn0/FIfdVXBU3fErlwc28VXcwWQ6XYtrnrftmq7Fp4EqvlfRSl7pMl5Uq2vsHuPYCNjQldVRdcgKvpAmq7x5gzf9pV/TuhE4t/whFp3J2ZRV8Ea2wcmDsRP6ry5ZDQcgjqQNABo7pLJywntEXFmn4e/&#x2B;&#x2B;reU8Ozhuy/dcA4FCtZm0z1rHXcLAxV8&#x2B;tYv3Y2E5qEq2sFxyNgwjNsJS&#x2B;SGYeJl7LIE9iui7reM&#x2B;o38r48UAmdi9B7wWTvTKpoScgkV8hEDNbilMoKADWVI2gAg22UtZOM6SsFUhLPmpTlB2eQ/TToCsgq5lZm5o9lU9vb1X/6Uu1eDB6i1mnly8G2wDceMcvatomDu38jvIzHbKt93ZGyQg8gNpsqJHGueHpkkfMw&#x2B;qMdvULWQfC4LObz9Zi8P3SHU6eUAbI9WA2qQtAFAiYJbfpaunTeZBNI8aGYClxX8LH0Yp0sptIOXRNbj2z794P3n//HPY160jJUXqv8W5G1lEzopKSfI3otHIsXgj1j4Zfn/&#x2B;99vtXdoLWO80BjQweeOe5OHwCE4p6m5XBfM&#x2B;F35ipXUHm5T0uJ3TW0zUG&#x2B;ulMM4pmbLp4n9MAOqi4wN9UjaAKBQbiCxYouryQ6H3jjd/RKEPp30Vmt6Ifn0g/cT12ZTnrx4Fp9AcuSAtvqpLHMbM5X3lXslvrr16S934YKrZqE&#x2B;c0TjQgXDCthutJYhzKxqIbWyhUQ&#x2B;lNxKWtm4n7ZFVPi3RjrhA7u3Oc5xh7xNAGOQsaEVkjYAm5jVYcEUQFr9NN/e5UxQSQc86QPa3KfHH1l8Q1zKgm0SRGK219/8MHgGy1zWnE7NA1RM1zv9WihdU&#x2B;7v7sw2Dk1lzBUPS6ZMI6xel4rrukKfXasSRcAW4g0syypaEGunEgukO3OIGwEbmiNpA7A874SE4xG5ReiPJtKzc1qtrquUgU2tCqp3O6GaeiRay82rhOdblsujXblMi4sr0iEis4e17Ulf4hJNaxnLWXHCA3QyuDB4X876jbc6d1RvbMGb1V&#x2B;&#x2B;wz7QvT8LLpJAV8c2FWk1oBOSNgALc6sFEtp&#x2B;dHBfhmqhp6Cf5kHOGKEJJNeaN9ISHzjodiiUjUWLJKCJe4XDrTXkhdYy1kU/MrJ4xxmH1gJs9UIpD9usGMfrZu7D5s6tsp&#x2B;2lRAus4DLPcsOOU1oNaArkjYAa1iov087KnJLGbITSuAOqdJNtFaPucUN29YazXapycpqBS9knpKtXgLF0m8T8faxxs/x4o94ibJhf6HQWoZgE2uGS9cE4FV/iW4YP4j6vqhPv7x3c6bcCDXyLBN1zLtqclTLlioEznHCGUHGhgFI2gCguxNqLVk4ICN5j3bWcMOU0VGXExDV6BGtJaZ3zQe03d7uAAod2wHnCDGbHOnnY6RH77RudE&#x2B;XGa1lyBOZMXti2HZ55eer4Vi6BnLyvBRl5&#x2B;aAM3rFQ11zWE6r2ADjrXhVKUPGhmFI2gCsIb3Vd051QSbz&#x2B;NNASlEQq1weVfd8MV&#x2B;i64dSdgIOHqbm5mevv/lhzD7E1yms/2hUcbLu5g6VBMhndosXF4&#x2B;si4z8EsIgNqAYlTThzMt17uSNiS6/UEK3Urm1C2kqa9Rlk3VXSq&#x2B;hyTzmcWOuMCenwgDiCNgwHkkbAJ/3Pvb88u9/HL4ftlad0aiUO5CChk1IbmGuLPzFQ2c078e91ucbGqbWL2wbfMnyfkAS1rDELXMxUf1RWr2H1ml4zsdKxoadSA66WNNIsrb3TqnPOrE0iioV1vdpwaEIzaqt1Gw5dy7o4o3gEocROBMZG2YhaQPwNm/GZv1pduQWaWFSme6qU1MTY9x/8sWvf/YL9e&#x2B;v//Kn4u007&#x2B;UfOaCtx2yQ9YbNFYm50tezdB/cY9UZTX7xIGPDQiK3hRWMWOrKGqUkYZeQaMyHJf/bQamP2VrJvZNmD972eJP3GLku0QkAwIuMDXORtAEwRGI278NmR243&#x2B;gWGYFKO8by96jVF/fU3P&#x2B;iY7Xa7/eH/eP7f/&#x2B;cr7&#x2B;umfIi5H/STF89kRlw9xFv&#x2B;5iUrMvisgPtczseNJXZj6VIRn7ZUMjI2LCp&#x2B;ksqpu1KRFs77AdV/ZFZtxDusTf4XRCK3Ut2jzHtr7LnHcOIxL56yomBOewDogYwNEpC0AYh5/vlHt9vt1Vff&#x2B;/&#x2B;sIjcBeZvGdDdtZTWKOPKtmIfdW6Rzm6yvv/nhd3/9m/7vpx&#x2B;8f7vdfv2zX4RGto1ch2OzAW3eD2VYP6b8NVROVtbhfmwnOAEb9rBEFzPfF6tr9U2xX0mIzw95c87QyDK3BRKP59zD3nte&#x2B;jHvzlxNcMDLAZCGjA1yvDN7BwCI8faAtueff6RiNv1v/V/PE9XPJFaVWnh3xpbUnbCz92IT6XcuJx5zK15SMZtijnJr9XIh3kRtZMzWyeVbyLoiNblLnfNRuNzlW9TjW32m8svG/SdfvPX2Hx9pLWN1y513mCg&#x2B;EPnmfEEUly75xXIYM6fRh7T4jEh8ooQKW3xXvU2SlHfX9mISuuMQAO7v7tSP&#x2B;q9qNdBwwFyMaQPgEQrVkoa43SaMcpt41/&#x2B;xI0hOe79d6UXdmy9H783SEjW/P3RurtZ8QJsaJvj1J69uvnufjx2KhDLxApMbznm3LP&#x2B;izTg2bMYcQBM5Aaefm3xbSVBQbagvOdPLXnPFs3HUz9beaQJ2IXLn2&#x2B;h9VVn0MAJohUFsEIukDcDtdntrQFtw7JrzgFjkNiNsu03tLDgkctv73Y2UvsBSyoNzmZNJokD8AI48TTgllxPvjEvsmr/s8zLJLyRkbNhMaDI61/TTk5htLd7P6/APMatGnfL4fnsiWSRr9A5uy52xvO1SxACORcYG4UjaALzlMmbzPtgTuU1awm16h8Vt08htp/eyBD1fXE3DMjSgzUyJrMfwQUe46Zpe6C4xHQE6WfR7x72&#x2B;0VrGBkJZSGgADVCgoAidWepy37U7e3PZcqprHe0me5s7F2WutQ4pgObI2LAEkjYADQQjtxmD2&#x2B;RYtOvTtO6eS2OP2PBNujKmwLhxUeJ0N3vQb99cry7iyYtnr7/5wTuCTcdsXjUdCud8HOeo7GAaP6VYbwxiw4GO&#x2B;rZFEykDoNNXBWu2W7K1qlHPeq40oanRL8e9tbXTIQWQi4wNCyFpA/CTrAFtkS0EZ5U81XKR2yr7uYqUaW3KnpgiNM/hpx&#x2B;8/7u//u3TD95//h//XP8qS8idM1Mdf&#x2B;/QQBWzWTcy688x94OzJuHx4qyUI3HZs9CVv/6jNLfsLYGSkbHhZGbYtlzlEMMk1iKWqzYULxqa/k0Xmaa1XxS04ndxAXe&#x2B;jeJ6762iMAA4BwEbVkTSBuCtRdqaeP75Rz&#x2B;FbbsPa8u6n5RelQPFZ5Hqt97G629&#x2B;iPxVjehKHNd1Guv4q1DNzNt0zHb53LiuS/FhrtCSMFaxKSgA7gDZVbqryNgAL8a6QUlJgxITI4Elqqyek/hm6ytRocknDhwyWHC7WMNX3&#x2B;lIAihGxoZ1kbQB6OKosO2W3x5bpWMUleTEJ4RquQPaLN5BbD2w3tsGPMuP5ZQcM36LPHGhokLGhjN5K4fScrUB32voTVSJaihlycN&#x2B;L82pkbK05OGHCEBzZGxY3TuzdwDAAspmg3xrLsqmw&#x2B;buP/lC/TTcZisP332pfmbvCIbSZTJSMmsKBiWqoU8/eN/KHVUI9&#x2B;TFs/gT02cLTHkwkGXFbxb3kvjw&#x2B;EiDGQcKDWYVYrlrC0zSPj6xbbQU5sGMvAtpx7yVms/OqqVY9xmsWyQADHN/d2fGbLQasCjGtAFI8uqr7wtWcXtrZFsjku8Lxpnc1qNbMssKamh&#x2B;wsQ5S1PGsV3GS3vTA91&#x2B;99e/ff3JK/eAl93RHPm4Q1P/xZ8FsSIfn3meJi7W6L2YuA&#x2B;Tj0FswG3xaurSO7&#x2B;HyJJjg/ckXf0Ukd6RoFlz9VfuQJzkgx9xWdX0jsWv32xo4wBgYhwbdkLSBiBVWdj2kz5zSC7REdC7fYiJeqyW4b2jljW9QhLnYv36L38y11q7vT2fpJoc0tIwH234eAiUeBf85dPNRdcWPc3J2ACTrqZaJ7W0E5yaKqbod7Na4qsnro3XaQd6G3xGcwEBkIWADVsiaQOQoSBs6zGszbJE2HajF2N9uXMDWp81H70Qv/vr3z794H1vzFZzMcn9uJe4aiFu2Em9RGkhYwO8QmGbQJdx4BLXoqV5CwmHva30e9eOPfJN3rhVmI89mABcZGzYGEkbgDy1I9v6WCVsw7rcHMXbgDSb7pXDXIqfle6cqSPVkXSHtd1ut08/eL/hgDbz5aytMUvk6rLOx4Iw3vrTQuWEjA0wyU/UIuI7v9alCT00rMxkTQsx4JzSiXjvF&#x2B;qk7UeTuxHvB2SO1L98MIATkLFhe&#x2B;/M3gEA68kdo/ZTMvfex233xFx7mSo7&#x2B;kkfn&#x2B;S2S5usDB9q/KtTYN1OgfGsUO3rv/zpyYtnbQ9g6OPmw1pa5Czu8ZkuUU7Uxe2tGw5Yuhy43W5rrrClseTSXAfWFqz3e7lk6f/P3v2z2m6seQJWXyZzcD6CMycGBw4OB5yd5oYXM&#x2B;lpmo7HMJ6OzP0IF0eNA&#x2B;fDMCdtTIeXMZMYjAMHBicOBvwRHDj2BOqrK&#x2B;tPqVQqSVWl56Hpe7z22mtrSdpr16uf6q2TtuHsH3Geyd/itdAr8B4TTrnIGwoXX7n2UBNI8Orly3HMpmqgVea0ASnWZrb1Idxdk97cacsZrr&#x2B;oFK5XI29ZfeeTD3798ofwE9I27y67fsED/Wre/NufrpleVvW0BjblOriXLUiTkUlssGntT0AVfxqq&#x2B;CCiavORWLhXRF7NNzacjJkj3&#x2B;Ckr&#x2B;YkS4s5Iv0rxPy49vY5sGgyia1TONA6SRuQX5kdJnmIxS4lucSvn/Hp&#x2B;x/9&#x2B;uUPX/3089Cu8Isfv0m7vlbjhfjsImcUJV&#x2B;ROX7p09oqLYm/AJdw9apqMjaIF3/RmcdyegSc&#x2B;nezhD2f5fPhstFFuDV6V8lMtbYTViiKRpE8k&#x2B;6RQKJwD8nJV88L3tq4dkkuF9TkMVXZ4mJg/&#x2B;e/vll7ft/1JXu9F5i1Vt2EtiMuu9A5dMh5Wt&#x2B;nxswXZRz&#x2B;/eQjq1EkJFj8xHjsxwiPFTM&#x2B;zzKGz9Kz/RoJ2zk0bU7oDxkpvifk&#x2B;IdePzqq5SjDM2kUyZOZ0wakC89dW/7qi9fdL1&#x2B;fu1k8TPIktphBtXdDAAAgAElEQVRvXGszGJihMsRsX/30895Nmr/sGYVrYzHbqbMYE5SzJSTYe&#x2B;1mLceNyXdrOVXMY4PsmpnnCgFHArbsnSRr&#x2B;Zs7t/jGnzxfdteZEHjyk/chnMQ8NpC0ASc6o43kpIN83hfPaBi4l7yR9Tq4V&#x2B;fLhu8qtAJPXlwa7eP33u3/8fZf/&#x2B;PIiydoLFSLd&#x2B;ryHms/jhqt9RE6fh289g9/ARucSthGwzKe27UPsU69hW5zubsE856QF9wFeAYfsHCl//d/f5cvKBx4LEkbcMgtS7IVdW1is9t7LdVIRdKO/trsNOiOLfCWd0u40tpxf/hhlbHBNYoa0EIJct0pVcLf8bS5aOGCJfyhkf3zpN/a4YeWsFeP88ELGU0Ctk7hwONJ2oB93nz2YWCFtvlXr4zibh/9y3KKNZ/EdobxhLaP33t33D1yrZNkRbXrr1/&#x2B;cPsMuch9dfbOLP9gPVP8J3CWD4Hhl3dy1Wzt7u8qThsZG1zs1E&#x2B;GzbvBIMYFscTa&#x2B;RnZI2T8l7eEUz1mj823c75M7Lx3/ZGfeEQJezUs8gQo/41ALV69fDnOFFQN0JO0AbtN4rRJlhaO4nK5uDXcXkUVe20L3Ja4eXqccUvjYqI2fvDT9z/64sdvJpuRdxuyGxLE4R8XR25F/aaXf7xYE5jBNv9SrrOulhNGxgbAXK7V0WImkS/&#x2B;LY4crtfy17ZbitCKGuh2fxsX1bJLYxLK0vYwVM1ibBAgaQMyuCVs62qoqRa759&#x2B;3Oa05MlMk5rbQtecsVnSLK7Ql/PSirL2pvfPb9pbrF8/z2zzitRwvjstyG0dFJ8z8naqWAZ5sPCg6u7d2zNPW4reUzbrJ4tBi71g3fiW2LDunrj0c0MwbgRLI2GCTpA1IcVmW1oxaOgSWL3m&#x2B;4GJdOn7w&#x2B;N2OkwltkwaS/SNd1735tz8d/EEVSdir4yMS3zYnTczFGr&#x2B;29Yr5uNhs3xSw1kCyCiaxwaPoJMmm6&#x2B;f9jP967k34qjiNw82l174l7UBM9mQV&#x2B;&#x2B;e4tMXwgL0UDhBJ0gbkceV6bEWJXD9g8Kji5xoxu/SMHT5J6T59/6PhS32i1v0&#x2B;bBserEV4ll72ZdsCpfKpXV8WX9lvaAMmqzNOrnZ166fcBdt2L6UyPMTaX09/&#x2B;JiLmSZ12Z/ItdvjrvnpYaeWckO7jr27em9Buvi9hSvqFIWH0P0C9pK0AYnm09qGsO2Z0912VTjytt6RBe2O7MMje35vCVddwNbb1QxzrvCbScNXcEreciIdv9Sy6zpXLeeMjA2eJv6jzBrDTCz2wM&#x2B;eZES&#x2B;YAmn5eQOnq6MrTqiou2/oGEmMKZqgDSSNiDdYth218aU48hNhZxqfoHg1y9/6OeiDf/ouu6LH7&#x2B;JX16if8HFCW2L8s4DK9PxsPn6pcuV6M3bdUYlrJtSONUyPNYw1SPyb2vh98pwxPRvQXkHuq7bnvL&#x2B;slTxlq807N61D64sxYKbDGBC1QBHSNqAbU&#x2B;eqbYpsO6FyC27g&#x2B;sWTMynbfUh2WJUFnmJqtIZbOcJL4K1mLddU&#x2B;iOrzxe8OM4z&#x2B;Ztzmd8Atdy2mj5AvSGrnRdxGjKH8cmzY/74oG&#x2B;pn65/p6qXeYD1ONbe&#x2B;r7jY/Sr7dr/l&#x2B;ZbwEeQsYGx0nagFiLy7DNp7U92do9ca5WFGgtZhu&#x2B;Op98tpiq9v842GuxNOe9ndLqZ7&#x2B;bbTupT2wVp41SGViz&#x2B;CE2&#x2B;dAQtj1EUQe6kC05ez2wk97m2t2ft&#x2B;zVtIlim3vVYmxwEoUD5CJpA44Sts0F7t0r9n7D6lw288nxOmjXrayFXGThLnsXPln89ZzPm0zbjIlaTk6lMjAR89GqE0MzFkOOAg/rODUp/C9ssRPawnVK4Xt1YrNFZF1vB6qgaoDsJG1ABoGwbXEm3EOY4rbXZimVK/c6OGdrvnnvfPJBzGs&#x2B;YZG2QXxPv2vup/Z714Bwt97FvljHf&#x2B;i45VrhVMtwu6JmCE1Mtq2oGTD0jsdO8T26I&#x2B;8pOft8qOt8G/e0iBxjXJ9x3r5L4xds7grY2l4hmwGXUTXASSRtQJRJkDbPzxbXcntyzDZWWi1RpsmlgfP21afvf7Tr&#x2B;RXdclu4yS/CZfMFHbVahM&#x2B;HQGezkw5xRWeOahnKUdqoL&#x2B;YuhNK2&#x2B;ZnOmzhV4IS2YuXdVwurpeb&#x2B;Fbu9Tgm3cpn8Y/wtw79j7p06jw89nkbVAKeStAHb4ptDPjBa29Vsx4WMNQVeApgs1Xb8kD1hQltpx9EvWu0yTkqLfLW6zpmFS3iqZShGgaO&#x2B;zY/BArf5gdJuODvpb1yuu98KOaOml5iv3arzflwhu3dRzDDs4rvxSt5dcB4ZG1xA0gYc0odwDwzY5nYt0WyC1NO0F7MN72jvVTkrwRBj7fSY9B1d&#x2B;9LwSPjV6qVUhorcG1&#x2B;NPxutPlus&#x2B;OOymRVFliQPPBkWZ3MeXM0uPol8SN03/7i7vux9yK6GeAoHuIykDdgQM6FN3jZo&#x2B;MLuIPnm1l1Xmk5qILm3dWS8yKXaWrK5Etvic478amzW6krrNgRitm7/xcHGprIplYG9Yj42H5i71CihP2TGw9r2GZJ9aNE7Y4BxV5fIwgdLgYNS&#x2B;JbDSVQNcD1JG5DN28&#x2B;/f2DYtrmefDNF6fGAZPyfgRXXC9ljCbPQFsO29maz9QL3BV98BBXPbUi&#x2B;nf85VMtQvjLzqrWpwIvPoViLx2gyqB6vjDXcn3TZpKKSh2S3nOEl75BddnVt6SLeeN6SwccXTKga4C6SNiCnh09uW6wuSguQ9jppefai7ov8&#x2B;L13c71Uq7naxD/&#x2B;&#x2B;9tcL1XOaUCZJtdi9l4mDvRMq&#x2B;Xcsxgb1KXMsI26zMfJCSdVrj9zjZ3Pt9wWdkQtw5V4a&#x2B;9o7ztd/LAdh80J2wa1k7HBvSRtwD4xKdrD87auicjtOdOSMsZsTfrqp5&#x2B;Hfy/uq7RLijcu3kD51lKxyDNt&#x2B;PbF51d0simVoVKLH1mFfPhUFzMwl&#x2B;UgOgcWhYe1fQJ6za4r5BMj3jULUjpvYY3CAUogaQPO8sxmkhPhyK1MyQXMYiPN&#x2B;YO3F0iitU1DG8xxzDb&#x2B;avfvb7vUMzlt5fnCf2u4wPGPjorOIqUyVGrzGv2VGzNYvH1h8xEuE5h&#x2B;PTc/i05KOAIbU9Hf017kLopcSXrvtySobg9fYO32qWsSPijXi9evXr4cP6BwgBtJ2oBD3nz2YT&#x2B;DbZHJbYM2Ju6sbX/MpZlC3ruYLcarP/750/c/mj/&#x2B;1U8/v/m3P7kSR7LA9alwC6BJZr/3JCzk8yeGjA04g2itaoEjFX8cj2e9Ff0xTdD2u6vC2kre4TPcgeOxVA1QIEkbwCF19YRMEy5g0pZhK7woeshyawFf/PjNPGz74sdv3nR/mjy498zvz41fv/zhq59&#x2B;/vT9j7748ZvAyVD4efJwe28izvIhObl5ea1L5DCDtqJTSLUMnGrxEvYtW0KMtdRh8d8ncYb0zg6qG9jPeQvhhstqyELVAMWStAEbJrPW9IRc017kltBBJdfLZtFA1XqvL378pv9HYLJRwgnw6fsf9a0px/85jzYdvsbkitlOff4tFn65VMvQlkK6Z1OFjBFOuJdplh9Ri8l4IKHfYPYuhVUMUa4XM63NruPJZGxQOEkbsFsgbOsfD/STvMa9rRrbi9wizS8N3NI3//jPqnRC23mrdHQr1xfSYrZuZfk3HuLsK84VXX9RKsNDlDwgLHnbyC7Qpfk5ks/5tJWGS7Nrun/a2zzYUWBtPbbkF4Q2KBygCn&#x2B;4ewOAKr39/Ps&#x2B;Trs3VCu8yGm&#x2B;JJjfXXj7W97cgEpTtLxe/fHPw/8lfO/wCnu/d3Htt37lvF&#x2B;//OHbv/7l9vOHs6Ud4vHJFl7prZZTaPIb9O1336mWoSUVfRbdvQmcdadU2rStjBtQprWbAhs2HnLser9X7pwnnHuQZl62KxygZOa0AdsmDSQHt89d626aNbW4AYvbkL3TSJnufWt5f3p1Udypt6bGvHJ8m6OP33t3Mputj9mo2uIcx4TFHWM0cJuz21HhIaroGBn4C35vfwh6m2O84TANN0ItPn/tQF&#x2B;86lvVKv2NCNyrFP&#x2B;NkcanWV0L5UKZVA1QI3PagCjlr82WPEfnsm0o/GpLFlW8x0CWVmPMdv0rRAYqk9&#x2B;Ffm22cbQmZqvdeA5Z/E3iJS/ueCq3o8ID9Z&#x2B;TJX&#x2B;ITbat5E1l4uCfWse6F7Ov0trj17KHSyiiO7kvjKgaoF7mtAGtub1O6Kq97TFsM1&#x2B;J3/NHjlGWvfrOJx/0wc/kweOvPDb&#x2B;EWdkeHt3Y/ZfjbRjsRaw/frlD9UlncR/1mWc3lHXR&#x2B;vCojhKZXiekj&#x2B;4wjfNlLzljcnyJ3LtRSbT2uo9rIEm0jGuWU67ot07mfQ2Ga3tHbzFN7pY&#x2B;/bk74U2mMcGtZO0AbHWekje6OBo/mwlb1u8wLs4WKzee/hODXXmMV7/SMIPTUttN5uadvmOWszrLK7QRu32LvtxJIwfTryKrsIoleGxqvu8Gpv8oRe23evg/m9sntB8eJC8f9LKkDaKu0Hk/ozZV/PvSutvX0XfXTiDwgHaIGkDduh7SK7lbbd0mLzmzsRnyn71PO351ZnHbBebJ2G7Fu3Iq//Rt&#x2B;8TrjFcH1m84DJ&#x2B;Wts9JJXKQFfAWsLJCr&#x2B;VrSW59vPiIavuxCtWvbt3rQ3JeRu/69PjYJcUaIDuF9AYSRuwrY/WhiBtMW&#x2B;7fSG3uyK3h0d9573rKsrXuXCkdGODxJOu9y2eAJUeO3JpY9mSNDI2YK6EKW5Heu6Z1naxQFYx7&#x2B;8XeJH8W3arzX1ypUJ&#x2B;nRMmja29yBk1XcKhaaPHKcRQNUCTJG1ArMW8rUB33Yf7kGYXm9fQF/dA/HWBzR/B3MHuNzFl8Nph3ftzAyzSVqZdV3M2ryaHPwfGHyB1fQ64HRXYVFRetTlBx7S26006Pa7NBV8LTcs5uw7aTIVvuc2x0iHKkSXWsr/NivYbnErGBg2TtAH7DFPZik3a7hWo/aquLjabe2z2Jzy7eCvBlT0Sw5VzIM8446pEf6CbPKZPFtmGdO0bk9dNSfiuG8nYgLkCGx5sJmclTLx7ssCef9QQa23lsOO/SsfP8GaOwtmr980LwM2fckHOByWQsUHzJG1AoskUt7Hwcm4Zldxfoo0pbpF7VdUa78YGkglirm70R/Bpx7FGhVxFrf1TcaBUBjYVNRqMiSsK&#x2B;UtBpAaO1PiUO6/1xWbvxDLt3cj40nh&#x2B;N9X&#x2B;rYsSv3uHD6iSjwgkUzjAQ0jagEMCU9wunvR2V70U/rlV995J2JORb7a9RjfdtRPaJiaXJ3bVtJvPmRftLR011uz64Ir/oKv383BMqQysWfw8LOfvZmSe0d9nU/Ugtgq7Rm7zfpJnbdYeB6ORwAkWPv0uODML2cPxNm&#x2B;Mu6zXRfeYxgawSfcLeBpJG5BHOV0l77obbrNaflTvl4FmIGUaN7Yq4YhUNM&#x2B;vSYGLd5GXZQtslXYGGRuwqYS/qmGbLcG7YoYHT1b&#x2B;EDrvX/zI3PHgD43v1lCLtffiVxjupWqAZ5K0AdvefPZhfCvIt59/f1nYFl6M6q7qoopuJGdYq/Seth&#x2B;yiAk20q41jA/H3nlLCT&#x2B;O8gWuriYc9Mgzs67Tye2oQPMecsMEN9p7N&#x2B;RJQ4UCpwYWYrI3hgGhzwTYRcYGTyZpA6IM4dkFq6/tVWwNUOAmneQ57/Qa1&#x2B;xPMduT7Tr6Wdb1qXT5DaUy8DR1fUq3zbHYFL&#x2B;kdIHVSvZxUVpRPEnZ926PsxQGCgdA0gbs00duheRtBZZMTxAuw8osZcPGS6yltTGMX6Rt8/WL2nvXFM9aR5Zg/Js7PgnjT8jNjkx1XYtRKgPNi1xSrq5Pb/JK69VxpMNHzJyzSYeGulYFq2ioX9SmQrlevH718uX4AYUDPJakDUhR8hS3ixU7o&#x2B;4MkWs1VXRFZp6Q/frlDzcGP5edSBefse988sFaGClmu974&#x2B;tc8OE/uL5rw/DLJ2IAnWOu&#x2B;3v&#x2B;jxhun6tJqt/m8C/7Fj1I29&#x2B;ft&#x2B;/nsX6iDb9DvOyTQYR6YkLQBh&#x2B;xawq1hbS9uEViAreqlDtaynwvCts0l7s9LcDd/9JXEbEU5krEFXqoiMjaAiUo/z7nFkcWzGw53q3tf82PhcwAmVA3AIkkbsO3t598Pk9jmJmFb4JnZFVgGBCK327dtr5iysLo3NQj3ezw1bJvv2IM3/Ma4/fpFvz&#x2B;PN&#x2B;p8uPhTZe3m7sXHw3eCb548t59dB7kdFYCL1TuELkQDkwJL2PK11t/jB0vYTiiHjA0IkLQBUYYs7cogLcakNrggsQgbmpyoSUoWv6zaouR8951PPggEEvOC9uwA4/qzVLp2xK4l08b/jj/Q4TZNMer66FMqA6yp6/Oc200aXSSMYJvpEVJ&#x2B;K8u11XmPjACheQoHYJOkDdhnMXIbT2sLT4DLK7DCRCF5243bcJIm31SktbK/TzIOpncXqL3b58ONL4gcX74&#x2B;8hXiu5hWdzoplYGHm48Kao83KMSwbHP80GXxFcJLCdaokMHS7XemQmVevH718uX4AYUDsEbSBiTqo7XSprgNSighStiGXJp5I13ShLaEqv6rn34e/v3xe&#x2B;92swlt563EFtDScWQsfPd04LPo&#x2B;KXV6k4qGRsAXCBhjJGWyaX9rIcrcBUGKI0O88BekjbgkPEKbbTnyRXXrqXaXv3xz//nv74Z/nMcs/X/2Ydtgyp2bBUbyaQCPDIdbe/N43WdIUplADhb8tigxhVh6&#x2B;1i0ieaw16t8S3AqdyZB6SRtAGwQMUVsJhMvPPJB/1suUnMNnz1vO3JnoU4&#x2B;s1bvGd8fhmrwKtaCWRswI1K7ttcZnpB4a5p6rjwtzvYBd2ZnKa0DyW4nYwNOELSBmwbL8NWlGbWzS5K2xXXwdXUJjtnUvO/88kHb//1P&#x2B;bf9cWP33zxx2/G/W36f5x93rZ9KJ9ss7dS/KEf38vc3gepUhm4V3jaMdTlmnFCsZPpa//9HZctlb4FOJXCAThO0gZE6ddjKzNv60RunCBtFtoXP37z6fsfdX9bm&#x2B;0f//3t&#x2B;Kt5T9TFW9FVzo81ScuOnGPh28aroFQGSlbg9W5DaMJynSHJK7FtPq2iFbLv&#x2B;gSoZf/AlXS/ADKStAE79HlbV3zk5mIBN/rix2&#x2B;6rnvzb3/quu7bTz6Yn43x5&#x2B;euM1nx3LC9n2nh&#x2B;8H7r44vSAV6NFV3XsnYgIrc/kmrgeST3RtNTf9eH76BrIoRS8Zft/j3W8WegeupGoDsJG1AisAUtyGNu5FygmskdIXKez3LqU4vVzPJ8ZPrOrvcjgoAMcZ/MdOy3uO3NsZ8b1HjkCwD&#x2B;OtfpKh9COWQsQEnkbQB6eZ5Wwkx273cGvxMa3XsWhQ3fFfgbHEiMbf3nAlfYWmj&#x2B;6iMDeAIY9dHWTzW8ZPbdo0T1m5BWzvfahyEFMhuhAAZG3AqSRuw7e3n3wcitDeffTiEbeFnPoRF4x7iYEh22bw3mjE&#x2B;Z8IXxeafQuMnjy&#x2B;qTv6dd4PPplQGaqG9ObWrbpBQuL2Zpc8QOOTF61cvX44fUDgAZ5C0AVGGLO3GIK3k6ReLZU85m8de73zyQeCrx6vcxXPDTeUclHYK1fhJJWMD6jK5PSLtLod6b4zgLpNz5oJx5q613&#x2B;49k&#x2B;M7Z0but1NbYs4bY2R5WWie7hfAlSRtwD595DbJ2&#x2B;6a1javHm8pM9bKqttXuSe7tEh1cnVj76xHp9DDnZTsBh4vmYwNaMMQtkUOX&#x2B;d/C8aPHPw8d69PS3blPWcc9/6UXrxFMuNJW5Qbh/Qt7UbIS9UAXE/SBqSYTHEbL9V2knABM3z1&#x2B;rBts7K6K/8jWXhC20RMB79dr9bqNQiOi78ctnaRa1DdqeV2VKB2eSON&#x2B;UKw1X2wM3d8EJh8mh08hSajjrU30uRZel5KvTaWa3I3QkYyNuAukjbgkAsytr0KvNZQ4CY91juffPDrlz&#x2B;c/VMm62lNvhpOQZwqRAp/sDRzaUapDNRr7c/9GSPDvEkJF1sbLh58kcWvrjUyfZRddy&#x2B;duiV71TiWg8soHIB7SdqAKoV7nhSYbBW4SSzaNaGtSz2ypRXtNGw4P6v7CFIqA40Zpxrnde3b9fzs20CCQCP68/52X3P0qxt7HJSwHl54uYGn7UBI9OL1q5cvxw8oHIBbSNqAui1GbnfVJOGZTGS0eFtu/Hd9&#x2B;v5HXdd9/N67kydsxmx7l7WYnJZrS1aooom32RaygQ8fGRvQjOFjOdff&#x2B;jY&#x2B;5xnsPZrTP5HrpVB4JensimqBHv6lS9gDJzXl9rsMB&#x2B;kwDxRF0gZs6xdj64rsFTkoLatIuKWRU42PxRc/ftOHbYO9U9kmr7x5&#x2B;i0&#x2B;oX&#x2B;wtFOXYkWeKtmv6l5Jxga0p9hP48Bgtd6/I7WbL3gW05N88gqLL3WBQk6YjO865qUKedfwNKoGoECSNmCHGyO3Bm7gNXXpRvOT54sfv/nix2&#x2B;Sj0j4hAyswZY2G4/HSjthqju73I4KPMQZA9qDrxn4dmPXsy1OAgss73fGNjztENdeUQIyNqBYkjZgwSRIGwK2ySOLedv8yc&#x2B;xeFepcu6ILJd4bj8Ek5Xnb9wS2jB8sNx&#x2B;bh&#x2B;nVAae5uDgMPy9aQOnybcE5lRxks0K4oyAtpAXOWJ&#x2B;fobP3rTdePvbBHoKB6BwkjZgKn6&#x2B;2nyK2wNjtnCPF5IlVMJrC1fMH8xytWJ86PvjLliFeEpl4AkWpyZnHCueMew0ninH3tFszPmwFj7tPZdKWIktWcxJfsFcT79rEOXF61cvX44fUDgAZZK0ARvWOkaOQ7UHBmwBwrZb7Fq44kpOBs5T6dklYwMeYnFwMvx7b1tgV&#x2B;QfZe30WHw8&#x2B;dzQ1RwomQ7zQF0kbUCU&#x2B;US36&#x2B;exzacQXfNzN02ufQwb5oLIZWKWTJvcS37etLbjLwsT8/OqxjNNqQw83LwfYLEtsosddT/T7XlYYydAOSG3ahHWuDMPqNEf7t4AoALhfpLx3SYPOnu5Aq736o9/vv443vJD4cnmv3Tffvedghl4lMWxx64BScxdF40lIqzJstRfzIvcextZP35IeLNrNz7Gv51de2nXJu36EjzQ5Lde1QBUxJw2IIO3n39/9sy2tcsThVQmWvokOGOPBRauOPsAFXIq0pIGPlXcjgrQWxsrRo5m&#x2B;&#x2B;8dv4iBR0tiDmvGthkxaxvXqMyBUzO7F86mcABqJ2kD8rggbCvcPONZ6ypJXmvXJq7Z4Q4rZ6v0HFMqAwzSPsmHdC3wiJu9GrNYO6RlbE6Mk0T&#x2B;Osc8rdIxHmT24vWrly/HDygcgEpJ2oCQXeHZlWFbsWVJsRv2KCpb2lDpWSpjA5hLjj3iv7HSvxqsmcx3jDkTAlMk10JZp82mQM&#x2B;MwPOBTVZxBhojaQN2e/PZh2trsz12ZtvCGPGvf&#x2B;kUWteK7L80vi/YAYJclMoA8TLORTOYqdfmaTAMVsNPm7/OWqjWat/IgCMD/ifsH7iFO/OAJknagH36IK3//2t529MEVgVTnl0s0K5z7abgX7/84auffu7//fF773Zd984nH8xf2aGENTI2gLC0UC2wtFu3MrBJGK4Yst4rIXMNZ2&#x2B;RmVzDR3y43/FImN3w/oF7ydiAhknagHTytk1mTV0gcB1qc&#x2B;f/&#x2B;uUPiw9OwjYHERYplQESZBlX5M1LDFlvNN/zgQlqxw9Tqwf6&#x2B;nXpWt2TcAqLsQEP8Ie7NwAoWkyKNmkXeVLwVmwls1nUWY28WJ&#x2B;&#x2B;/9HdmwC1evXHP//uwt9336mWASYCw9dc48PJp3HCy467amfZJI4LrLV28ZYAHPXi9as//nkcsykcgFaZ0wZsMGXtOLcJny3cXmn497jZTjhmm09rA3rmsQEcFJ9pXRODDeOoyFXBuN3iEtHzNdjaO44x72j&#x2B;nCy1mGoO9tJhHngaSRuwz9vPv59MYuu67s1nH14cyBWbXa1dnih2g5uxtgzb2PB4H7P1q7INJv8JjCmVARJUl3&#x2B;UvG0sGqqMoQxpsuhwZkJF3JkHPJOkDZjajM0Ww7brFVhGDtvjduCJvMtLbBpfw4q5niVjgwClMkCataXUDoZtgW9PHmUVnv&#x2B;1au9iezHHaD4PsrSKaW5zPzg5oRYKB&#x2B;DJJG1AiknYdleHyQLDtrHJNYvCtzZsfjt22jeeZFKfh68sLE5om9NAEpTKAGeLHFNNnnZGV8m1sK3e4Wvh8g6SK8rVJs4rFuTHcJ0Xr8crsXUKB&#x2B;CRJG3AgphukNZvi9FAgbe2/llMGX/ke&#x2B;Nt7uH5UTCJDcJkbAC5BEY&#x2B;pa0dpStDIXbNXUt&#x2B;hUotnqWb/TOqvuURSqbDPMBA0gZ03S9fdy9eTx5LXnrtpMaSyXOqzjZOcdor4QJV&#x2B;uKb3dsD5&#x2B;BW9T&#x2B;on6PWdd3bf/2Pj9979x///e38W4bD9O1f//Lrlz&#x2B;cunlQL6UywBnmo6aEwdJlE84aG82Wb3J6zEOjxdX&#x2B;Aq92wjbmMX9ru6bi5XoOkIXCAWBC0gas6jOzXXnbZeu3XZPoJGgpbNtbqE8Sx0ktfVLZP4nNvvrp50/f/&#x2B;iLH7/pVvosxcdsWkfyKEplgIvtyhj23vxEXeI7NOw91m2cGxYghKLofgGwSNIG/N1k9bXerrytf9qVeVuB1WOZW3VcoKFQuIJduxv3oE/f/2gtNhvCNmCTUhngAsP48Izr/q0OPtu2OTY&#x2B;Pg/y3rNiniXPF7G&#x2B;YbP&#x2B;xq8MJFA4AARI2oAoQ3hW2vJsJVxZmNfJDdw7ubbaQWS3zIyrsgc66vQ&#x2B;fu/dr376efLg7WcFlE&#x2B;pDHCqK3OFEobEZJQwd62oZvuTM3&#x2B;t53wv16b6FYCzvHj96uXL8QMKB4A5SRuwT0JLyTOU1gmktO3J6K6SdXGXDo98&#x2B;v5HH7/37vD4OGzrH//1yx&#x2B;0f4Q1MjaAk0xa/J09RGx1/PkQa6dH2vC7nJxpcQx/3ubF/BaUs3OgLjrMA8STtAFd13XdL193L153Kw0k50qY4qZeOs9mK5vAExY7Ix28DDT59k/f/2j&#x2B;nHHwBixSKgNc49QVhddGYqa11Wi&#x2B;tvGNG5PFkW7821sAACAASURBVDriDA3sUriFwgFgL0kbcEghU9xKsLn2Ro1lXvKi6&#x2B;F&#x2B;j8ednauZD0djlMoA17tgqk3DbRWeo4QaIS2mDbeLn3dPXXva3p8LnEr3C4A0kjbgb3ZOaxu7a4pbgXeA5m0CU7szLv0sTmgD1iiVAUqTd1gobOOItJNn3r5i8abDtQedsVAii7EBHCNpA3LaG9EdsVbgXa&#x2B;o5cePK6f0XazDdYmESDI2gDIdHLUGhmoaSBLpSIPTMtdFc&#x2B;ZDOhkbQA5/uHsDgJL88nX/v5V2g7wlIlpc8fv6zThDcuvIXpYAcvxd3/71L9eU0FpHUrtXf/zz76b8fvedahngGpFjlckHda6XhRhXViubP&#x2B;v4xlxWI0B7&#x2B;j9G45hN4QCQzJw2YFlCD0kGbijOOM8v755855MPfv3yh/ATMv44uJLF2ABKMAxdIjOGk&#x2B;a3pX37w0ewjC0uwzbp3j/857z8OTXPc6LCQQoHgOzMaQN&#x2B;72/T2rqyZ7bVMm9s7w3LTaqoEhazUan5R43bUQFul3eqTcxL7fpxi2NUY1d649MgsAr1cMrFx2wNdwSBKix2v1A4ABwnaQNmKgnbFpVTp21Wpw8Rf1t3jPB0tEhrcZqYjRoplQEK1&#x2B;dteyO3QLYBZ9sVhg2nd3i07&#x2B;yFm714rcM8wKl0jwQ29GHbLZ0kIzvqjPuW3CuwJfpJFqUP1YbcTsZGjeaT2O7aEgBi7L39aLF3XznjXsq0eNqkvUIWgc2IPJnVUHDUi9fjldg6hQPAOSRtwJJfvu5evB4/cGPeFjb0LSnkokM5W1KUyT65IHeMCc8EbNTImgoA1ZncPRYzAWj&#x2B;7d3WuHfv4MqolV0mA/jJgm3z58&#x2B;j5b13JcrY4CCFA8CVJG3AilnY1h3I2/7ehXLUmjIssLz2YPHxi2ePxV&#x2B;keOa0tnCrmSu3BGqnVAaozmI78ckCV3tfLe/ybzC2mJ9tFjuTMif7moLAXrpfAFxP0gas61Oxlbytu3CK28L15SJrs3mW1uTNwsnvaNgbyYfvnU8&#x2B;iFmqzWQ1GqNUBqhRYMh05Aas4&#x2B;0BB02OVMkiy8qCgceHn&#x2B;IMhLwUDgB3kbQBW1byti56itvfJ7TtMa67Sq7B5n0Rx/8uMxHMZde7S759G55MqQzQqvBAMWb0e/AGpsCPzvuCZJScs&#x2B;YqpgJn5vCltVaQWbqeAsssxgZwN0kbEGcrb&#x2B;tWIre0mC1ByWncA00Ox5UltAlttEHGBtC8zbCti2vcN37&#x2B;XobQT7D3EIfPvfiFBsOvAOQhYwMog6QN2GNYZS1iittCxha9SNtEZHFYYM1W9ZWLxas/8e&#x2B;owMMB5bMYG0CTxoHWrhYIyWtlpW0bpTneLDT&#x2B;4C6eomvCZ6YzCi6gcAAoiqQNSBIxxW35W2jFXUFaeKk2E9qol1IZgID4iUQ0o6jDPY7W9hYC2shDXrpfABRI0gYcEJzitvxMqjIppAup9hfDtjwZ2&#x2B;RMdt5yCaUywKMcmUMWP8Vt78uO5zNJRKqzdj7M27knnDnx5cDiue10gowUDgDFkrQBOaxPcfv7V/eropXNpHQsf4M3TXZ7f7VlOqD//bu&#x2B;vn7OPHdt7dTtH5e3cRqlMsAzHR/lnhS5UbjFUfeuZo/x517gHBvi2HlzyxtXa4aWWYwNoHiSNiCfEwKJtVLw&#x2B;IoFJ2mysU9jb&#x2B;d3Nqdj9s8RtpGbjA3gUY6PptamCjU5&#x2B;HyOK5dhi7e2MWvLDUZ&#x2B;O5BAh3mAWkjagKKdt/b7qRbvAC1wO9eE73Wt6I2ExGRs4ycL28hBqQzwHIEB1d50JHDnmRWw6pUWko2Pu4QVGqZwAKiLpA2oQLiSvD1sC8Rp7V31qP4dbQVsbz77sP/H28&#x2B;/n36jsI0DlMoA9PKmI/Ej4dvHzOwSbuwxF0h29x738akSM&#x2B;vOeQV56X4BUCNJG1CutbXBirp5c7Ix81q00osa83SzxnfxO8GMbQjYxo9MwzZIolQGeKxrVh2OGW32m7GYoHQNDPMeb5jaOFlu&#x2B;eDLLvYsDa/fDKSzGBtAzSRtQH2qKOcW&#x2B;7pUseVj1W3wguhJbItf&#x2B;l3YZlobO8nYAJ5sGA0WErZRsoQjmP28sgwb3EbGBlA/SRtQqHrTqbGipt89zs5JbGtPM7ONvTSKBGBwRhyy&#x2B;LKBqGYyz2ke/hmyVu2CcqnqigxKpnAAaIakDSidW3TZ58AktrXn/z1sM62NIKUyAIvW4rHkUW54GWMe64w5lGoxOIPCAaAxkjaA67QxUa9cOSaxQRqlMgCb4keAkYPGyFjlmg6WZHTe8Qq/smXY4AI6zAM0SdIGkM3iCvOcLvcktsVX0EOSNUplAM6za1QZaAUxJCiCk2Jl7&#x2B;QxHPRdr&#x2B;wMgbNYjA2gaZI2gEMWW/fo53MRk9i4lYwNgEgZQ5TJS2WfryZoqZoCBEokYwN4AEkbUKjxVYPyl2pb3LxA3lb&#x2B;Oyra&#x2B;ZPYIECjSAASnBe2RTo1n6NwDjfcQuEA8BySNoA8rMF2BRkbt1IqA3BE3rBt/mD4xXWPrM4FgajzAU6icAB4GkkbUIeSJ4FNxtCByG08y63kd1SichpFvnjd/fL1dT&#x2B;OMmgUCUAWkfdmZV/9d94rYpzi1NVMgiwcZTiJwgHgmSRtQLlqb2sz3Di8uIobUYqZxPbmsw/ffv79NT&#x2B;LoiiVAThD5AyzLKv/zm8Lm4dtlKA/NMkHZWEOjUoELmMxNoBnk7QBRSv/BtvNSrjMza5AOZPYeCoZGwBHxIRkkQPF86a4UYKDkWf4LBqfh6oSOIWMDQBJG1CXyW2etdSKwrYdipnExmNZUwGAjLJMSjv4aptBjuCtdptHUDECZ1A4ADCQtAGlm1wamPxb0dgOk9i4m1IZgJPknZSW8GoaRVYnprOoYwp3UTgAMCFpAyoQKCOLCtsCdxkXtZ1lKWMSW78GmzzvsTSKBOAayVPcFps67Hq1fkQ9H5FKa1qi4oBzaRQJwApJG1CHvI13KEIZk9j6jI3HkrEBcL29k9IWGzwMLxIfriw&#x2B;0zC7KLsOxOR&#x2B;RDEbnEjGBkCQpA2oSV3V4&#x2B;SyhWlt/6mMSWw8nH4vAJTgyOCw/1tmeNmG5FaQTgA4nYwNgAiSNqAOxcZU46q42I0sRQEZmxlsyNgAuExMdnJw9GhKE8BJFA4AxJO0AdWo4r5djXcWFBCw9cRsD6dUBuBsxQ4FqxhIE8lxhLMpHADYS9IGVGZxNXgKVUzG1onZns1ibAA82bwBw/Qvo3F1YdaOiCMF59IoEoBUkjagDvOlCxbuMrup8hxv26SZ5C3bU4RgxmYlNi4jYwOgJcmreQ0Wv/3Ro9YaCNjgdDI2AI6RtAHV2LyyMHTFuX69tONXPRpR0iS2MRPanka/FwBaZdjZqsUjK2OD08nYAMhB0gbUZLHdzUT/VWHb1Y5NYuuTsCM53DhLM2fuyWRsABRoMohNHqZOhrhPH38CHKBwACAjSRtQn5i8rbspbEv&#x2B;aq2OTWLLNdVs8jpvP/9&#x2B;/HPnP2X4qrluLVEqA1CmvIPA&#x2B;RJrm6PitVbnlKbNegHKo3AAIDtJG1CrSSG6tubE9fXqU9aZzzGJLQtpGRZjA6AQizlWwoh0/CKB741/ZQEbgEaRAJxH0gY0IiZ4O8&#x2B;z1lQ4kLFlT8XWXnAyrW1Mb8mWyNgAKE2usG3zNYdXjn&#x2B;RzVfjYi2XDFAUGRsAJ5O0ARy1Np2ua694Xs/YrpnENlmMzWy2x9LvBYCSrYVtWV4z0Ef9lnYOJHOw4AIKBwCuIWkDOCR80aSp6x0rMds1U8TmoVpkzDZ52mRrxXXVUSoDUIXIdYX3vmauFzxj8wCKonAA4EqSNqBN5eRbjYRtSzGbNoxcSaNIAKqTvU9juAPk3jHneJ6c1I1yzSuRX76&#x2B;YzuohsIBgOtJ2gBOV33Y9vvi9rKAzWwzekplAOp1xrJtGRWyGbBsrXf9i9fCNhZYjA2A&#x2B;0jaAHJauyO4nOspu8XFbJMV1Pb&#x2B;kMm37M3Y&#x2B;m&#x2B;XzLVHxgZAA04K2yYdIBdfreIhKE&#x2B;2vjg0LJOxAXA3SRtANv2FjOFyRntNeBYjtMUV1OLDtuMz5I68gnCuTNZUAKAxR8K2ocHj2itvfruwjWoEM7Y&#x2B;SvnPYaFpbXRdp3AAoBiSNoBDAstaTL5U5WWOUa07D7QCMdVm2GaNNxYplQFo1cGZbeG5a&#x2B;FvqXIUyqNsTWKbTFeCTuEAQGEkbQDZzK9i1L28fDBmOyLjq0nsmqFRJADNyzIyDE9xC3yXsI0SaRTJXhpFAlAkSRvAIRUHacds9l3c1UMyhsXYWiVjA&#x2B;A5JourJUvI28Y/VOrG/Y5nbBpIPo2MDYCCSdoAcmrnfuHUvpGLjsdjZ8xdE9rdS78XAB4rV9uDcEvJ8U&#x2B;ZdzU//tMhhUlsJJCxAVA8SRtAZmktfZ5mknJdtqhbhpl27pw9TMYGAPFhW8wz18afw/f2d4MJ2LiTjI39FA4A1ELSBnCKui9kZJ3QNjd/heytJhO2Ie/zWaRUBoDBrrCtSxpeTuax5epdCTsI2EiicACgLpI2gIs0PMstywpql4VtMrNbWIwNAOZ2jQ&#x2B;HJ58alTU8ZOVqMjYSaBQJQJ0kbQCHxN8aXGNXyZjoa3jOm88&#x2B;FGIxJ2MDgLzix5&#x2B;TpdrmD05eEzIQsJFGxgZAzSRtABnE32JcQd7WVm0s/7uLfi8AcKrI8Wdkj8qhtySka6uO4DoyNgDqJ2kDyCnyFuMK8raVCW2nplbXr9YmhzuDjA0ADtrVKHJz/Dkfc8YvEQdRZGwkUTgA0AxJG0B&#x2B;16yiUYKLgzEKp1EkAOQVf2NW4bdw0abTArZhhpPxZKtkbAA0RtIGcKL4VTQ4z9rEtfiY8O/f/svXubaqMTI2AKiLaW0cck7GNmkhuPgIddMoEoBGSdoATlfTFLcDNfMkzQrkWMOXLuvcOA/b&#x2B;m3QOvI4GRsAwFOc2SVSqNY4GRsATZO0AVynoilum/O9UiaELb3IlWHbNT/oIfR7AYDamdbGDievxCZma5mMDYAHkLQBXK3qVTSO51XVJV5aR07I2ACgGcI2tp2csXVitnYpHAB4DkkbABlETk27N2brN/L63pXN0CgSANpT9U1gnOj8ldj6weRazPbtd99J4OolYwPgaSRtAOQ3TtRun8S2mKjNH1zcTmlcT8YGAPAUp01ii0zOhqGmsK0&#x2B;GkUC8FSSNgCOKjCOCsR7iVv7yNaR7kUFAHiKO1Zi20xlhG3VkLEB8GySNgCaknEKXYEJ4mVkbAAAT3FmxhafkxltVkrhAACdpA2AgyLbMF7gyM&#x2B;df&#x2B;/v3teTJrQplQEAHuGOSWy7ntAzra1YCgcAGEjaALhNIZPGbl9JrhAWYwMAeISTM7ZN/ThznJ8ZedZk1iiycwQBeDxJGwDp4ie0Dc8MxFp7E6/zErKnTWiTsQEAPMLdGVtnqFk1i7EBwApJGwCnyzt3LWPAtvhSz4nZ9HsBAHiE0wK2//m//nfXdf/yz/8U&#x2B;fxhtGlCW2VkbAAQJGkDIFHkhLbJ095&#x2B;/n3/tLT4LSFme/PZh2mb2jAZGwDAI5yTsfUB2/w/w5GbAWeNFA4AEEPSBsDVFgOtUxdL23zx5YytxQltSmUAgPadPIkt8NW1sC15zDlfEoxrKBwAIJ6kDYA8zojKTo3feqvz2JqL2SzGBgDQvjNXYgvHbDRi1iiyUzsAwBZJGwApzm60eGfG1rUWs8nYAAAad2bA1ouM2RantRl/1sFibACQStIG1RiulX/717/cuyUwNwnG&#x2B;hArPi2bPPPUmG0jI2woY9PvBQCgfednbN19s9m0jryIjA0AjpG0QX36q&#x2B;fyNm4UCKvmX3rz2YfhcOuC6Ws9GRsAAO24JGPrVmK2YeLabS0lGxq930jhAABZSNqgDsNgd7jRTN5Gac7uJ3nEYzM2dTIAQGuuCtgCxv0h/&#x2B;Wf/&#x2B;mksM2EtlPJ2AAgI0kbVKYf&#x2B;8rbKM3mrLXFJ5w9m&#x2B;05AVsnYwMAaN45GduuKWvzNdi6Wdi2uFRbwKuXL&#x2B;djVzHbWWaNIju1AwAcJmmDKi3mbZ3IjUukzV2bh20WY8vCvagAAI07bRJbYC7a3rQsLzHbKSzGBgCnkbRBxSZ5W2eKG2W7Zj02GRsAAI04s1FkTMvHmAltWQzT2mIztoZG9VeQsQHAySRtUD15G/RkbAAAtOD8ldgSVlY7e4rbWsb27Xff9V8y4k2gcACAa0jaoBHDcNkSbpwqrXXkqZ4TsHUWYwMAaNv5GVsXF7PtzdUmS7VtGvKzzad180FvWyP8U1iMDQCuJWmD1ljCjUJc0CtSxgYAQCMuydi69Zitj9bGX92VnCVMkttkxJtCo0gAuIOkDdqkpSQ3krFlpN8LAEDjrsrY1oynr61NTds1xS3yyeFpbauD3oaG&#x2B;pnJ2ADgPpI2aJm8jSsJ2PKSsQEAtC93zBbOyeZfXUzFzl6SbbAWtonZ9pGxAcDdJG3QPku4cTYZW14yNgCAR8gaswX6N/7P//W/4xO1y2K23o6Bbltj/iwUDgBQCEkbPMjiEm7yNo6QseVlMTYAgKe4KmZbe8LFidohbY35M5hNYuvUDgBwK0kbPM5i3taJ3IgwhF4XBGxdOGNrrtiWsQEAPMi1MVu3vgDbZRuQorkxfwYaRQJAkSRt8FCWcCPB/QFb11q9rd8LAABHpKVc501oy/PKbY3585CxAUDBJG3waJZwoygytlu2BACAS2Wd0Laoj7uGEO74hLa1ld667BPa2hrz5yFjA4DiSdqArrOEG3eTsd2yJQAAVC28&#x2B;tqpHSMXNyB9QltbA/5cFA4AUAtJG/B3lnDjYo8K2DqLsQEAsNN4MtPm6HEedC1GX7laR8bEeNsj3ubG/BnMJrF1agcAKJukDZiyhBsXeFTG5l5UAAD&#x2B;U1zryHnQ0j84HkZmm08Wp/9xk76UgQ2QsaXQKBIA6iRpA5bJ2ziJjO2WLQEAoAqLGdv4q4vjyYwx27Ak22LzyQztKNsa8GcjYwOAmknagJBhcG8Jt6d5&#x2B;/n3bz77MO8Lhr7cXL0tYwMAYK9wzDZ26gJsQ9gWL&#x2B;r5zY35s1A4AEADJG1AFEu4kezhGZs6GQCAGPEx23nSArztmK25MX8WMjYAaIakDdhBS0l2kbHdtSUAANTlSMy2d/5ZzJS1/jmLDSR3/OjmBvx5zBpFdmoHAKicpA3YTd7Wsl&#x2B;&#x2B;HhZpP9JA8lEZm3tRAQA4YjFmGw8pr5nuthiqBcK2UMzW1oA/G4uxAUCjJG1AIku4MfeogK2TsQEAcFjC9KYzFmkLvOa&#x2B;OXPNjfnzkLEBQNMkbcBRi0u4ydvaED&#x2B;tTcamVAYA4LhrRpWTBpLzmG1vR8qua3DMn4XCAQCeQNIG5LGYt3UitxqNGkjGeHjGpk4GACCXxbHlwdaRayuumcR2LouxAcCTSNqAnCzh1p4&#x2B;SJvPbHtawNbJ2AAAyG0zRTsesx359g0tjvkzkLEBwPNI2oD85G3Vm01rG&#x2B;dtT8vY9HsBgOcwaqUoB2O2NFET2pob8&#x2B;dhMTYAeCpJG3CWoaiwhFszZGxKZQB4AqNWbjEeambJ2IYJbWsNJOc2YrbmBvzZyNgA4NkkbcDpLOFWpV2rtTVXcsvYAOBp3CVGOc6byhYI22RsaRQOAEAnaQMuo6VkfTbDthbrbYuxAcDDLd4lZsjKqeZB7y79lLX5g4tP7p85/qqMLYXF2ACAkX/47bff7t4G4HEWahIXLw44fZrgPG9rsd6WsQEAE0atDLJlriu3sgUytm&#x2B;/&#x2B;2781X6YOg/ShsBsMWOLWn1trMUBfx4yNgBgxpw24Aaa81Sm6TJbvxcAYI2uDFxjLWbbNS4NrMG2L2ZrevB/iMXYAIAVkjbgTpZw40YyNgAghryNU2WJ2QJ2xGwytjUyNgAgSNIG3M/FCy4mYwMA9tKVgcuEh6avXr789rvv/uWf/ykwiW0QFbMJ2NYpHACAGJI2oBTyNi5gMTYA4CBdGcgoZsWv&#x2B;XP6R/7bf/8f4RffjtlkbGssxgYA7CFpA8riZmHO4F5UACAvd4lxhl1j1PC0to2YTca2RsYGAOwnaQMK5WZhspCxAQDnkbeR0eIwdW0Vt14fp03ytlDGJmALsBgbAJBK0gYUzcULksnYAIBr6MpAmnCKFvOEnsXYjpKxAQDHSNqACsjb2MVibADALRa7MhiykiYyZtsmY1ujUSQAkImkDaiGvI1NMjYA4Ha6oHPQYvyTMulKxrZGxgYAZCVpAyqjOQ9zGkUCAKVxlxh7hSex7RjfCtgCZGwAwAkkbUCt3CxMJ2MDAMomb&#x2B;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&#x2B;ZtJrEBAJCFJdwaJ2MDANhD0gZQnOx5m4wNAIDstJRskIwNAGA/SRtAodaa83R7Ll7I2AAAOJW8rRGzjE3hAAAQSdIGULq0ixcWYwMA4DKWcKuVSWwAAIdJ2gDqEJm3mcQGAMCNFpdwk7eVSMYGAJDJP/z22293bwMA&#x2B;8xL4kXqZAAAbrQQ5FQbuTUVGcrYAACykrQBVGwtclMnAwBQiDbytkaSNhkbAMAJJG0A1RtXy&#x2B;pkAAAKVHveVn3SNsvYFA4AALlI2gAAAICLTPOeSrKrWpM2k9gAAM73X&#x2B;7eAAAAAOAp&#x2B;phniH/6BKurMcQqnIwNAOAqkjYAAADgUpO8rat30liBZGwAANeStAEAAAA3kLdlZjE2AIA7SNoAAACA2wxp0KSlpLxtBxkbAMB9JG0AAADA/SzhtptGkQAABZC0AQAAAKXQUjKKjA0AoBiSNgAAAKAs8rZVMjYAgMJI2gAAAIASydt&#x2B;x2JsAABFkrQBAAAA5RrypIcu4fbidff7uLGTsQEAlETSBgAAAFTgcVPcNIoEAKiBpA0AAACoxiPyNhkbAEA9JG0AAABAZZrN22RsAAC1kbQBAAAAVVpbwq3KvG2WsQnYAACqIGkDAAAA6jaZ4tbnbV0VkZtJbAAAlZO0AQAAAC2orKWkjA0AoAmSNgAAAKAdFeRtMjYAgIZI2gAAAIDWFLqEm4wNAKA5kjYAAACgWaUs4TbL2ARsAABtkLQBAAAAjbutpaRJbAAArZO0AQAAAI9wad4mYwMAeAZJGwAAAPAgp&#x2B;dtMjYAgCeRtAEAAACPM0RfOZdwk7EBADyPpA0AAAB4rgxT3F68nrxCJ2ADAHgMSRsAAADwdIl5m0lsAACP9w&#x2B;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&#x2B;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" />
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>